


**CUMULATIVE
SUPPLEMENT 8
AUGUST 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 8

August 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

**CUMULATIVE SUPPLEMENT 8
August 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352	16543		
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)		
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)		
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)		
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)		
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)	75 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	13	22	12		
NUMBER OF APPLICANTS	927	935	957		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

FIORICET

@ ACTAVIS LABS UT INC 325MG; 50MG; 40MG

A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG; 50MG; 40MG; 30MG

N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA SUN PHARM INDS LTD 300MG; 30MG

A085868 001

Apr CAHN

AA 300MG; 60MG

A087083 001

Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG; 2.5MG

A040846 001

Jun 09, 2010 Feb CTEC

@ SUN PHARM INDS LTD 325MG; 10MG

A040826 001

Aug 16, 2007 Apr CAHN

NORCO

AA ACTAVIS LABS FL INC 325MG; 2.5MG

A040148 004

Jul 07, 2014 Feb NEWA

AA 325MG; 5MG

A040148 005

Jul 07, 2014 Feb NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

DIAMOX

AB + TEVA BRANDED PHARM 500MG

N012945 001

Jun CAHN

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

@ ANI PHARMS INC 250MG

A070869 001

Feb 09, 1987 Jul CAHN

@ 500MG

A070870 001

Feb 09, 1987 Jul CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML)

A203173 001

Mar 24, 2015 Mar NEWA

AP MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML)

A203624 001

Jun 19, 2015 Jun NEWA

ACITRETIN

CAPSULE; ORAL

ACITRETIN

>A> AB MYLAN PHARMS INC 10MG

A202148 001

Sep 10, 2015 Aug NEWA

>A> AB 17.5MG

A203707 001

Sep 10, 2015 Aug NEWA

>A> AB 22.5MG

A203707 002

Sep 10, 2015 Aug NEWA

>A> AB 25MG

A202148 002

Sep 10, 2015 Aug NEWA

AB SIGMAPHARM LABS LLC 10MG

A204633 001

May 22, 2015 May NEWA

AB 17.5MG

A204633 002

May 22, 2015 May NEWA

AB 22.5MG

A204633 003

May 22, 2015 May NEWA

AB 25MG

A204633 004

May 22, 2015 May NEWA

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

>D> + ASTRAZENECA PHARMS 0.375MG/INH

N202450 001

Jul 23, 2012 Aug CPOT

+ 0.375MG/INH

N202450 001

Jul 23, 2012 Apr CAHN

>A> + 0.4MG/INH

N202450 001

Jul 23, 2012 Aug CPOT

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

AB SUN PHARM INDS LTD 400MG

A074980 001

Sep 30, 1998 Apr CAHN

AB 800MG

A074980 002

Sep 30, 1998 Apr CAHN

ADAPALENE; BENZOYL PEROXIDEGEL; TOPICAL
EPIDUO FORTE

>A>	+	GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug CAHN
>D>	+	GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug CAHN
	+		0.3%;2.5%	N207917	001	Jul 15, 2015	Jul NEWA

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

AP		EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun CAHN
	@	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May DISC

ALBENDAZOLETABLET, CHEWABLE; ORAL
ALBENZA

+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun NEWA
---	-------------------	-------	---------	-----	--------------	----------

ALBUTEROL SULFATEPOWDER, METERED; INHALATION
PROAIR RESPICLICK

+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar NEWA
---	--------------------	---------------------	---------	-----	--------------	----------

SYRUP; ORAL

AA		G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr CAHN
----	--	------------------	-----------------	---------	-----	--------------	----------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDEAEROSOL, METERED; INHALATION
COMBIVENT

@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH; 0.018MG/INH	N020291	001	Oct 24, 1996	May DISC
---	----------------------	---------------------------------	---------	-----	--------------	----------

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

@	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb DISC
---	---------------	------	---------	-----	--------------	----------

UROXATRAL

AB	+	CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun CAHN
----	---	----------------------	------	---------	-----	--------------	----------

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATETABLET; ORAL
TEKAMLO

@	NOVARTIS	EQ 150MG BASE; EQ 5MG BASE	N022545	001	Aug 26, 2010	May DISC
@		EQ 150MG BASE; EQ 10MG BASE	N022545	002	Aug 26, 2010	May DISC
@		EQ 300MG BASE; EQ 5MG BASE	N022545	003	Aug 26, 2010	May DISC
@		EQ 300MG BASE; EQ 10MG BASE	N022545	004	Aug 26, 2010	May DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDETABLET; ORAL
AMTURNIDE

@	NOVARTIS	EQ 150MG BASE; EQ 5MG BASE; 12.5MG	N200045	001	Dec 21, 2010	May DISC
@		EQ 300MG BASE; EQ 5MG BASE; 12.5MG	N200045	002	Dec 21, 2010	May DISC
@		EQ 300MG BASE; EQ 5MG BASE; 25MG	N200045	003	Dec 21, 2010	May DISC
@		EQ 300MG BASE; EQ 10MG BASE; 12.5MG	N200045	004	Dec 21, 2010	May DISC
@		EQ 300MG BASE; EQ 10MG BASE; 25MG	N200045	005	Dec 21, 2010	May DISC

ALMOTRIPTAN MALATETABLET; ORAL
ALMOTRIPTAN MALATE

AB		TEVA PHARMS USA	EQ 6.25MG BASE	A078027	001	Jul 07, 2015	Jun NEWA
AB			EQ 12.5MG BASE	A078027	002	Jul 07, 2015	Jun NEWA

AXERT

AB		JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun CFTG
AB	+		EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun CFTG

ALOSETRON HYDROCHLORIDETABLET; ORAL
ALOSETRON HYDROCHLORIDE

AB		ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr NEWA
AB			EQ 1MG BASE	A200652	002	May 04, 2015	Apr NEWA

TABLET;ORAL
LOTRONEX

AB	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr CFTG
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr CFTG

ALPRAZOLAM

TABLET;ORAL
ALPRAZOLAM

	@ ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994	Jul CAHN
	@	0.5MG	A074085	002	Feb 16, 1994	Jul CAHN
	@	1MG	A074085	003	Feb 16, 1994	Jul CAHN
	@	2MG	A074085	004	Feb 26, 1996	Jul CAHN
AB	AUROBINDO PHARMA LTD	0.25MG	A203346	001	Jul 31, 2015	Jul NEWA
AB		0.5MG	A203346	002	Jul 31, 2015	Jul NEWA
AB		1MG	A203346	003	Jul 31, 2015	Jul NEWA
AB		2MG	A203346	004	Jul 31, 2015	Jul NEWA
AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar NEWA
AB		0.5MG	A200739	002	Apr 15, 2015	Mar NEWA
AB		1MG	A200739	003	Apr 15, 2015	Mar NEWA
AB		2MG	A200739	004	Apr 15, 2015	Mar NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL
AMANTADINE HYDROCHLORIDE

AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

SYRUP;ORAL
AMANTADINE HYDROCHLORIDE

	@ G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May CAHN
--	--------------------	----------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE;INJECTION
AMIKACIN SULFATE

	@ IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar CAHN
	@	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL
AMILORIDE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul NEWA
----	----------------------	-----	---------	-----	--------------	----------

AMINO ACIDS

INJECTABLE;INJECTION
BRANCHAMIN 4% IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb DISC
--	-------------------	----------------	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995	Feb DISC
--	-------------------	--	---------	-----	--------------	----------

AMINOCAPROIC ACID

SYRUP;ORAL
AMINOCAPROIC ACID

AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May CAHN
----	----------------	------------	---------	-----	--------------	----------

TABLET;ORAL
AMINOCAPROIC

AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May CAHN
----	----------------	-------	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL
AMITRIPTYLINE HYDROCHLORIDE

>A>	@ ANI PHARMS INC	10MG	A084910	003		Aug CAHN
>A>	@	25MG	A085031	001		Aug CAHN
>A>	@	50MG	A085032	001		Aug CAHN
>A>	@	75MG	A085030	001		Aug CAHN
>D>	@ TEVA	10MG	A084910	003		Aug CAHN
>D>	@	25MG	A085031	001		Aug CAHN
>D>	@	50MG	A085032	001		Aug CAHN
>D>	@	75MG	A085030	001		Aug CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL

@ HERITAGE PHARMS INC EQ 12.5MG BASE;5MG

N016949 001

Jul CAHN

LIMBITROL DS

@ HERITAGE PHARMS INC EQ 25MG BASE;10MG

N016949 002

Jul CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB CHINA RESOURCES

EQ 5MG BASE

A090752 001 Apr 15, 2011

Mar CAHN

AB

EQ 10MG BASE

A090752 002 Apr 15, 2011

Mar CAHN

AB SOVEREIGN PHARMS

EQ 2.5MG BASE

A204900 001 Jul 23, 2015

Jul NEWA

AB

EQ 5MG BASE

A204900 002 Jul 23, 2015

Jul NEWA

AB

EQ 10MG BASE

A204900 003 Jul 23, 2015

Jul NEWA

AB SUN PHARM INDS LTD

EQ 2.5MG BASE

A077974 001 Jul 09, 2007

Apr CAHN

AB

EQ 5MG BASE

A077974 002 Jul 09, 2007

Apr CAHN

AB

EQ 10MG BASE

A077974 003 Jul 09, 2007

Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB LUPIN LTD

5MG;12.5MG;160MG

A200797 001 Jun 03, 2015

May NEWA

AB

5MG;25MG;160MG

A200797 002 Jun 03, 2015

May NEWA

AB

10MG;12.5MG;160MG

A200797 003 Jun 03, 2015

May NEWA

AB

10MG;25MG;160MG

A200797 004 Jun 03, 2015

May NEWA

AB

10MG;25MG;320MG

A200797 005 Jun 03, 2015

May NEWA

AB PAR PHARM

5MG;12.5MG;160MG

A201087 001 Jun 01, 2015

May NEWA

AB

5MG;25MG;160MG

A201087 002 Jun 01, 2015

May NEWA

AB

10MG;12.5MG;160MG

A201087 003 Jun 01, 2015

May NEWA

AB

10MG;25MG;160MG

A201087 004 Jun 01, 2015

May NEWA

AB

10MG;25MG;320MG

A201087 005 Jun 01, 2015

May NEWA

AB TEVA PHARMS

5MG;12.5MG;160MG

A200435 001 Sep 25, 2012

May CAIN

AB

5MG;25MG;160MG

A200435 002 Sep 25, 2012

May CAIN

AB

10MG;12.5MG;160MG

A200435 005 Sep 25, 2012

May CAIN

AB

10MG;25MG;160MG

A200435 003 Sep 25, 2012

May CAIN

AB

10MG;25MG;320MG

A200435 004 Sep 25, 2012

May CAIN

AB TORRENT PHARMS LTD

5MG;12.5MG;160MG

A201593 001 Jun 04, 2015

May NEWA

AB

5MG;25MG;160MG

A201593 002 Jun 04, 2015

May NEWA

AB

10MG;12.5MG;160MG

A201593 003 Jun 04, 2015

May NEWA

AB

10MG;25MG;160MG

A201593 004 Jun 04, 2015

May NEWA

AB

10MG;25MG;320MG

A201593 005 Jun 04, 2015

May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGinine

TABLET;ORAL

PRESTALIA

SYMPLMED PHARMS LLC

EQ 2.5MG BASE;3.5MG

N205003 001 Jan 21, 2015

Jan NEWA

EQ 5MG BASE;7MG

N205003 002 Jan 21, 2015

Jan NEWA

+

EQ 10MG BASE;14MG

N205003 003 Jan 21, 2015

Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB ALEMBIC PHARMS LTD

EQ 5MG BASE;160MG

A202713 001 Apr 03, 2015

Mar NEWA

AB

EQ 5MG BASE;320MG

A202713 003 Apr 03, 2015

Mar NEWA

AB

EQ 10MG BASE;160MG

A202713 002 Apr 03, 2015

Mar NEWA

AB

EQ 10MG BASE;320MG

A202713 004 Apr 03, 2015

Mar NEWA

AB LUPIN

EQ 5MG BASE;160MG

A090245 001 Mar 30, 2015

Mar NEWA

AB

EQ 5MG BASE;320MG

A090245 003 Mar 30, 2015

Mar NEWA

AB

EQ 10MG BASE;160MG

A090245 002 Mar 30, 2015

Mar NEWA

AB

EQ 10MG BASE;320MG

A090245 004 Mar 30, 2015

Mar NEWA

AB MATRIX LABS LTD

EQ 5MG BASE;160MG

A090483 001 Mar 30, 2015

Mar NEWA

AB

EQ 5MG BASE;320MG

A090483 003 Mar 30, 2015

Mar NEWA

AB

EQ 10MG BASE;160MG

A090483 002 Mar 30, 2015

Mar NEWA

AB

EQ 10MG BASE;320MG

A090483 004 Mar 30, 2015

Mar NEWA

AB MYLAN PHARMS INC

EQ 5MG BASE;160MG

A090483 001 Mar 30, 2015

Apr CAHN

AB

EQ 5MG BASE;320MG

A090483 003 Mar 30, 2015

Apr CAHN

AB

EQ 10MG BASE;160MG

A090483 002 Mar 30, 2015

Apr CAHN

AB

EQ 10MG BASE;320MG

A090483 004 Mar 30, 2015

Apr CAHN

AB NOVEL LABS INC

EQ 5MG BASE;160MG

A202829 001 Mar 30, 2015

Mar NEWA

AB

EQ 5MG BASE;320MG

A202829 003 Mar 30, 2015

Mar NEWA

AB

EQ 10MG BASE;160MG

A202829 002 Mar 30, 2015

Mar NEWA

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
>A>	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015	Aug NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD
@

200MG/5ML
400MG/5ML

A065113 001 Nov 29, 2002 Apr CAHN
A065113 002 Nov 29, 2002 Apr CAHN

TABLET; ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr CAHN

TABLET, CHEWABLE; ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr CAHN
	@	200MG	A065060	001	Nov 29, 2000	Apr CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr CAHN
	@	400MG	A065060	002	Nov 29, 2000	Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD
AB

500MG;EQ 125MG BASE
875MG;EQ 125MG BASE

A065109 001 Nov 04, 2002 Apr CAHN
A065102 001 Sep 17, 2002 Apr CAHN

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

EVEKEO

ARBOR PHARMS LLC

5MG
10MG

A200166 001 Aug 09, 2012 Mar CTNA
A200166 002 Aug 09, 2012 Mar CTNA

+

AMPICILLIN SODIUMINJECTABLE; INJECTION
AMPICILLIN SODIUM

>A>	AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015	Aug NEWA
>A>	AP		EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015	Aug NEWA
>A>	AP		EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015	Aug NEWA
>A>	AP		EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015	Aug NEWA
>A>	AP		EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Aug NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECIDFOR SUSPENSION; ORAL
PROBAMPACIN

@ G AND W LABS INC	EQ 3.5GM BASE/BOT; 1GM/BOT	A061741	001			Apr CAHN
--------------------	----------------------------	---------	-----	--	--	----------

ANASTROZOLETABLET; ORAL
ANASTROZOLE

@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar CAHN
------------------------	-----	---------	-----	--------------	----------

ARGATROBANINJECTABLE; INJECTION
ACOVA

>D>	AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Aug CTNA
			ARGATROBAN					
	AP		FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr CDFR
>A>	AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Aug CTNA
			INJECTABLE; IV (INFUSION)					
			ARGATROBAN					
	AP		FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar NEWA

ARIPIPIRAZOLESOLUTION; ORAL
ARIPIPIRAZOLE

>A>	AA		AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Aug NEWA
>A>	AA		SILARX PHARMS INC	1MG/ML	A204171	001	Aug 14, 2015	Aug NEWA

TABLET; ORAL

ABILIFY

AB			OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr CFTG
AB	+			5MG	N021436	005	Nov 15, 2002	Apr CFTG
AB	+			10MG	N021436	001	Nov 15, 2002	Apr CFTG
AB				15MG	N021436	002	Nov 15, 2002	Apr CFTG
AB				20MG	N021436	003	Nov 15, 2002	Apr CFTG
AB				30MG	N021436	004	Nov 15, 2002	Apr CFTG

ARIPIPIRAZOLE

AB			ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr NEWA
AB				5MG	A202101	002	Apr 28, 2015	Apr NEWA
AB				10MG	A202101	003	Apr 28, 2015	Apr NEWA
AB				15MG	A202101	004	Apr 28, 2015	Apr NEWA
AB				20MG	A202101	005	Apr 28, 2015	Apr NEWA
AB				30MG	A202101	006	Apr 28, 2015	Apr NEWA
AB			APOTEX INC	2MG	A078583	001	Jul 24, 2015	Jul NEWA
AB				5MG	A078583	002	Jul 24, 2015	Jul NEWA
AB				10MG	A078583	003	Jul 24, 2015	Jul NEWA
AB				15MG	A078583	004	Jul 24, 2015	Jul NEWA
AB				20MG	A078583	005	Jul 24, 2015	Jul NEWA
AB				30MG	A078583	006	Jul 24, 2015	Jul NEWA
AB			HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr NEWA
AB				5MG	A205064	002	Apr 28, 2015	Apr NEWA
AB				10MG	A205064	003	Apr 28, 2015	Apr NEWA
AB				15MG	A205064	004	Apr 28, 2015	Apr NEWA
AB				20MG	A205064	005	Apr 28, 2015	Apr NEWA
AB				30MG	A205064	006	Apr 28, 2015	Apr NEWA
AB			TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr NEWA
AB				5MG	A078607	002	Apr 28, 2015	Apr NEWA
AB				10MG	A078608	001	Apr 28, 2015	Apr NEWA
AB				15MG	A078708	001	Apr 28, 2015	Apr NEWA
AB				20MG	A078708	002	Apr 28, 2015	Apr NEWA
AB				30MG	A078708	003	Apr 28, 2015	Apr NEWA
AB			TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr NEWA
AB				10MG	A201519	003	Apr 28, 2015	Apr NEWA
AB				5MG	A201519	002	Apr 28, 2015	Apr NEWA

TABLET;ORAL
ARIPIPIRAZOLE

AB		15MG	A201519	004	Apr 28, 2015	Apr NEWA
AB		20MG	A201519	005	Apr 28, 2015	Apr NEWA
AB		30MG	A201519	006	Apr 28, 2015	Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY

AB	+	OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr CFTG
AB			15MG	N021729	003	Jun 07, 2006	Apr CFTG

ARIPIPIRAZOLE							
AB		ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr NEWA
AB			15MG	A202102	002	Apr 28, 2015	Apr NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION
M.V.I.-12 LYOPHILIZED
@ IGI LABS INC

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun CAHN
--	---------	-----	--------------	----------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

>D>	MOVIPREP						
>D>	@ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Aug CTNA	
>A>	PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID						
>A>	@ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Aug CTNA	

ASENAPINE MALEATE

TABLET;SUBLINGUAL
SAPHRIS

FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun CAHN
+	EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
FIORINAL

AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan CAHN
TABLET;ORAL							
FIORINAL							
		@ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORINAL W/CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan CAHN
----	---	---------------------	----------------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL
SYNALGOS-DC

>D>	+	CARACO	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983	Aug CAHN
>A>	+	SUN PHARM INDS	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983	Aug CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL
NORGESIC

@ MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar DISC
-----------	-----------------	---------	-----	--------------	----------

NORGESIC FORTE

@ MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar DISC
-----------	-----------------	---------	-----	--------------	----------

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar CTEC
+	770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL						
OXYCODONE AND ASPIRIN						
AA	ACTAVIS LABS FL INC	325MG; 4.8355MG	A090084	001	Mar 22, 2011	Mar CAHN

ATAZANAVIR SULFATE; COBICISTAT

TABLET; ORAL						
EVOTAZ						
+	BRISTOL MYERS SQUIBB	EQ 300MG BASE; 150MG	N206353	001	Jan 29, 2015	Jan NEWA

ATENOLOL

TABLET; ORAL						
ATENOLOL						
AB	ALVOGEN IPCO SARL	25MG	A073646	001	Jul 31, 1992	Jul CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jul CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jul CAHN
	@ DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Jun DISC
TENORMIN						
AB	ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
AB		50MG	N018240	001		Feb CAHN
AB	+	100MG	N018240	002		Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL							
ATENOLOL AND CHLORTHALIDONE							
AB	ALVOGEN IPCO SARL	50MG; 25MG	A072301	001	May 31, 1990	Jul CAHN	
AB		100MG; 25MG	A072302	001	May 31, 1990	Jul CAHN	
TENORETIC 100							
AB	+	ALVOGEN IPCO SARL	100MG; 25MG	N018760	001	Jun 08, 1984	Feb CAHN
TENORETIC 50							
AB	ALVOGEN IPCO SARL	50MG; 25MG	N018760	002	Jun 08, 1984	Feb CAHN	

ATORVASTATIN CALCIUM

TABLET; ORAL						
ATORVASTATIN CALCIUM						
AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL						
LIPTRUZET						
	@ MERCK SHARP DOHME	EQ 10MG BASE; 10MG	N200153	001	May 03, 2013	May DISC
	@	EQ 20MG BASE; 10MG	N200153	002	May 03, 2013	May DISC
	@	EQ 40MG BASE; 10MG	N200153	003	May 03, 2013	May DISC
	@	EQ 80MG BASE; 10MG	N200153	004	May 03, 2013	May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL						
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE						
AB	GLENMARK GENERICS	62.5MG; 25MG	A091211	002	Apr 06, 2015	Mar NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION						
ATRACURIUM BESYLATE						
AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
ATRACURIUM BESYLATE PRESERVATIVE FREE						
AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC						
ATROPINE SULFATE						
+	AKORN	1%	N206289	001	Jul 18, 2014	May CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN
	MOTOFEN HALF-STRENGTH					
@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jul CAHN
---	----------------	---------------	---------	-----	--	----------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb NEWA
---	------------	------------------------	---------	-----	--------------	----------

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015	Jul NEWA
---	----------------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

AB	BRECKENRIDGE PHARMS	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Jul NEWA
----	---------------------	-----------------------	---------	-----	--------------	----------

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	May NEWA
AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	May NEWA

INJECTABLE; INJECTION

AZITHROMYCIN

AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jun NEWA
----	----------------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

AZITHROMYCIN

AB	LUPIN LTD	EQ 250MG BASE	A065398	001	May 15, 2015	May NEWA
AB		EQ 500MG BASE	A065399	001	May 15, 2015	May NEWA
AB		EQ 600MG BASE	A065400	001	May 15, 2015	May NEWA

BALSALAZIDE DISODIUM

CAPSULE; ORAL

COLAZAL

AB	+ VALEANT PHARMS INTL	750MG	N020610	001	Jul 18, 2000	Jul CAHN
----	-----------------------	-------	---------	-----	--------------	----------

TABLET; ORAL

BALSALAZIDE DISODIUM

>A> AB	PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Aug NEWA
	GIAZO					

>D>	+ VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Aug CFTG
>A> AB	+	1.1GM	N022205	001	Feb 03, 2012	Aug CFTG
	+	1.1GM	N022205	001	Feb 03, 2012	Jul CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan CAHN
AB		10MG	A076820	002	Feb 03, 2006	Jan CAHN
AB		20MG	A076820	003	Feb 03, 2006	Jan CAHN
AB		40MG	A076820	004	Feb 03, 2006	Jan CAHN
AB	SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr CAHN
AB		10MG	A076344	002	Feb 11, 2004	Apr CAHN
AB		20MG	A076344	003	Feb 11, 2004	Apr CAHN
AB		40MG	A076344	004	Feb 11, 2004	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr CAHN
AB		10MG;12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
AB		20MG;12.5MG	A077483	003	Sep 08, 2005	Apr CAHN
AB		20MG;25MG	A077483	004	Sep 08, 2005	Apr CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan NEWA
AA		200MG	A091310	002	Jan 16, 2015	Jan NEWA
AA	BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN
AA	CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul NEWA
>D> AA	STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Aug CAHN
AA		100MG	A091133	001	Jul 30, 2015	Jul NEWA
>D> AA		200MG	A091133	002	Jul 30, 2015	Aug CAHN
AA		200MG	A091133	002	Jul 30, 2015	Jul NEWA
>A> AA	STRIDES PHARMA	100MG	A091133	001	Jul 30, 2015	Aug CAHN
>A> AA		200MG	A091133	002	Jul 30, 2015	Aug CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

AB	+ DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun CFTG
	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB	ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun NEWA
	ONEXTON					
	+ DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	+ KVK TECH	50MG	A090968	001	Jul 20, 2010	Jun CRLD
	DIDREX					
	@ PHARMACIA AND UPJOHN	50MG	N012427	002		Jun DISC

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
AA		1MG	A204713	002	Apr 14, 2015	Mar NEWA
AA		2MG	A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
	@	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETA-VAL

>A> AB	G AND W LABS INC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	Aug CAHN
>D> AB	TEVA	EQ 0.1% BASE	N018642	001	Mar 24, 1983	Aug CAHN

LOTION; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN
----	------------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar CAHN
AA		10MG	A091256	002	May 04, 2010	Mar CAHN
AA		25MG	A091256	003	May 04, 2010	Mar CAHN
AA		50MG	A091256	004	May 04, 2010	Mar CAHN
AA	LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb CMFD
AA		50MG	A040677	001	Mar 27, 2008	Feb CMFD

TABLET;ORAL
DUVOID

AA	WELLSPRING PHARM	10MG	A086262	001		Jan	CMFD
AA		25MG	A086263	001		May	CMFD
AA		50MG	A085882	003		May	CMFD

BEXAROTENE

CAPSULE;ORAL
BEXAROTENE

AB	BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun	CMFD
	@	75MG	A203174	001	Aug 12, 2014	Jan	CAHN
AB	+ VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun	CTEC

BICALUTAMIDE

TABLET;ORAL
BICALUTAMIDE

AB	APOTEX INC	50MG	A200274	001	May 21, 2015	May	NEWA
AB	STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May	NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC
BIMATOPROST

AT	ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr	NEWA
AT	APOTEX INC	0.03%	A090449	001	Jul 20, 2015	Jul	NEWA
AT	+ LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr	CTEC
	+	0.03%	A203991	001	Feb 20, 2015	Mar	CTEC
AT	+	0.03%	A203991	001	Feb 20, 2015	Feb	NEWA

>D> BIPERIDEN HYDROCHLORIDE

>D> TABLET;ORAL
>D> AKINETON

>D>	+ ABBVIE	2MG	N012003	001		Aug	DISC
>A>	@	2MG	N012003	001		Aug	DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL
PYLERA

+	FOREST LABS LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul	CAHN
---	-----------------	-------------------	---------	-----	--------------	-----	------

BIVALIRUDIN

INJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP	HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun	NEWA
AP		250MG/VIAL	A090816	001	Jul 14, 2015	Jun	NEWA

BOSUTINIB MONOHYDRATE

TABLET;ORAL
BOSULIF

+	WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun	CRLD
		EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun	CRLD

BREXPIRAZOLE

TABLET;ORAL
REXULTI

	OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015	Jul	NEWA
		0.5MG	N205422	002	Jul 10, 2015	Jul	NEWA
		1MG	N205422	003	Jul 10, 2015	Jul	NEWA
		2MG	N205422	004	Jul 10, 2015	Jul	NEWA
		3MG	N205422	005	Jul 10, 2015	Jul	NEWA
+		4MG	N205422	006	Jul 10, 2015	Jul	NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMDAY

AT2	+ BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May	CTEC
	BROMFENAC SODIUM						
AT2	APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May	CTEC
AT1	+ COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May	CRLD
AT2	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
AT1	PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan	NEWA

BUDESONIDEAEROSOL, FOAM;RECTAL
UCERIS+ VALEANT PHARMS INTL 2MG/ACTUATION
SPRAY, METERED;NASAL
BUDESONIDE

N205613 001 Oct 07, 2014 Apr CAHN

APOTEX INC 0.032MG/INH
TABLET, EXTENDED RELEASE;ORAL
UCERIS

A078949 001 May 12, 2014 Mar CTEC

>D> + SANTARUS INC 9MG

N203634 001 Jan 14, 2013 Aug CAHN

>A> + VALEANT PHARMS INTL 9MG

N203634 001 Jan 14, 2013 Aug CAHN

BUMETANIDEINJECTABLE;INJECTION
BUMETANIDE

AP EUROHLTH INTL SARL 0.25MG/ML

A079196 001 Apr 30, 2008 Jun CAHN

BUPRENORPHINE HYDROCHLORIDEINJECTABLE;INJECTION
BUPRENORPHINE HYDROCHLORIDE

AP PAR STERILE PRODUCTS EQ 0.3MG BASE/ML

A206586 001 Jul 28, 2015 Jul NEWA

TABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB ACTAVIS ELIZABETH EQ 2MG BASE

A090819 001 Feb 19, 2015 Feb NEWA

AB EQ 8MG BASE

A090819 002 Feb 19, 2015 Feb NEWA

AB MYLAN PHARMS INC EQ 2MG BASE

A201066 001 Mar 06, 2015 Feb NEWA

AB EQ 8MG BASE

A201066 002 Mar 06, 2015 Feb NEWA

AB SANDOZ INC EQ 2MG BASE

A090279 001 Jun 10, 2015 May NEWA

AB EQ 8MG BASE

A090279 002 Jun 10, 2015 May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDETABLET;SUBLINGUAL
ZUBSOLV

OREXO AB EQ 2.9MG BASE;EQ 0.71MG BASE

N204242 005 Jun 04, 2015 Jun NEWA

BUPROPION HYDROBROMIDETABLET, EXTENDED RELEASE;ORAL
APLENZIN

VALEANT PHARMS NORTH 174MG

N022108 001 Apr 23, 2008 Feb CAHN

348MG

N022108 002 Apr 23, 2008 Feb CAHN

+ 522MG

N022108 003 Apr 23, 2008 Feb CAHN

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB1 PRINSTON INC 100MG

A202304 001 May 26, 2015 May NEWA

AB1 150MG

A202304 002 May 26, 2015 May NEWA

AB1 200MG

A202304 003 May 26, 2015 May NEWA

AB2 SANDOZ INC 150MG

A077475 001 Mar 12, 2008 Mar CAHN

@ WOCKHARDT LTD 100MG

A201331 001 Aug 30, 2012 May DISC

@ 150MG

A201331 002 Aug 30, 2012 May DISC

@ 200MG

A201331 003 Aug 30, 2012 May DISC

BUTABARBITAL SODIUM

ELIXIR;ORAL

BUTISOL SODIUM

@ MEDA PHARMS 30MG/5ML

A085380 001 Jul DISC

TABLET;ORAL

BUTISOL SODIUM

@ MEDA PHARMS 50MG

N000793 003 May DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

@ ELAN PHARMA INTL LTD 2%

N019881 001 Feb 07, 1997 May CTNA

GYNazole-1

+ PERRIGO ISRAEL 2%

A200923 001 May 18, 2012 Jun CTNA

CALCIPOTRIENECREAM; TOPICAL
CALCIPOTRIENE

AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May NEWA
----	---------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMONINJECTABLE; INJECTION
CALCITONIN-SALMON

	@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar CAHN
--	----------------	-----------	---------	-----	--------------	----------

MIACALCIN

>A>	@ MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug CAHN
>A>	+	200 IU/ML	N017808	002	Mar 29, 1991	Aug CAHN
>D>	@ SEBELA IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug CAHN
>D>	+	200 IU/ML	N017808	002	Mar 29, 1991	Aug CAHN

SPRAY, METERED; NASAL
MIACALCIN

>A> AB	+	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Aug CAHN
>D> AB	+	SEBELA IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Aug CAHN

CALCITRIOLCAPSULE; ORAL
CALCITRIOL

AB	BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
AB		0.5MCG	A091174	002	May 24, 2013	Jan CAHN
AB	STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan CAHN
AB		0.5MCG	A091356	002	Dec 12, 2014	Jan CAHN

INJECTABLE; INJECTION
CALCIJEX

	@ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun DISC
	@	0.002MG/ML	N018874	002	Sep 25, 1986	Jun DISC

CALCITRIOL

	@ AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun DISC
	@ FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun DISC
	@	0.002MG/ML	A075836	002	Dec 31, 2002	Jun DISC
	@ FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun DISC
	@	0.002MG/ML	A075766	002	Feb 20, 2003	Jun DISC
	@ LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun DISC
	@	0.002MG/ML	A075746	002	Sep 26, 2003	Jun DISC
	@ SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun DISC

CALCIUM ACETATECAPSULE; ORAL
CALCIUM ACETATE

AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun NEWA
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun NEWA

TABLET; ORAL

CALCIUM ACETATE

AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan NEWA
----	----------------------	------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA
---	---------------	--	---------	-----	--------------	----------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan NEWA
---	---------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

@	ALCON PHARMS LTD	0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N022193	001	Jul 24, 2008	Jun DISC
---	------------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 11	N017390	001		Mar	DISC
	9MG/100ML; 161MG/100ML; 94MG/100ML; 1					
	38MG/100ML					

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/1	N017438	001		Mar	DISC
	000ML; 640MG/100ML; 496MG/100ML; 89.6M					
	G/100ML					

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1	N207026	002	Jan 13, 2015	Feb	CAIN
		000ML; 2.21GM/1000ML; 6.95GM/1000ML;					
		0.187GM/1000ML (5000ML)					

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML; 3.05GM/1000ML; 0.314G	N207026	001	Jan 13, 2015	Feb	CAIN
		M/1000ML					
		; 3.09GM/1000ML; 6.34GM/1000ML; 0.187					

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG; 12.5MG	A204100	001	Feb 27, 2015	Feb	NEWA
AB		32MG; 12.5MG	A204100	002	Feb 27, 2015	Feb	NEWA
AB		32MG; 25MG	A204100	003	Feb 27, 2015	Feb	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr	NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr	NEWA

CAPTOPRIL

TABLET; ORAL

CAPOTEN

@	PAR PHARM	12.5MG	N018343	005	Jan 17, 1985	May	DISC
@		25MG	N018343	002		May	DISC
@		50MG	N018343	001		May	DISC
@		100MG	N018343	003		May	DISC

CAPTOPRIL

@	G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996	Jul	CAHN
@		12.5MG	A074462	001	Feb 13, 1996	Apr	CAHN
@		12.5MG	A074483	001	Feb 13, 1996	Jul	CAHN
@		12.5MG	A074590	004	Aug 30, 1996	Apr	CAHN
@		25MG	A074433	002	Feb 13, 1996	Jul	CAHN
@		25MG	A074462	002	Feb 13, 1996	Apr	CAHN
@		25MG	A074483	002	Feb 13, 1996	Jul	CAHN
@		25MG	A074590	002	Aug 30, 1996	Apr	CAHN
@		50MG	A074433	003	Feb 13, 1996	Jul	CAHN
@		50MG	A074462	003	Feb 13, 1996	Apr	CAHN
@		50MG	A074483	003	Feb 13, 1996	Jul	CAHN
@		50MG	A074590	001	Aug 30, 1996	Apr	CAHN
@		100MG	A074433	004	Feb 13, 1996	Jul	CAHN
@		100MG	A074462	004	Feb 13, 1996	Apr	CAHN
@		100MG	A074483	004	Feb 13, 1996	Jul	CAHN
@		100MG	A074590	003	Aug 30, 1996	Apr	CAHN
AB	+	MYLAN	A074434	004	Feb 13, 1996	May	CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG; 15MG	A074827	001	Dec 29, 1997	Apr	CAHN
AB		25MG; 25MG	A074827	002	Dec 29, 1997	Apr	CAHN
AB		50MG; 15MG	A074827	004	Dec 29, 1997	Apr	CAHN

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE					
AB	50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB		200MG	A076697	002	May 20, 2011	May CAHN
AB		300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL
RYTARY

	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
+		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA

SUSPENSION;ENTERAL
DUOPA

+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA
---	------------	-------------------	---------	-----	--------------	----------

CARISOPRODOL

TABLET;ORAL
CARISOPRODOL

AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
AA		350MG	A205126	002	Jul 08, 2015	Jun NEWA
AB	+ SOMA					
AB	+ MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL

TABLET;ORAL
CARVEDILOL

	@ HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
	@	6.25MG	A077887	002	Sep 07, 2007	Jun DISC
	@	12.5MG	A077887	003	Sep 07, 2007	Jun DISC
	@	25MG	A077887	004	Sep 07, 2007	Jun DISC
AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL
CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION
CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN
>A>	SOLUTION;INTRAVENOUS					
>A>	CEFAZOLIN IN PLASTIC CONTAINER					
>A>	CELERITY PHARMS	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Aug NEWA

CEFIXIME

FOR SUSPENSION;ORAL
CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
	SUPRAX					
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUMINJECTABLE;INJECTION
CEFOTAN

@ IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN
CEFOTAN IN PLASTIC CONTAINER					
@ IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET;ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTAZIDIME

INJECTABLE;INJECTION

FORTAZ

AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

FORTAZ IN PLASTIC CONTAINER

@ CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun CAHN
+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun CAHN
+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;IV (INFUSION)

ZERBAXA

>D>	+	CUBIST PHARMS	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug CAHN
>A>	+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN
----	-------------	-------------------	---------	-----	--------------	----------

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

@ FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN
@ FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul DISC

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN

TABLET;ORAL

CEFUROXIME AXETIL

AB	ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
AB		EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN
AB	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN

CEFUROXIME SODIUMINJECTABLE;INJECTION
CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN
	ZINACEF					
AP	+ CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN
	ZINACEF IN PLASTIC CONTAINER					
	@ CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
	+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN
	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
	CEFUROXIME SODIUM					
AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN
	ZINACEF					
AB	+ CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN

CELECOXIBCAPSULE;ORAL
CELECOXIB

>A>	AB	ALEMBIC PHARMS LTD	50MG	A204519	001	Aug 21, 2015	Aug NEWA
>A>	AB		100MG	A204519	002	Aug 21, 2015	Aug NEWA
>A>	AB		200MG	A204519	003	Aug 21, 2015	Aug NEWA
>A>	AB		400MG	A204519	004	Aug 21, 2015	Aug NEWA
	AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
	AB		100MG	A204197	002	Jun 02, 2015	May NEWA
	AB		200MG	A204197	003	Jun 02, 2015	May NEWA
	AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
	AB		200MG	A202240	003	Jun 09, 2015	May NEWA
	AB		400MG	A202240	004	Jun 09, 2015	May NEWA
	AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
	AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
	AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
	AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
	AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
	AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
	AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN
	FOR SUSPENSION;ORAL					
	CEPHALEXIN					
	@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
	@	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN

CETIRIZINE HYDROCHLORIDESYRUP;ORAL
ZYRTEC

>A>	AA	+ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug CAHN
>D>	AA	+ MCNEIL CONSUMER	5MG/5ML	N020346	001	Sep 27, 1996	Aug CAHN

CHLOROTHIAZIDE SODIUMINJECTABLE;INJECTION
CHLOROTHIAZIDE SODIUM

AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA
----	---------------	--------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATETABLET, EXTENDED RELEASE;ORAL
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE
SPRIASO LLC 8MG;54.3MG

N206323	001	Jun 22, 2015	Jun NEWA
---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATESOLUTION;ORAL
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
	VITUZ					
AA	+ CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
AA	COASTAL PHARMS	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Jul NEWA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUZISTRA XR

+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr NEWA
+	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

@	CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun CAHN
@		100MG/ML	A088158	001	Apr 27, 1983	Jun CAHN

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+	EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb CAHN
---	--------------------	---------	---------	-----	--	----------

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

@	CYCLE PHARMS LTD	10MG	A085331	001		Jun CAHN
@		25MG	A085331	002		Jun CAHN
@		50MG	A085331	003		Jun CAHN
@		100MG	A085331	004		Jun CAHN
@		200MG	A085331	005		Jun CAHN
@	SANDOZ	10MG	A080439	001		May DISC
@		25MG	A080439	002		May DISC
@		50MG	A080439	003		May DISC
@		100MG	A080439	004		May DISC
@		200MG	A080439	005		May DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

	@ G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr CAHN
AB	MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar CMFD
AB	+	MYLAN	A086831	001		Jun CTEC
	THALITONE					
	@ CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Jun DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>A>	@ ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Aug CAHN
>A>	@	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Aug CAHN
>D>	@ TEVA PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Aug CAHN
>D>	@	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Aug CAHN

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

	ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar NEWA
+		250MG	N205750	002	Mar 17, 2015	Mar NEWA
	RTRX	50MG	N205750	001	Mar 17, 2015	Apr CAHN
+		250MG	N205750	002	Mar 17, 2015	Apr CAHN

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP	+	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CRLD
		VISTIDE					
		@ GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

@ G AND W LABS INC

EQ 300MG BASE/5ML

A074176 001 Jun 01, 1994 Apr CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

AP CLARIS PHARMASERVICE 200MG/20ML (10MG/ML)

A078062 001 Apr 29, 2008 Apr CAHN

AP 400MG/40ML (10MG/ML)

A078062 002 Apr 29, 2008 Apr CAHN

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP CLARIS PHARMASERVICE 200MG/100ML

A078024 001 Mar 18, 2008 Apr CAHN

AP 400MG/200ML

A078024 002 Mar 18, 2008 Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB SUN PHARM INDS LTD EQ 250MG BASE

A075747 001 Jun 09, 2004 Apr CAHN

AB EQ 500MG BASE

A075747 002 Jun 09, 2004 Apr CAHN

AB EQ 750MG BASE

A075747 003 Jun 09, 2004 Apr CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP FRESENIUS KABI USA EQ 2MG BASE/ML

A203183 001 Feb 26, 2015 Feb NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP FRESENIUS KABI USA EQ 2MG BASE/ML

A203182 001 Feb 26, 2015 Feb NEWA

AP EQ 10MG BASE/ML

A203182 002 Feb 26, 2015 Feb NEWA

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

>A> AP ACCORD HLTHCARE 1MG/ML

A206774 001 Aug 18, 2015 Aug NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB G AND W LABS INC EQ 10MG BASE

A077048 001 Nov 16, 2004 Apr CAHN

AB EQ 20MG BASE

A077048 002 Nov 16, 2004 Apr CAHN

AB EQ 40MG BASE

A077048 003 Nov 16, 2004 Apr CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

AB SUN PHARM INDS LTD 125MG/5ML

A065382 001 Aug 30, 2007 Apr CAHN

AB 250MG/5ML

A065382 002 Aug 30, 2007 Apr CAHN

TABLET;ORAL

CLARITHROMYCIN

AB SUN PHARM INDS LTD 250MG

A065174 001 Sep 24, 2004 Apr CAHN

AB 500MG

A065174 002 Sep 24, 2004 Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

>A> AB LUPIN LTD 500MG

A202532 001 Sep 15, 2015 Aug NEWA

AB + TEVA 500MG

A065154 001 May 18, 2005 Jan CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION

TIMENTIN

@ GLAXOSMITHKLINE

EQ 100MG BASE/VIAL;EQ 3GM
BASE/VIAL

A062691 001 Dec 19, 1986 May DISC

@

EQ 100MG BASE/VIAL;EQ 3GM
BASE/VIAL

N050590 001 Apr 01, 1985 May DISC

@

EQ 200MG BASE/VIAL;EQ 3GM
BASE/VIAL

N050590 002 Apr 01, 1985 May DISC

@

EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL

N050590 003 Aug 18, 1987 May DISC

TIMENTIN IN PLASTIC CONTAINER

@ GLAXOSMITHKLINE

EQ 100MG BASE/100ML;EQ 3GM
BASE/100ML

N050658 001 Dec 15, 1989 May DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

@ ANI PHARMS INC

1.34MG

A073282 001 Jan 31, 1992 Jul CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB G AND W LABS INC

EQ 150MG BASE

A063029 001 Sep 20, 1989 Apr CAHN

AB EQ 300MG BASE

EQ 300MG BASE

A063029 002 Aug 05, 2005 Apr CAHN

AB SUN PHARM INDS LTD

EQ 150MG BASE

A065061 001 Feb 02, 2001 Apr CAHN

AB EQ 300MG BASE

EQ 300MG BASE

A065061 002 Feb 02, 2001 Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

@ IGI LABS INC

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989 Mar CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ BOCA PHARMA LLC

EQ 1% BASE

A062944 001 Jan 11, 1989 Jan CAHN

AT VINTAGE PHARMS

EQ 1% BASE

A203343 001 May 29, 2015 May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB ACTAVIS MID ATLANTIC

1.2%;0.025%

A202564 001 Jun 12, 2015 Jun NEWA

ZIANA

AB + MEDICIS

1.2%;0.025%

N050802 001 Nov 07, 2006 Jun CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2 + FOUGERA PHARMS

0.05%

A075430 001 May 26, 1999 May CRLD

CORMAX

AB1 + HI TECH PHARMA

0.05%

A074220 001 May 16, 1997 Jun CRLD

TEMOVATE

@ FOUGERA PHARMS

0.05%

N019322 001 Dec 27, 1985 Jun DISC

TEMOVATE E

@ FOUGERA PHARMS

0.05%

N020340 001 Jun 17, 1994 May DISC

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB + FOUGERA PHARMS

0.05%

A075368 001 Feb 15, 2000 May CRLD

TEMOVATE

@ FOUGERA PHARMS

0.05%

N020337 001 Apr 29, 1994 May DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB G AND W LABS INC

0.05%

A074089 001 Feb 16, 1994 Feb CAHN

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT G AND W LABS INC

0.05%

A074331 001 Dec 15, 1995 Mar CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

SEROPHENE

@ EMD SERONO

50MG

N018361 001 Mar 22, 1982 Jun DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB ACTAVIS LABS UT INC

0.1MG/24HR

A090873 001 May 06, 2014 Mar CAHN

AB 0.2MG/24HR

0.2MG/24HR

A090873 002 May 06, 2014 Mar CAHN

AB 0.3MG/24HR

0.3MG/24HR

A090873 003 May 06, 2014 Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ DAVA PHARMS INC

0.1MG

A071783 001 Apr 05, 1988 May DISC

@

0.2MG

A071784 001 Apr 05, 1988 May DISC

@

0.3MG

A071785 001 Apr 05, 1988 May DISC

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

AB2		ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	May NEWA
AB1			0.1MG	A203320	001	May 15, 2015	May NEWA
>D>	AB2		0.2MG	A202792	002	May 15, 2015	Aug DISC
>A>	@		0.2MG	A202792	002	May 15, 2015	Aug DISC
	AB2		0.2MG	A202792	002	May 15, 2015	May NEWA
>D>	AB1		0.2MG	A203320	002	May 15, 2015	Aug DISC
>A>	@		0.2MG	A203320	002	May 15, 2015	Aug DISC
	AB1		0.2MG	A203320	002	May 15, 2015	May NEWA
>D>	AB2	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Aug DISC
>A>	@		0.1MG	A202983	001	Apr 02, 2014	Aug DISC
	AB2		0.1MG	A202983	001	Apr 02, 2014	May CTEC
>D>	AB2		0.2MG	A202983	002	Apr 02, 2014	Aug DISC
>A>	@		0.2MG	A202983	002	Apr 02, 2014	Aug DISC
	AB2		0.2MG	A202983	002	Apr 02, 2014	May CTEC
CLONIDINE HYDROCHLORIDE							
	AB1	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May CTEC
>D>	AB1		0.2MG	A202984	002	Sep 30, 2013	Aug DISC
>A>	@		0.2MG	A202984	002	Sep 30, 2013	Aug DISC
	AB1		0.2MG	A202984	002	Sep 30, 2013	May CTEC
KAPVAY							
>D>	AB1	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Aug CRLD
>A>	AB1	+	0.1MG	N022331	003	Sep 28, 2010	Aug CRLD
	AB1		0.1MG	N022331	003	Sep 28, 2010	Jun CRLD
	AB1	+	0.1MG	N022331	003	Sep 28, 2010	May CTEC
>D>	AB1	+	0.2MG	N022331	004	Sep 28, 2010	Aug DISC
>A>	@		0.2MG	N022331	004	Sep 28, 2010	Aug DISC
	AB1	+	0.2MG	N022331	004	Sep 28, 2010	Jun CRLD
	AB1		0.2MG	N022331	004	Sep 28, 2010	May CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL
CLORAZEPATE DIPOTASSIUM

AB		SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr CAHN
AB			7.5MG	A076911	002	Sep 29, 2004	Apr CAHN
AB			15MG	A076911	003	Sep 29, 2004	Apr CAHN

CLOZAPINE

TABLET;ORAL
CLOZARIL

>A>	AB	HERITAGE LIFE	25MG	N019758	001	Sep 26, 1989	Aug CAHN
>A>	AB	+	100MG	N019758	002	Sep 26, 1989	Aug CAHN
>D>	AB	NOVARTIS	25MG	N019758	001	Sep 26, 1989	Aug CAHN
>D>	AB	+	100MG	N019758	002	Sep 26, 1989	Aug CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
>A>		CLOZAPINE					
>A>	AB	MYLAN PHARMS INC	25MG	A201824	002	Sep 15, 2015	Aug NEWA
>A>	AB		100MG	A201824	003	Sep 15, 2015	Aug NEWA
FAZACLO ODT							
>D>		JAZZ PHARMS III	25MG	N021590	001	Feb 10, 2004	Aug CFTG
>A>	AB		25MG	N021590	001	Feb 10, 2004	Aug CFTG
>D>	+		100MG	N021590	002	Feb 10, 2004	Aug CFTG
>A>	AB	+	100MG	N021590	002	Feb 10, 2004	Aug CFTG

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL
PREZCOBIX

+	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan NEWA
---	---------------	---------------------	---------	-----	--------------	----------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

>A>	AA	AMNEAL PHARMS	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A200963	001	Aug 26, 2015	Aug NEWA
-----	----	---------------	-------------------------------	---------	-----	--------------	----------

CODEINE SULFATE

SOLUTION;ORAL
CODEINE SULFATE

@	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jan DISC
---	--------	----------	---------	-----	--------------	----------

COLCHICINECAPSULE;ORAL
MITIGARE

HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014 Jan CAHN

COLCHICINE; PROBENECIDTABLET;ORAL
PROBENECID AND COLCHICINE

>A>	@ ANI PHARMS INC	0.5MG;500MG	A083734	001		Aug	CAHN
>D>	@ IVAX SUB TEVA PHARMS	0.5MG;500MG	A083734	001		Aug	CAHN

COLISTIMETHATE SODIUMINJECTABLE;INJECTION
COLISTIMETHATE SODIUM

AP XELLIA PHARMS APS EQ 150MG BASE/VIAL A205356 001 May 29, 2015 May NEWA

CORTICOTROPININJECTABLE;INJECTION
H.P. ACTHAR GEL

>A>	@ MALLINCKRODT ARD	40 UNITS/ML	N008372	006		Aug	CAHN
>A>	+	80 UNITS/ML	N008372	008		Aug	CAHN
>D>	@ QUESTCOR PHARMS	40 UNITS/ML	N008372	006		Aug	CAHN
>D>	+	80 UNITS/ML	N008372	008		Aug	CAHN

CYANOCOBALAMININJECTABLE;INJECTION
CYANOCOBALAMIN

@ EUROHLTH INTL SARL 1MG/ML A080515 002 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDETABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB	ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun	NEWA
AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr	CAHN
AB		7.5MG	A078722	002	May 12, 2008	Apr	CAHN
AB		10MG	A078722	003	May 12, 2008	Apr	CAHN

DABRAFENIB MESYLATECAPSULE;ORAL
TAFINLAR

	NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar	CAHN
+		EQ 75MG BASE	N202806	002	May 29, 2013	Mar	CAHN

DACLATASVIR DIHYDROCHLORIDETABLET;ORAL
DAKLINZA

	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jul	NEWA
+		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jul	NEWA

DALTEPARIN SODIUMINJECTABLE;INJECTION
FRAGMIN

	@ PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun	CAHN
	@ PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr	CAHN

INJECTABLE;SUBCUTANEOUS
FRAGMIN

	PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun	CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun	CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun	CAHN
	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun	CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun	CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun	CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun	CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun	CAHN
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun	CAHN
	@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun	CAHN
	PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr	CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr	CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr	CAHN
	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr	CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr	CAHN

INJECTABLE;SUBCUTANEOUS
FRAGMIN

		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr CAHN
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr CAHN
@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr CAHN

DANTROLENE SODIUM

CAPSULE;ORAL
DANTROLENE SODIUM

AB	ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May CAHN
AB		50MG	A076686	002	Oct 24, 2005	May CAHN
AB		100MG	A076686	003	Oct 24, 2005	May CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

AB	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar NEWA
AB		EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar NEWA
	ENABLEX					
AB	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar CFTG
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar CFTG

DECITABINE

INJECTABLE;INTRAVENOUS
DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
----	---	---------------------	-----------	---------	-----	--------------	----------

DEFERASIROX

TABLET;ORAL
JADENU

	NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar NEWA
		180MG	N206910	002	Mar 30, 2015	Mar NEWA
+		360MG	N206910	003	Mar 30, 2015	Mar NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL
DEMECLOCYCLINE HYDROCHLORIDE

>A>	AB	EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015	Aug NEWA
>A>	AB		300MG	A065447	002	Aug 18, 2015	Aug NEWA

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS
KYBELLA

+	KYThera BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr NEWA
---	-------------------	--------------------	---------	-----	--------------	----------

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS
IPRIVASK

+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May CAHN
---	----------------------	-----------	---------	-----	--------------	----------

DESLORATADINE

SOLUTION;ORAL
CLARINEX

AA	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun CFTG
		DESLORATADINE					
AA		TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun NEWA

DESMOPRESSIN ACETATE

TABLET;ORAL
DDAVP

AB	FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan CAHN
AB	+	0.2MG	N019955	002	Sep 06, 1995	Jan CAHN
	DESMOPRESSIN ACETATE					
AB	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May NEWA
AB		0.2MG	A201831	002	May 28, 2015	May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

BEKYREE

AB		LUPIN LTD	0.15MG,N/A;0.02MG,0.01MG	A202226	001	Aug 12, 2015	Jul	NEWA
		CYCLESSA						
>A>	AB	+ ASPEN GLOBAL INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N021090	001	Dec 20, 2000	Aug	CAHN
>D>	AB	+ ORGANON USA INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N021090	001	Dec 20, 2000	Aug	CAHN
		ISIBLOOM						
AB		SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Jul	NEWA
		KARIVA						
AB		+ BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr	CTEC
		KIMIDESS						
AB		VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr	NEWA

DESONIDE

CREAM; TOPICAL

DESONIDE

AB		TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May	CMFD
----	--	-------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

>A>	AB	ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug	NEWA
	AB	VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun	NEWA

OINTMENT; TOPICAL

DESOXIMETASONE

AB		PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr	NEWA
----	--	------------------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB		ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun	NEWA
AB			EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun	NEWA
AB		LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun	NEWA
AB			EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun	NEWA
AB		MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	NEWA
AB			EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	NEWA
AB		SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun	NEWA
AB			EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun	NEWA
		PRISTIQ						
AB		+ WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun	CFTG
AB			EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun	CFTG

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

		@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar	CAHN
AP		+	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

AT		+ ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar	CAHN
----	--	------------------	---------------------------------------	---------	-----	--	-----	------

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

AT		+ ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar	CAHN
----	--	------------------	---------------------------------------	---------	-----	--	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

>A>	AP	SUN PHARM INDS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	Aug	NEWA
		PRECEDEX						
		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015	Aug NEWA
>A>	AB		10MG	A204266	002	Aug 25, 2015	Aug NEWA
>A>	AB		15MG	A204266	003	Aug 25, 2015	Aug NEWA
>A>	AB		40MG	A204266	007	Aug 25, 2015	Aug NEWA
	AB	WATSON LABS INC	5MG	A079108	001	Aug 05, 2015	Jul NEWA
	AB		10MG	A079108	002	Aug 05, 2015	Jul NEWA

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;36	N017451	001			Mar DISC
		8MG/100ML;526MG/100ML;502MG/100ML					

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION

MD-76R

AP	+	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Feb CAHN
		SOLUTION;ORAL, RECTAL					
		MD-GASTROVIEW					

AA		LIEBEL-FLARSHEIM	66%;10%	A087388	001		Jan CAHN
----	--	------------------	---------	---------	-----	--	----------

DICHLORPHENAMIDE

TABLET;ORAL

KEVEYIS

>A>							
>A>		TARO	50MG	N011366	002	Aug 07, 2015	Aug NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

VOLTAREN

>A>	+	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Aug CAHN
>D>	+	NOVARTIS	1%	N022122	001	Oct 17, 2007	Aug CAHN

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT		IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun NEWA
>A>	AT	LUPIN LTD	1.5%	A204132	001	Aug 20, 2015	Aug NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Mar CAHN
		TABLET, EXTENDED RELEASE;ORAL					

AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Mar CAHN
		TENUATE DOSPAN					

DIFLORASONE DIACETATE

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		VERSAPHARM INC	0.05%	A206572	001	Jul 24, 2015	Jul NEWA
----	--	----------------	-------	---------	-----	--------------	----------

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar CAHN
----	--	-----------------	-------	---------	-----	--------------	----------

DIGOXIN

INJECTABLE;INJECTION

DIGOXIN

AP		EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb CAHN
----	--	--------------------	-----------	---------	-----	--	----------

TABLET;ORAL

DIGOXIN

AB		MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan CTEC
AB			0.25MG	A040282	002	Dec 23, 1999	Jan CTEC
AB		SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb CMFD
AB			0.25MG	A076363	002	Jan 31, 2003	Feb CMFD

LANOXIN

		CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr CAHN
AB			0.125MG	N020405	002	Sep 30, 1997	Apr CAHN

TABLET;ORAL
LANOXIN

		0.1875MG	N020405	003	Sep 30, 1997	Apr CAHN
AB	+	0.25MG	N020405	004	Sep 30, 1997	Apr CAHN
	@	0.375MG	N020405	005	Sep 30, 1997	Apr CAHN
	@	0.5MG	N020405	006	Sep 30, 1997	Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb CRLD
		TIAZAC					
AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb CAHN
		INJECTABLE;INJECTION					
		DILTIAZEM HYDROCHLORIDE					
AP		EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jun CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002		Jun CAHN
----	---	--------------------	---------	---------	-----	--	----------

DIPYRIDAMOLE

INJECTABLE;INJECTION
DIPYRIDAMOLE

AP		EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996	Jun CAHN
----	--	--------------------	--------	---------	-----	--------------	----------

DISULFIRAM

TABLET;ORAL
DISULFIRAM

AB		MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb NEWA
AB			500MG	A203916	002	Mar 04, 2015	Feb NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

AB		AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May NEWA
AB			EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May NEWA
	@	G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jul CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

	@	IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar CAHN
--	---	--------------	-------------------	---------	-----	--------------	----------

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

>A>	AP	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015	Aug NEWA
>A>	AP		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015	Aug NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB		HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan NEWA
AB			10MG	A203034	002	Jan 30, 2015	Jan NEWA
AB		SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr CAHN
AB			10MG	A076786	002	Nov 26, 2010	Apr CAHN
AB			23MG	A204293	001	Jun 05, 2015	May NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC

		FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Mar CAHN
+			10MG;28MG	N206439	002	Dec 23, 2014	Mar CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

@	IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar CAHN
@		40MG/ML	N018656	001	Jun 28, 1983	Mar CAHN
@		80MG/ML	A070089	001	Oct 23, 1985	Mar CAHN
@		80MG/ML	A070090	001	Oct 23, 1985	Mar CAHN
@		80MG/ML	A070091	001	Oct 23, 1985	Mar CAHN
@		160MG/ML	A070092	001	Oct 23, 1985	Mar CAHN
@		160MG/ML	A070093	001	Oct 23, 1985	Mar CAHN
@		160MG/ML	A070094	001	Oct 23, 1985	Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOPRAM

AP	+	EUROHLTH INTL SARL	20MG/ML	N014879	001	Jun CAHN
----	---	--------------------	---------	---------	-----	----------

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan CRLD

CREAM; TOPICAL
ZONALON

	+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar CAHN
--	---	-------------------	----	---------	-----	--------------	----------

DOXERCALCIFEROL

INJECTABLE; INJECTION
DOXERCALCIFEROL

AP		AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr NEWA
----	--	-----------	--------------------	---------	-----	--------------	----------

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB		NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May NEWA
AB			EQ 75MG BASE	A204446	002	May 28, 2015	May NEWA
AB			EQ 100MG BASE	A204446	003	May 28, 2015	May NEWA
AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr CAHN
AB			EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr CAHN
AB			EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr CAHN

TABLET; ORAL
DOXYCYCLINE

AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr CAHN
AB			EQ 75MG BASE	A065356	002	May 31, 2006	Apr CAHN
AB			EQ 100MG BASE	A065356	003	May 31, 2006	Apr CAHN

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION
DOXYCYCLINE

@	EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun CAHN
@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun CAHN

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar CAHN
@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar CAHN
@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
DROSPIRENONE AND ETHINYL ESTRADIOL

>A>	AB	GLENMARK PHARMS LTD	3MG;0.02MG	A204296	001	Aug 17, 2015	Aug NEWA
-----	----	---------------------	------------	---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	EQ 20MG BASE	A203197	001	Aug 26, 2015	Aug NEWA
>A>	AB		EQ 30MG BASE	A203197	002	Aug 26, 2015	Aug NEWA
>A>	AB		EQ 60MG BASE	A203197	003	Aug 26, 2015	Aug NEWA

ECONAZOLE NITRATECREAM; TOPICAL
ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATETABLET; ORAL
SAVAYSA

	DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan NEWA
		EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan NEWA
+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan NEWA

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
ENLON

+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD
	TENSILON					
	@ IGI LABS INC	10MG/ML	N007959	001		Apr CAHN
	@ VALEANT PHARMS	10MG/ML	N007959	001		Mar DISC
	TENSILON PRESERVATIVE FREE					
	@ IGI LABS INC	10MG/ML	N007959	002		Apr CAHN
	@ VALEANT PHARMS	10MG/ML	N007959	002		Mar DISC

>A> ELTROMBOPAG OLAMINE>A> FOR SUSPENSION; ORAL
>A> PROMACTA

>A>	+	NOVARTIS PHARMS CORP	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Aug NEWA
		TABLET; ORAL					
		PROMACTA					
		NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar CAHN
			EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar CAHN
			EQ 50MG ACID	N022291	002	Nov 20, 2008	May CRLD
	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar CAHN
	+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May CRLD
			EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar CAHN
	+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May CRLD
			EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar CAHN

ELUXADOLINETABLET; ORAL
VIBERZI

	FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	Jul CAHN
+		100MG	N206940	002	May 27, 2015	Jul CAHN
	FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May NEWA
+		100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTINTABLET; ORAL
GLYXAMBI

	BOEHRINGER INGELHEIM	10MG; 5MG	N206073	001	Jan 30, 2015	Jan NEWA
+		25MG; 5MG	N206073	002	Jan 30, 2015	Jan NEWA

>A> EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE>A> TABLET; ORAL
>A> SYNJARDY

>A>		BOEHRINGER INGELHEIM	5MG; 500MG	N206111	001	Aug 26, 2015	Aug NEWA
>A>			5MG; 1GM	N206111	002	Aug 26, 2015	Aug NEWA
>A>			12.5MG; 500MG	N206111	003	Aug 26, 2015	Aug NEWA
>A>	+		12.5MG; 1GM	N206111	004	Aug 26, 2015	Aug NEWA

ENALAPRIL MALEATETABLET; ORAL
ENALAPRIL MALEATE

AB	SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB		5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB		10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB		20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@ SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@	5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@	10MG	A075556	003	Aug 22, 2000	Apr CAHN

TABLET;ORAL

ENALAPRIL MALEATE

@

20MG

A075556 004 Aug 22, 2000 Apr CAHN

VASOTEC

AB VALEANT PHARMS NORTH 2.5MG

N018998 005 Jul 26, 1988 Apr CAHN

AB 5MG

N018998 001 Dec 24, 1985 Apr CAHN

AB 10MG

N018998 002 Dec 24, 1985 Apr CAHN

AB + 20MG

N018998 003 Dec 24, 1985 Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB G AND W LABS INC 5MG;12.5MG

A075727 001 Sep 18, 2001 Apr CAHN

AB 10MG;25MG

A075727 002 Sep 18, 2001 Apr CAHN

ENTACAPONE

TABLET;ORAL

ENTACAPONE

AB AUROBINDO PHARMA LTD 200MG

A203437 001 Jun 19, 2015 Jun NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

>A> AB AUROBINDO PHARMA LTD 0.5MG

A206217 001 Aug 26, 2015 Aug NEWA

>A> AB 1MG

A206217 002 Aug 26, 2015 Aug NEWA

>A> AB HETERO LABS LTD V 0.5MG

A205740 001 Aug 21, 2015 Aug NEWA

>A> AB 1MG

A205740 002 Aug 21, 2015 Aug NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N204200 001 Dec 07, 2012 Jul CAIN

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML)

N204640 001 Dec 18, 2013 Jul CAIN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEVETEN HCT

@ ABBVIE

600MG;12.5MG

N021268 001 Nov 01, 2001 Jun DISC

@

600MG;25MG

N021268 002 Nov 01, 2001 Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP TEVA PHARMS USA 2MG/ML

A090854 001 Jun 12, 2015 Jun NEWA

AP 75MG/100ML

A091555 001 Jun 05, 2015 May NEWA

INTEGRILIN

AP + SCHERING 2MG/ML

N020718 001 May 18, 1998 Jun CTEC

AP + 75MG/100ML

N020718 002 May 18, 1998 May CFTG

ERGOCALCIFEROL

CAPSULE;ORAL

VITAMIN D

AA BANNER LIFE SCIENCES 50,000 IU

A080704 001 Jan CAHN

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOSTAT

>D> @ PARKE DAVIS 2MG

A088337 001 Jun 08, 1984 Aug CAHN

>A> @ WATSON LABS INC 2MG

A088337 001 Jun 08, 1984 Aug CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

>A> AB TEVA PHARMS USA EQ 100MG BASE

A091059 002 Aug 28, 2015 Aug NEWA

>A> AB EQ 150MG BASE

A091059 003 Aug 28, 2015 Aug NEWA

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

@ G AND W LABS INC

EQ 125MG BASE/5ML

A062169 001 Oct 17, 1990 Apr CAHN

@

EQ 250MG BASE/5ML

A062169 002 Oct 17, 1990 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ ANI PHARMS INC

EQ 200MG BASE/5ML

A062055 001

Jul CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA ANTRIM PHARMS LLC

EQ 5MG BASE/5ML

A203967 001 May 26, 2015 May NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB MYLAN PHARMS INC

EQ 5MG BASE

A077550 001 May 14, 2015 Apr NEWA

AB

EQ 10MG BASE

A077550 002 May 14, 2015 Apr NEWA

AB

EQ 20MG BASE

A077550 003 May 14, 2015 Apr NEWA

>A> AB PRINSTON INC

EQ 5MG BASE

A078032 001 Aug 28, 2015 Aug NEWA

>A> AB

EQ 10MG BASE

A078032 002 Aug 28, 2015 Aug NEWA

>A> AB

EQ 20MG BASE

A078032 003 Aug 28, 2015 Aug NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP AUROBINDO PHARMA LTD

10MG/ML

A205520 001 Jul 23, 2015 Jul NEWA

AP LUITPOLD

10MG/ML

A201126 001 Feb 20, 2015 Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB IVAX SUB TEVA PHARMS

EQ 20MG BASE

A078003 001 Jan 26, 2015 Jan NEWA

AB

EQ 40MG BASE

A078003 002 Jan 26, 2015 Jan NEWA

AB MYLAN LABS LTD

EQ 20MG BASE

A078936 001 Aug 02, 2015 Jul NEWA

AB

EQ 40MG BASE

A078936 002 Aug 03, 2015 Jul NEWA

NEXIUM

AB ASTRAZENECA PHARMS

EQ 20MG BASE

N021153 001 Feb 20, 2001 Jan CFTG

AB +

EQ 40MG BASE

N021153 002 Feb 20, 2001 Jan CFTG

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

>D> HANMI PHARM CO LTD

EQ 20MG BASE

N202342 001 Aug 06, 2013 Aug CPOT

>A>

24.65MG

N202342 001 Aug 06, 2013 Aug CPOT

>D> +

EQ 40MG BASE

N202342 002 Aug 06, 2013 Aug CPOT

>A> +

49.3MG

N202342 002 Aug 06, 2013 Aug CPOT

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX ACTAVIS LABS UT INC

0.025MG/24HR

N020655 004 Apr 05, 2002 Mar CAHN

BX

0.05MG/24HR

N020655 001 Dec 20, 1996 Mar CAHN

BX

0.075MG/24HR

N020655 002 Dec 20, 1996 Mar CAHN

BX

0.1MG/24HR

N020655 003 Dec 20, 1996 Mar CAHN

MINIVELLE

NOVEN

0.025MG/24HR

N203752 005 Sep 23, 2014 Jan NEWA

TABLET;VAGINAL

ESTRADIOL

@ AMNEAL PHARMS

10MCG

A205256 001 May 29, 2015 May DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB MACLEODS PHARMS LTD

1MG

A202929 001 Jan 30, 2015 Jan NEWA

AB

2MG

A202929 002 Jan 30, 2015 Jan NEWA

AB

3MG

A202929 003 Jan 30, 2015 Jan NEWA

ETHACRYNATE SODIUMINJECTABLE; INJECTION
EDECRIN

AP	+	ATON	EQ 50MG BASE/VIAL	N016093	001		Jul	CFTG
AP		ETHACRYNATE SODIUM						
AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Jul	NEWA

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL
ETHAMBUTOL HYDROCHLORIDE

AB		VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan	CMFD
AB			400MG	A075095	002	Nov 30, 1999	Jan	CMFD

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
ASHLYNA

AB		GLENMARK GENERICS	0.03MG; 0.01MG; 0.15MG, N/A	A203163	001	Feb 23, 2015	Feb	NEWA	
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
AB		GLENMARK GENERICS	0.02MG; 0.09MG	A202791	001	Apr 09, 2015	Mar	NEWA	
AB		GLENMARK PHARMS LTD	0.03MG; 0.15MG	A203164	001	Jun 12, 2015	Jun	NEWA	
AB	+	WATSON LABS	0.02MG; 0.09MG	A079218	001	Jun 06, 2011	Mar	CTEC	
		TABLET; ORAL-28							
		LEVORA 0.15/30-28							
>D>	AB	WATSON LABS	0.03MG; 0.15MG	A073594	001	Dec 13, 1993	Aug	CRLD	
>A>	AB	+	0.03MG; 0.15MG	A073594	001	Dec 13, 1993	Aug	CRLD	
>D>		NORDETTE-28							
>D>	AB	+	TEVA BRANDED PHARM	0.03MG; 0.15MG	N018782	001	Jul 21, 1982	Aug	DISC
>A>		@	0.03MG; 0.15MG	N018782	001	Jul 21, 1982	Aug	DISC	
		VIENVA							
AB1		SANDOZ INC	0.02MG; 0.1MG	A201088	001	May 21, 2015	May	NEWA	

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE; TRANSDERMAL
ORTHO EVRA

		@ JANSSEN PHARMS	0.035MG/24HR; 0.15MG/24HR	N021180	001	Nov 20, 2001	Feb	DISC
		XULANE						
AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR; 0.15MG/24HR	A200910	001	Apr 16, 2014	Feb	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

		BREVICON 21-DAY						
		@ ACTAVIS LABS UT INC	0.035MG; 0.5MG	N017566	001		Mar	CAHN
		NORINYL 1+35 21-DAY						
AB		ACTAVIS LABS UT INC	0.035MG; 1MG	N017565	001		Feb	CAHN
		TRI-NORINYL 21-DAY						
		@ ACTAVIS LABS UT INC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	001	Apr 13, 1984	Feb	CAHN

TABLET; ORAL-28

		BREVICON 28-DAY						
AB		ACTAVIS LABS UT INC	0.035MG; 0.5MG	N017743	001		Mar	CAHN
		NORETHINDRONE AND ETHINYL ESTRADIOL						
AB		FAMY CARE LTD	0.035MG; 0.4MG	A200897	001	May 11, 2015	Apr	NEWA
AB	+	JAI PHARMA LTD	0.035MG; 0.4MG	A200897	001	May 11, 2015	Jul	CRLD
	+		0.05MG; 1MG	A203006	001	Aug 05, 2013	Jul	CTEC
		NORINYL 1+35 28-DAY						
AB		ACTAVIS LABS UT INC	0.035MG; 1MG	N017565	002		Feb	CAHN
		OVCON-35						
		@ WARNER CHILCOTT LLC	0.035MG; 0.4MG	N017716	001		Jul	DISC
		TRI-NORINYL 28-DAY						
AB	+	ACTAVIS LABS UT INC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	002	Apr 13, 1984	Feb	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATETABLET; ORAL
FEMHRT

AB		WARNER CHILCOTT LLC	0.0025MG; 0.5MG	N021065	001	Jan 14, 2005	Mar	CTEC
		LARIN 24 FE						
AB		NOVAST LABS LTD	0.02MG; 1MG	A202994	001	Feb 18, 2015	Feb	NEWA
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	+	BARR LABS INC	0.005MG; 1MG	A076221	001	Nov 06, 2009	Mar	CTEC
AB		GLENMARK GENERICS	0.0025MG; 0.5MG	A203038	001	Apr 02, 2015	Mar	NEWA

TABLET;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL									
AB		0.005MG;1MG	A203038	002	Apr 02, 2015	Mar	NEWA		
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE									
AB	+	AMNEAL PHARMS 0.02MG;1MG	A078267	001	Sep 01, 2009	Jan	CRLD		

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL									
>A> AB	JAI PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132	001	Sep 09, 2015	Aug	NEWA		
AB	OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG	A200383	001	Apr 07, 2015	Mar	NEWA		
AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar	NEWA		
TRI-LO-ESTARYLLA									
AB	SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015	Jun	NEWA		

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28									
AB	WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb	CMFD		

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE									
AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan	CAHN		

ETONOGESTREL

IMPLANT;IMPLANTATION

IMPLANON									
	@ ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun	DISC		

EZETIMIBE

TABLET;ORAL

EZETIMIBE									
AB	@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun	DISC		
		10MG	A078560	001	Jun 26, 2015	Jun	NEWA		
ZETIA									
AB	+	MSD INTL GMBH 10MG	N021445	001	Oct 25, 2002	Jun	CTEC		
	+	10MG	N021445	001	Oct 25, 2002	Jun	CFTG		

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE									
AP	+	EUROHLTH INTL SARL 10MG/ML	A075488	001	Apr 16, 2001	Jun	CAHN		
FAMOTIDINE PRESERVATIVE FREE									
AP	+	EUROHLTH INTL SARL 10MG/ML	A075486	001	Apr 16, 2001	Jun	CAHN		

TABLET;ORAL

PEPCID									
AB		VALEANT PHARMS NORTH 20MG	N019462	001	Oct 15, 1986	Feb	CAHN		
AB	+	40MG	N019462	002	Oct 15, 1986	Feb	CAHN		

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE									
AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May	NEWA		
AB		5MG	A203032	002	May 21, 2015	May	NEWA		
AB		10MG	A203032	003	May 21, 2015	May	NEWA		
AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr	CAHN		
AB		5MG	A091200	002	Dec 13, 2013	Apr	CAHN		
AB		10MG	A091200	003	Dec 13, 2013	Apr	CAHN		

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE									
AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr	CAHN		
AB		130MG	A201748	002	Oct 31, 2014	Apr	CAHN		

TABLET;ORAL

FENOFIBRATE									
>A> AB	LUPIN LTD	54MG	A204019	001	Aug 17, 2015	Aug	NEWA		
>A> AB		160MG	A204019	002	Aug 17, 2015	Aug	NEWA		

TABLET;ORAL

FENOFIBRATE

AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr CAHN
		107MG	A076635	002	Oct 31, 2005	Apr CAHN
AB		160MG	A076635	003	Oct 31, 2005	Apr CAHN
>D> AB	VALEANT BARBADOS SRL	48MG	A090715	001	Apr 05, 2012	Aug CAHN
>D> AB		145MG	A090715	002	Apr 05, 2012	Aug CAHN
>A> AB	VALEANT PHARMS NORTH	48MG	A090715	001	Apr 05, 2012	Aug CAHN
>A> AB		145MG	A090715	002	Apr 05, 2012	Aug CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

	TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
	FENTANYL-12					
AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun NEWA
	FENTANYL-25					
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
	FENTANYL-50					
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
	FENTANYL-75					
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar CAHN
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar CAHN
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar CAHN
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar CAHN
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
----	---	--------------------	-------------------	---------	-----	--------------	----------

FENTANYL HYDROCHLORIDE

SYSTEM;IONTOPHORESIS, TRANSDERMAL

IONSYS

@	THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr CAHN
+		EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun CMFD

FERRIC CITRATE

TABLET;ORAL

AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan CTNA
---	-----------------	---------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)

TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan NEWA
---	----------------------	----------------------------------	---------	-----	--------------	----------

FIDAXOMICIN

TABLET;ORAL

DIFICID

>D>	+	CUBIST PHARMS	200MG	N201699	001	May 27, 2011	Aug CAHN
>A>	+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Aug CAHN

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr CAHN
AB		100MG	A075882	002	Oct 28, 2002	Apr CAHN
AB		150MG	A075882	003	Oct 28, 2002	Apr CAHN
AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun NEWA
AB		100MG	A202821	002	Jul 08, 2015	Jun NEWA
AB		150MG	A202821	003	Jul 08, 2015	Jun NEWA

TABLET;ORAL

FLECAINIDE ACETATE

AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr CAHN

>A> FLIBANSERIN

>A> TABLET;ORAL

>A> ADDYI

>A>	+	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015	Aug NEWA
-----	---	---------------	-------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr CAHN
AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr NEWA
		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr CAHN

TABLET;ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May CMFD
AB		100MG	A078423	002	Mar 07, 2011	May CMFD
AB		150MG	A078423	003	Mar 07, 2011	May CMFD
AB		200MG	A078423	004	Mar 07, 2011	May CMFD

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

>A>	AP	IBA MOLECULAR N AM	20-300mCi/ML	A203591	001	Aug 31, 2015	Aug NEWA
	AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr NEWA
>A>	AP	MIPS CRF	20-300mCi/ML	A204472	001	Sep 11, 2015	Aug NEWA
		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar NEWA
>A>		QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Aug NEWA
		SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr NEWA
	AP	UNIV MICHIGAN	20-300mCi/ML	A204531	001	Jul 17, 2015	Jul NEWA

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

	@	CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr CAHN
	@		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr CAHN
AP		EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun NEWA
----	----------------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

>A>	AT	GAVIS PHARMS LLC	0.01%	A206422	001	Sep 02, 2015	Aug NEWA
-----	----	------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

GEL;TOPICAL

FLUOCINONIDE

AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr CAHN
----	------------------	-------	---------	-----	--------------	----------

FLUOROURACILCREAM; TOPICAL
CARAC

AB	+	VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr CFTG
	+		0.5%	N020985	001	Oct 27, 2000	Feb CAHN
FLUOROURACIL							
AB		SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

	@	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar DISC
	@		EQ 20MG BASE	A076287	002	May 20, 2008	Mar DISC
	+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar CRLD
			EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar CTEC
	@	SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar DISC
	@		EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar DISC
AB1		SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar NEWA
AB1			EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar NEWA
AB			EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar NEWA
AB		SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr CAHN

FLURANDRENOLIDEOINTMENT; TOPICAL
CORDRAN

+	AQUA PHARMS	0.05%	N012806	001		Jun CRLD
		0.05%	N012806	001		May CMFD

TAPE; TOPICAL
CORDRAN

+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar CAHN
---	---------------------	---------------	---------	-----	--	----------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION
BREO ELLIPTA

GLAXO GRP LTD	0.2MG/INH; EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr NEWA
---------------	--------------------------------	---------	-----	--------------	----------

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL

>A>		FLUVASTATIN SODIUM					
>A>	AB	MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	Aug NEWA
		LESCOL XL					
>D>	+	NOVARTIS	80MG	N021192	001	Oct 06, 2000	Aug CFTG
>A>	AB	+	80MG	N021192	001	Oct 06, 2000	Aug CFTG

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB		ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001	Jul CAHN
	@		25MG	A075898	001	Mar 12, 2001	Jul CAHN
AB			50MG	A075897	002	Jan 25, 2001	Jul CAHN
	@		50MG	A075898	002	Mar 12, 2001	Jul CAHN
AB			100MG	A075897	003	Jan 25, 2001	Jul CAHN
	@		100MG	A075898	003	Mar 12, 2001	Jul CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

>A>	AA	AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Aug CAHN
>D>	AA	BICON PHARM	1MG	A091145	001	Jul 12, 2013	Aug CAHN
	AA	NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015	Jul NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	10MG; 12.5MG	A076739	001	Dec 17, 2004	Apr CAHN
AB			20MG; 12.5MG	A076739	002	Dec 17, 2004	Apr CAHN

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

@ IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar CAHN
@	10MG/ML	A070096	001	Sep 09, 1985	Mar CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr CAHN
AB		300MG	A076606	002	Oct 07, 2005	Apr CAHN
AB		400MG	A076606	003	Oct 07, 2005	Apr CAHN

TABLET; ORAL
GABAPENTIN

@ HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun DISC
@	800MG	A078782	002	Jul 21, 2011	Jun DISC

GADOVERSETAMIDE

INJECTABLE; INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb CAHN
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb CAHN

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb CAHN

GEFITINIB

TABLET; ORAL
IRESSA

+	ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul NEWA
---	--------------------	-------	---------	-----	--------------	----------

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

>A> AB	AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015	Aug NEWA
--------	----------------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE

AB	+	LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG
AB		GEMIFLOXACIN MESYLATE					
AB		ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun NEWA

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS
COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar CFTG
AP		GLATOPIA					
AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar NEWA

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

@ HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr DISC
@	2MG	A078952	002	Aug 01, 2013	Apr DISC
@	4MG	A078952	003	Aug 01, 2013	Apr DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDARYL

@ SB PHARMC	1MG; 4MG	N021700	001	Nov 23, 2005	Jun DISC
@	2MG; 4MG	N021700	002	Nov 23, 2005	Jun DISC
@	2MG; 8MG	N021700	004	Mar 30, 2007	Jun DISC
@	4MG; 4MG	N021700	003	Nov 23, 2005	Jun DISC
@	4MG; 8MG	N021700	005	Mar 30, 2007	Jun DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>A>	@ ANI PHARMS INC	5MG	A074387	001	Mar 04, 1996	Aug CAHN
>A>	@	10MG	A074387	002	Mar 04, 1996	Aug CAHN
>D>	@ TEVA	5MG	A074387	001	Mar 04, 1996	Aug CAHN
>D>	@	10MG	A074387	002	Mar 04, 1996	Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB	MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May NEWA
AB		5MG	A202298	002	May 19, 2015	May NEWA
AB		10MG	A202298	003	May 19, 2015	May NEWA

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May NEWA
---	--------------------	------------------	---------	-----	--------------	----------

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN
---	---------------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001	Jun CAHN
----	---	--------------------	----------	---------	-----	----------

TABLET; ORAL

GLYCOPYRROLATE

AA		SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr CAHN
AA			2MG	A040844	002	Aug 18, 2009	Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN
AP		EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+	MIKART INC	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	May NEWA
---	------------	--------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
AB		SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
AB			EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
AB			EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
AB			EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
AB		TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
AB		TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@ CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
@	1MG	A071129	001	Feb 17, 1987	Jun CAHN
@	5MG	A071131	001	Feb 17, 1987	Jun CAHN
@	10MG	A071132	001	May 12, 1987	Jun CAHN
@	20MG	A071133	001	May 12, 1987	May CAHN
@ ROXANE	2MG	A071130	001	Feb 17, 1987	Jun CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL INTENSOL

@ CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May CAHN
--------------------	----------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

HALOPERIDOL

@ CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr CAHN
@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

>D>	@ BAXTER HLTHCARE CORP	1,000 UNITS/ML	N017007	001		Aug CAHN
>D>	@	2,500 UNITS/ML	N017007	007		Aug CAHN
>D>	@	5,000 UNITS/ML	N017007	002		Aug CAHN
>D>	@	5,000 UNITS/0.5ML	N017007	010		Aug CAHN
>D>	@	7,500 UNITS/ML	N017007	003		Aug CAHN
>D>	@	10,000 UNITS/ML	N017007	004		Aug CAHN
>D>	@	15,000 UNITS/ML	N017007	005		Aug CAHN
>D>	@	20,000 UNITS/ML	N017007	006		Aug CAHN
>A>	@ EUROHLTH INTL SARL	1,000 UNITS/ML	N017007	001		Aug CAHN
AP	+	1,000 UNITS/ML	N017037	001		Jun CAHN
>A>	@	2,500 UNITS/ML	N017007	007		Aug CAHN
>A>	@	5,000 UNITS/ML	N017007	002		Aug CAHN
>A>	@	5,000 UNITS/0.5ML	N017007	010		Aug CAHN
AP	+	5,000 UNITS/ML	N017037	002		Jun CAHN
	@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jun CAHN
>A>	@	7,500 UNITS/ML	N017007	003		Aug CAHN
>A>	@	10,000 UNITS/ML	N017007	004		Aug CAHN
AP	+	10,000 UNITS/ML	N017037	003		Jun CAHN
>A>	@	15,000 UNITS/ML	N017007	005		Aug CAHN
>A>	@	20,000 UNITS/ML	N017007	006		Aug CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb CRLD
AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Jun NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014	Aug DISC
>A>		@	12.5MG	A090651	001	Apr 07, 2014	Aug DISC

MICROZIDE

AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb CAHN
----	---	---------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG; 10MG	A076007	001	Jul 01, 2002	Apr CAHN
AB			12.5MG; 20MG	A076007	002	Jul 01, 2002	Apr CAHN
AB			25MG; 20MG	A076007	003	Jul 01, 2002	Apr CAHN

ZESTORETIC

AB		ALVOGEN IPCO SARL	12.5MG; 10MG	N019888	003	Nov 18, 1993	Feb CAHN
AB	+		12.5MG; 20MG	N019888	001	Sep 20, 1990	Feb CAHN
AB	+		25MG; 20MG	N019888	002	Jul 20, 1989	Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DUTOPROL

CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun CAHN
	12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun CAHN
+	12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986	Jul CAHN
>A> AB	25MG;40MG	A072042	001	Mar 14, 1988	Aug CAHN
@	25MG;80MG	A070705	001	Oct 01, 1986	Jul CAHN
>A> AB	25MG;80MG	A072043	001	Mar 14, 1988	Aug CAHN
>D> AB	PLIVA 25MG;40MG	A072042	001	Mar 14, 1988	Aug CAHN
>D> AB	25MG;80MG	A072043	001	Mar 14, 1988	Aug CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr CAHN
AB		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr CAHN
AB		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A>	@ ANI PHARMS INC	25MG;37.5MG	A074970	001	Jan 06, 1998	Aug CAHN
>D>	@ BARR	25MG;37.5MG	A074970	001	Jan 06, 1998	Aug CAHN

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A> AB	ANI PHARMS INC	50MG;75MG	A073467	001	Jan 31, 1996	Aug CAHN
>D> AB	PLIVA	50MG;75MG	A073467	001	Jan 31, 1996	Aug CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr CAHN
		15MG	N202880	002	Oct 25, 2013	Apr CAHN
		20MG	N202880	003	Oct 25, 2013	Apr CAHN
		30MG	N202880	004	Oct 25, 2013	Apr CAHN
		40MG	N202880	005	Oct 25, 2013	Apr CAHN
		50MG	N202880	006	Oct 25, 2013	Apr CAHN
+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Jun CAHN
		15MG	N202880	002	Oct 25, 2013	Jun CAHN
		20MG	N202880	003	Oct 25, 2013	Jun CAHN
		30MG	N202880	004	Oct 25, 2013	Jun CAHN
		40MG	N202880	005	Oct 25, 2013	Jun CAHN
		50MG	N202880	006	Oct 25, 2013	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar CRLD
---	------------------	------	---------	-----	--------------	----------

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

AT	RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar CAHN
----	-------------------	------	---------	-----	--------------	----------

POWDER;FOR RX COMPOUNDING

HYDRO-RX

@ X GEN PHARMS	100%	A085982	001		Apr DISC
----------------	------	---------	-----	--	----------

TABLET;ORAL

HYDROCORTISONE

AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb NEWA
AB		10MG	A083365	003	Feb 23, 2015	Feb NEWA
AB		20MG	A083365	001		Feb CMFD

HYDROCORTISONE ACETATEPOWDER;FOR RX COMPOUNDING
HYDROCORTISONE ACETATE

@ X GEN PHARMS 100% A085981 001 Apr DISC

HYDROCORTISONE VALERATECREAM;TOPICAL
HYDROCORTISONE VALERATE

@ G AND W LABS INC 0.2% A074489 001 Aug 12, 1998 Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OTIC
CORTISPORIN

AT + CITRON PHARMA LLC 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N060613 001 Jun CMS2

HYDROMORPHONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
HYDROMORPHONE HYDROCHLORIDE

AB	PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar NEWA
AB		12MG	A204278	002	Apr 06, 2015	Mar NEWA
AB		16MG	A204278	003	Apr 06, 2015	Mar NEWA

HYDROXOCOBALAMININJECTABLE;INJECTION
CYANOKIT

	@ SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr CAHN
+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr CAHN

HYDROXYCHLOROQUINE SULFATETABLET;ORAL
PLAQUENIL

AB + CONCORDIA PHARMS INC 200MG N009768 001 Jun CAHN

HYDROXYPROGESTERONE CAPROATEINJECTABLE;INJECTION
HYDROXYPROGESTERONE CAPROATE

	@ ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar CAHN
	@	250MG/ML	N017439	002		Mar CAHN
>A>	+ MCGUFF	250MG/ML	A200271	001	Aug 24, 2015	Aug NEWA

HYDROXYZINE HYDROCHLORIDETABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

AB	ELITE LABS INC	10MG	A040600	001	Dec 28, 2004	Jun CAHN
AB		25MG	A040602	001	Dec 28, 2004	Jun CAHN
AB		50MG	A040604	001	Dec 28, 2004	Jun CAHN
AB	HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar CAHN
AB		25MG	A204279	002	Aug 20, 2014	Mar CAHN
AB		50MG	A204279	003	Aug 20, 2014	Mar CAHN
AB	MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar CMFD
AB		25MG	A040602	001	Dec 28, 2004	Mar CMFD
AB		50MG	A040604	001	Dec 28, 2004	Mar CMFD
	@ MUTUAL PHARM	10MG	A089381	001	May 19, 1986	Jul DISC
	@	25MG	A089382	001	May 19, 1986	Jul DISC
	@	50MG	A089383	001	May 19, 1986	Jul DISC
	@ WATSON LABS	10MG	A088348	001	Sep 15, 1983	Jul DISC
	@	25MG	A088349	001	Sep 15, 1983	Jul DISC
	@	50MG	A088350	001	Sep 15, 1983	Jul DISC

HYDROXYZINE PAMOATECAPSULE;ORAL
HYDROXYZINE PAMOATE

AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CAHN
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CAHN

IBANDRONATE SODIUMINJECTABLE;INTRAVENOUS
IBANDRONATE SODIUM

>A> AP	AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332	001	Aug 19, 2015	Aug NEWA
--------	----------------------	-----------------	---------	-----	--------------	----------

IBUPROFENTABLET;ORAL
IBUPROFEN

>A> AB	GRANULES INDIA LTD	400MG	A091625	001	Sep 15, 2015	Aug NEWA
>A> AB		600MG	A091625	002	Sep 15, 2015	Aug NEWA
>A> AB		800MG	A091625	003	Sep 15, 2015	Aug NEWA
	@ VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul DISC
	@	400MG	A071231	001	Oct 22, 1986	Jul DISC
	@	600MG	A071232	001	Oct 22, 1986	Jul DISC
	@	800MG	A072004	001	Nov 18, 1987	Jul DISC

ILOPERIDONETABLET;ORAL
FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan CAHN
		2MG	N022192	002	May 06, 2009	Jan CAHN
		4MG	N022192	003	May 06, 2009	Jan CAHN
		6MG	N022192	004	May 06, 2009	Jan CAHN
		8MG	N022192	005	May 06, 2009	Jan CAHN
		10MG	N022192	006	May 06, 2009	Jan CAHN
		12MG	N022192	007	May 06, 2009	Jan CAHN

IMIQUIMODCREAM;TOPICAL
IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr CAHN
----	------------------	----	---------	-----	--------------	----------

INDAPAMIDETABLET;ORAL
INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A074299	002	Apr 29, 1996	Jul CAHN
	@	1.25MG	A074498	002	Feb 12, 1998	Jul CAHN
AB		2.5MG	A074299	001	Jul 27, 1995	Jul CAHN
	@	2.5MG	A074498	001	Oct 31, 1996	Jul CAHN

INGENOL MEBUTATEGEL;TOPICAL
PICATO

+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May CRLD
---	---------------	--------	---------	-----	--------------	----------

INSULIN GLARGINE RECOMBINANTSOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Feb NEWA
---	--------------------	-----------------------------	---------	-----	--------------	----------

INSULIN LISPRO RECOMBINANTSOLUTION;SUBCUTANEOUS
HUMALOG KWIKPEN

+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015	May NEWA
---	------------------	--------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMANPOWDER;INHALATION
AFREZZA

	SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr NEWA
--	----------------	--------------	---------	-----	--------------	----------

IOHEXOLFOR SOLUTION;ORAL
ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar NEWA
--	----------------------	-----------	---------	-----	--------------	----------

IOPAMIDOLINJECTABLE;INJECTION
IOPAMIDOL-250

@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan DISC
---	--------------------	-----	---------	-----	--------------	----------

INJECTABLE; INJECTION

IOPAMIDOL-300

@ FRESenius KABI USA

61%

A074679 002 Apr 02, 1997 Jan DISC

IOPAMIDOL-370

@ FRESenius KABI USA

76%

A074679 003 Apr 02, 1997 Jan DISC

ISOVUE-200

+ BRACCO

41%

N018735 006 Jul 07, 1987 Feb CTEC

ISOVUE-250

+ BRACCO

51%

N018735 007 Jul 06, 1992 Feb CTEC

+

51%

N020327 002 Oct 12, 1994 Feb CTEC

ISOVUE-300

+ BRACCO

61%

N020327 003 Oct 12, 1994 Feb CTEC

ISOVUE-370

+ BRACCO

76%

N020327 004 Oct 12, 1994 Feb CTEC

SCANLUX-300

>A> AP

MYLAN INSTITUTIONAL

61%

A090394 001 Jun 18, 2010 Aug CAHN

>D> AP

SANOCHEMIA CORP USA

61%

A090394 001 Jun 18, 2010 Aug CAHN

SCANLUX-370

>A> AP

MYLAN INSTITUTIONAL

76%

A090394 002 Jun 18, 2010 Aug CAHN

>D> AP

SANOCHEMIA CORP USA

76%

A090394 002 Jun 18, 2010 Aug CAHN

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

+ LIEBEL-FLARSHEIM

60%

N013295 001 Feb CAHN

CONRAY 30

+ LIEBEL-FLARSHEIM

30%

N016983 001 Feb CAHN

CONRAY 43

+ LIEBEL-FLARSHEIM

43%

N013295 002 Feb CAHN

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

LIEBEL-FLARSHEIM

17.2%

N017057 002 Feb CAHN

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

@ LIEBEL-FLARSHEIM

34%

N019710 003 Dec 30, 1988 Feb CAHN

OPTIRAY 240

+ LIEBEL-FLARSHEIM

51%

N019710 002 Dec 30, 1988 Feb CAHN

@

51%

N020923 001 May 28, 1998 Feb CAHN

OPTIRAY 300

+ LIEBEL-FLARSHEIM

64%

N019710 004 Jan 22, 1992 Feb CAHN

+

64%

N020923 004 May 13, 1999 Feb CAHN

OPTIRAY 320

+ LIEBEL-FLARSHEIM

68%

N019710 001 Dec 30, 1988 Feb CAHN

@

68%

N020923 002 May 29, 1998 Feb CAHN

OPTIRAY 350

+ LIEBEL-FLARSHEIM

74%

N019710 005 Jan 22, 1992 Feb CAHN

+

74%

N020923 003 May 28, 1998 Feb CAHN

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

@ GUERBET

39.3%; 19.6%

N018905 002 Jul 26, 1985 May DISC

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB JUBILANT GENERICS

75MG

A203534 001 Feb 23, 2015 Feb NEWA

AB

150MG

A203534 002 Feb 23, 2015 Feb NEWA

AB

300MG

A203534 003 Feb 23, 2015 Feb NEWA

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP + ACTAVIS LABS UT INC

EQ 50MG IRON/ML

N017441 001 Mar CAHN

ISAVUCONAZONIUM SULFATECAPSULE; ORAL
CRESEMBA

+ ASTELLAS 186MG

N207500 001 Mar 06, 2015 Mar NEWA

POWDER; IV (INFUSION)
CRESEMBA

+ ASTELLAS 372MG

N207501 001 Mar 06, 2015 Mar NEWA

ISOSORBIDE DINITRATETABLET; ORAL
ISORDIL

AB VALEANT PHARMS NORTH 5MG

N012093 007 Jul 29, 1988 Feb CAHN

+ 40MG

N012093 001 Jul 29, 1988 Feb CAHN

ISOTRETINOINCAPSULE; ORAL
ABSORICA

RANBAXY 25MG

N021951 005 Aug 15, 2014 Feb NEWA

35MG

N021951 006 Aug 15, 2014 Feb NEWA

MYORISAN

>A> AB DOUGLAS PHARMS 30MG

A076485 004 Aug 25, 2015 Aug NEWA

SOTRET

AB SUN PHARM INDS LTD 10MG

A076041 001 Dec 24, 2002 Apr CAHN

AB 20MG

A076041 002 Dec 24, 2002 Apr CAHN

AB 30MG

A076503 001 Jun 20, 2003 Apr CAHN

AB 40MG

A076041 003 Dec 24, 2002 Apr CAHN

ZENATANE

AB DR REDDYS LABS LTD 30MG

A202099 004 Feb 23, 2015 Feb NEWA

ISRADIPINECAPSULE; ORAL
ISRADIPINE

AB ELITE LABS INC 2.5MG

A077169 001 Apr 24, 2006 Mar CAHN

AB 5MG

A077169 002 Apr 24, 2006 Mar CAHN

IVABRADINE HYDROCHLORIDETABLET; ORAL
CORLANOR

AMGEN INC EQ 5MG BASE

N206143 001 Apr 15, 2015 Apr NEWA

+ EQ 7.5MG BASE

N206143 002 Apr 15, 2015 Apr NEWA

IVACAFTORGRANULE; ORAL
KALYDECO

VERTEX PHARMS INC 50MG/PACKET

N207925 001 Mar 17, 2015 Mar NEWA

+ 75MG/PACKET

N207925 002 Mar 17, 2015 Mar NEWA

IVACAFTOR; LUMACAFTORTABLET; ORAL
ORKAMBI

+ VERTEX PHARMS INC 125MG; 200MG

N206038 001 Jul 02, 2015 Jul NEWA

IXABEPILONEINJECTABLE; IV (INFUSION)
IXEMPRA KIT

+ R-PHARM US LLC 15MG/VIAL

N022065 001 Oct 16, 2007 Jun CAHN

+ 45MG/VIAL

N022065 002 Oct 16, 2007 Jun CAHN

KANAMYCIN SULFATEINJECTABLE; INJECTION
KANAMYCIN

@ EUROHLTH INTL SARL EQ 75MG BASE/2ML

A062324 001 Jun CAHN

@ EQ 500MG BASE/2ML

A062324 002 Jun CAHN

@ EQ 1GM BASE/3ML

A062324 003 Jun CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

@ CLARIS PHARMASERVICE 15MG/ML

A075631 002 Jun 29, 2001 Apr CAHN

@ 30MG/ML

A075631 001 Jun 29, 2001 Apr CAHN

@ EUROHLTH INTL SARL 15MG/ML

A075772 001 Jul 21, 2004 Jun CAHN

@ 30MG/ML

A075772 002 Jul 21, 2004 Jun CAHN

SPRAY, METERED; NASAL

SPRIX

+ EGALET US INC 15.75MG/SPRAY

N022382 001 May 14, 2010 Jan CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

+ OMEROS EQ 4.24MG BASE/ML; EQ 12.4MG
BASE/ML

N205388 001 May 30, 2014 Feb CPOT

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

@ CLARIS PHARMASERVICE 5MG/ML

A076051 001 Jul 05, 2002 Apr CAHN

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB MUTUAL PHARM 100MG

A075215 001 Jul 29, 1999 Jan CMFD

AB 200MG

A075215 002 Jul 29, 1999 Jan CMFD

AB 300MG

A075215 003 Jul 29, 1999 Jan CMFD

LACTULOSE

SOLUTION; ORAL, RECTAL

LACTULOSE

AA BIO-PHARM INC 10GM/15ML

A203762 001 Mar 27, 2015 Mar NEWA

>D> LAMIVUDINE; RALTEGRAVIR POTASSIUM

>D> TABLET; ORAL

>D> DUTREBIS

>D> + MERCK SHARP DOHME 150MG; EQ 300MG BASE

N206510 001 Feb 06, 2015 Aug DISC

>A> @ 150MG; EQ 300MG BASE

N206510 001 Feb 06, 2015 Aug DISC

+ 150MG; EQ 300MG BASE

N206510 001 Feb 06, 2015 Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

>A> AB HETERO LABS LTD III 150MG; 300MG

A079124 001 Sep 17, 2015 Aug NEWA

>D> AB STRIDES ARCOLAB LTD 150MG; 300MG

A079128 001 May 13, 2015 Aug CAHN

AB 150MG; 300MG

A079128 001 May 13, 2015 Apr NEWA

>A> AB STRIDES PHARMA 150MG; 300MG

A079128 001 May 13, 2015 Aug CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ HIKMA PHARMS 25MG

A078134 001 Apr 19, 2011 May DISC

@ 100MG

A078134 002 Apr 19, 2011 May DISC

@ 150MG

A078134 003 Apr 19, 2011 May DISC

@ 200MG

A078134 004 Apr 19, 2011 May DISC

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+ NOVARTIS PHARMS CORP EQ 250MG BASE

N022059 001 Mar 13, 2007 Mar CAHN

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

+ EISAI INC EQ 4MG BASE

N206947 001 Feb 13, 2015 Feb NEWA

+ EQ 10MG BASE

N206947 002 Feb 13, 2015 Feb NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul NEWA
----	--------------------	----------------------	---------	-----	--------------	----------

SOLUTION;ORAL

LEVETIRACETAM

AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May NEWA
----	-------------	----------	---------	-----	--------------	----------

TABLET;ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul NEWA
		500MG	N207958	002	Jul 31, 2015	Jul NEWA
		750MG	N207958	003	Jul 31, 2015	Jul NEWA
		1GM	N207958	004	Jul 31, 2015	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

	SPARC	1GM	N204417	001	Mar 02, 2015	Mar NEWA
		1.5GM	N204417	002	Mar 02, 2015	Mar NEWA

LEVETIRACETAM

	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb NEWA
--	------------	-----	---------	-----	--------------	----------

>A>	AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015	Aug NEWA
-----	----	---------------	-------	---------	-----	--------------	----------

>A>	AB		750MG	A202167	002	Sep 04, 2015	Aug NEWA
-----	----	--	-------	---------	-----	--------------	----------

>A>	AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Aug CAHN
-----	----	---------------	-------	---------	-----	--------------	----------

>A>	AB		750MG	A201464	002	May 25, 2012	Aug CAHN
-----	----	--	-------	---------	-----	--------------	----------

	AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May NEWA
--	----	--------------	-------	---------	-----	--------------	----------

	AB		750MG	A203468	002	May 21, 2015	May NEWA
--	----	--	-------	---------	-----	--------------	----------

>D>	AB	VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Aug CAHN
-----	----	----------------	-------	---------	-----	--------------	----------

>D>	AB		750MG	A201464	002	May 25, 2012	Aug CAHN
-----	----	--	-------	---------	-----	--------------	----------

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

	@ TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr DISC
--	-------------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb NEWA
----	------------	-----	---------	-----	--------------	----------

AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun NEWA
----	--------------------	-----	---------	-----	--------------	----------

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr CAHN
----	----------------------	----------------------------	---------	-----	--------------	----------

AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul NEWA
----	-------------	----------------------------	---------	-----	--------------	----------

AP		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul NEWA
----	--	----------------------------	---------	-----	--------------	----------

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr CAHN
----	----------------------	---------------------------	---------	-----	--------------	----------

AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr CAHN
----	--	----------------------------	---------	-----	--------------	----------

AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr CAHN
----	--	----------------------------	---------	-----	--------------	----------

>A>	AP	HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015	Aug NEWA
-----	----	-------------	---------------------------	---------	-----	--------------	----------

>A>	AP		EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015	Aug NEWA
-----	----	--	----------------------------	---------	-----	--------------	----------

>A>	AP		EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015	Aug NEWA
-----	----	--	----------------------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+ NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul CRLD
----	----------------	------	---------	-----	--------------	----------

QUIXIN

	@ SANTEN	0.5%	N021199	001	Aug 18, 2000	Jul DISC
--	----------	------	---------	-----	--------------	----------

TABLET;ORAL

LEVOFLOXACIN

AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun NEWA
----	-------------------	-------	---------	-----	--------------	----------

AB		500MG	A203613	002	Jun 19, 2015	Jun NEWA
----	--	-------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

	SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb NEWA
--	--------	--------------------------------------	---------	-----	--------------	----------

	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb NEWA
--	------------	--	---------	-----	--------------	----------

+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar CRLD
---	--	--------------------------------------	---------	-----	--------------	----------

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE
LILETTA

MEDICINES360 52MG

N206229 001 Feb 26, 2015 Feb NEWA

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

+ SENTYNL THERAPY INC 2MG

A074278 001 Mar 31, 2000 Apr CAHN

LIDOCAINE

ointment; TOPICAL

LIDOCAINE

AT AMNEAL PHARMS 5%

A206297 001 Aug 07, 2015 Jul NEWA

PATCH; TOPICAL

LIDOCAINE

AB ACTAVIS LABS UT INC 5%

A200675 001 Aug 23, 2012 Mar CAHN

AB MYLAN TECHNOLOGIES 5%

A202346 001 Aug 07, 2015 Jul NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@ EUROHLTH INTL SARL 1%

A080407 001 Mar CAHN

@ 2%

A080407 002 Mar CAHN

>A> AP LUITPOLD 1%

A091564 001 Aug 14, 2015 Aug NEWA

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@ EUROHLTH INTL SARL 1%

A084625 001 Feb CAHN

@ 2%

A084625 002 Feb CAHN

JELLY; TOPICAL

ANESTACON

@ BANNER LIFE SCIENCES 2%

A080429 001 Jan CAHN

LIDOCAINE HYDROCHLORIDE

@ G AND W LABS INC 2%

A081318 001 Apr 29, 1993 Apr CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB + ACTAVIS LABS UT INC 2.5%; 2.5%

N019941 001 Dec 30, 1992 Feb CAHN

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS LLC 145MCG

N202811 001 Aug 30, 2012 Mar CAHN

+ 290MCG

N202811 002 Aug 30, 2012 Mar CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

AP + PHARMACIA AND UPJOHN EQ 300MG BASE/ML

N050317 001 May CFTG

LINCOMYCIN

AP X-GEN PHARMS INC EQ 300MG BASE/ML

A201746 001 Jun 04, 2015 May NEWA

LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID

AB ROXANE 100MG/5ML

A200068 001 Jun 03, 2015 May NEWA

ZYVOX

AB + PHARMACIA AND UPJOHN 100MG/5ML

N021132 001 Apr 18, 2000 May CFTG

SOLUTION; IV (INFUSION)

LINEZOLID

AP HOSPIRA INC 600MG/300ML (2MG/ML)

A205442 001 Jul 07, 2015 Jun NEWA

AP SANDOZ INC 200MG/100ML (2MG/ML)

A200904 001 Jul 16, 2015 Jul NEWA

AP 600MG/300ML (2MG/ML)

A200904 002 Jul 16, 2015 Jul NEWA

AP TEVA PHARMS 600MG/300ML (2MG/ML)

A200222 001 Jun 27, 2012 May CDFR

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA INC 600MG/300ML (2MG/ML)

N206473 001 Jun 18, 2015 Jun NEWA

ZYVOX

AP PHARMACIA AND UPJOHN 200MG/100ML (2MG/ML)

N021131 001 Apr 18, 2000 Jul CTEC

200MG/100ML (2MG/ML)

N021131 001 Apr 18, 2000 May CDFR

400MG/200ML (2MG/ML)

N021131 002 Apr 18, 2000 May NEWA

SOLUTION; IV (INFUSION)							
ZYVOX							
AP	+	600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May	NEWA
TABLET; ORAL							
LINEZOLID							
AB		TEVA PHARMS USA 600MG	A078061	001	May 18, 2015	May	NEWA
ZYVOX							
AB	+	PHARMACIA AND UPJOHN 600MG	N021130	002	Apr 18, 2000	May	CFTG
<u>LISINOPRIL</u>							
TABLET; ORAL							
LISINOPRIL							
AB		SUN PHARM INDS LTD 2.5MG	A075944	001	Jul 01, 2002	Apr	CAHN
AB		5MG	A075944	002	Jul 01, 2002	Apr	CAHN
AB		10MG	A075944	003	Jul 01, 2002	Apr	CAHN
AB		20MG	A075944	004	Jul 01, 2002	Apr	CAHN
AB		30MG	A075944	006	Feb 11, 2003	Apr	CAHN
AB		40MG	A075944	005	Jul 01, 2002	Apr	CAHN
ZESTRIL							
AB		ALVOGEN IPCO SARL 2.5MG	N019777	005	Apr 29, 1993	Feb	CAHN
AB		5MG	N019777	001	May 19, 1988	Feb	CAHN
AB		10MG	N019777	002	May 19, 1988	Feb	CAHN
AB		20MG	N019777	003	May 19, 1988	Feb	CAHN
AB		30MG	N019777	006	Jan 20, 1999	Feb	CAHN
AB	+	40MG	N019777	004	May 19, 1988	Feb	CAHN
<u>LITHIUM CARBONATE</u>							
TABLET, EXTENDED RELEASE; ORAL							
LITHIUM CARBONATE							
AB		ALEMBIC PHARMS LTD 300MG	A204445	001	Jun 10, 2015	May	NEWA
	@	HIKMA INTL PHARMS 450MG	A076490	001	Jun 17, 2003	Feb	DISC
AB		UNIQUE PHARM LABS 300MG	A204779	001	Jul 27, 2015	Jul	NEWA
<u>LOMITAPIDE MESYLATE</u>							
CAPSULE; ORAL							
JUXTAPID							
		AEGERION EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr	NEWA
		EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr	NEWA
		EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr	NEWA
<u>LOMUSTINE</u>							
CAPSULE; ORAL							
GLEOSTINE							
		CORDEN PHARMA 5MG	N017588	004	Dec 19, 2014	Jan	NEWA
<u>LOPERAMIDE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
IMODIUM							
	@	J AND J CONSUMER INC 2MG	N017690	001		Jul	CAHN
AB	+	2MG	N017694	001		Jul	CAHN
<u>LOPINAVIR; RITONAVIR</u>							
CAPSULE; ORAL							
KALETRA							
	@	ABBVIE 133.3MG; 33.3MG	N021226	001	Sep 15, 2000	Jun	DISC
<u>LORAZEPAM</u>							
INJECTABLE; INJECTION							
ATIVAN							
AP	+	EUROHLTH INTL SARL 2MG/ML	N018140	001		Jun	CAHN
AP	+	4MG/ML	N018140	002		Jun	CAHN
TABLET; ORAL							
LORAZEPAM							
AB		SUN PHARM INDS LTD 0.5MG	A076045	001	Aug 29, 2001	Apr	CAHN
AB		1MG	A076045	002	Aug 29, 2001	Apr	CAHN
AB		2MG	A076045	003	Aug 29, 2001	Apr	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Jul	NEWA
AB		50MG	A203835	002	Aug 12, 2015	Jul	NEWA
AB		100MG	A203835	003	Aug 12, 2015	Jul	NEWA
AB	WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb	CMFD
AB		50MG	A091129	002	Oct 06, 2010	Feb	CMFD
AB		100MG	A091129	003	Oct 06, 2010	Feb	CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

@	COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	May	CAHN
		20MG	N021316	002	Jun 26, 2002	May	CAHN
		40MG	N021316	003	Jun 26, 2002	May	CAHN
+		60MG	N021316	004	Jun 26, 2002	May	CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

@	ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar	CAHN
INJECTABLE; INJECTION							
LOXITANE IM							
@	ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar	CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May	CAHN
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May	CAHN
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May	CAHN
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May	CAHN
LOXITANE							
@	ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar	CAHN
@		EQ 10MG BASE	N017525	002		Mar	CAHN
@		EQ 25MG BASE	N017525	003		Mar	CAHN
@		EQ 50MG BASE	N017525	004		Mar	CAHN
TABLET; ORAL							
LOXITANE							
@	ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar	CAHN
@		EQ 25MG BASE	N017525	007		Mar	CAHN
@		EQ 50MG BASE	N017525	008		Mar	CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

@	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May	DISC
---	----------------	-------	---------	-----	--------------	-----	------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	32MG/100ML; 128MG/100ML; 234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC
---	-----------------	--------------------------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr	CDFR
AP	+ FRESenius KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr	CPOT
AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr	CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr	NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESenius KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr	NEWA
---	--------------------	--------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

>D>	SUCLEAR						
>D>	+ BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A; N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Aug	DISC
>A>	@	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A; N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Aug	DISC

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

@ IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar	CAHN
@	12.5GM/50ML	A089240	001	May 06, 1987	Mar	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>A>	@ ANI PHARMS INC	12.5MG	A084975	001		Aug	CAHN
>A>	@	25MG	A084657	001		Aug	CAHN
>D>	@ IVAX SUB TEVA PHARMS	12.5MG	A084975	001		Aug	CAHN
>D>	@	25MG	A084657	001		Aug	CAHN
	@ VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun	DISC
	@	25MG	A040179	002	Jan 30, 1997	Jun	DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar	CAHN
	14MG	N022525	002	Jun 21, 2010	Mar	CAHN
	21MG	N022525	003	Jun 21, 2010	Mar	CAHN
+	28MG	N022525	004	Jun 21, 2010	Mar	CAHN

SOLUTION; ORAL

NAMENDA

+ FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar	CAHN
-------------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

MEMANTINE

AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar	CMFD
AB		10MG	A090058	002	May 05, 2010	Mar	CMFD
	MEMANTINE HYDROCHLORIDE						
AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar	NEWA
AB		10MG	A090041	002	Apr 10, 2015	Mar	NEWA
AB	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun	CMFD
AB		10MG	A090048	002	Apr 14, 2010	Jun	CMFD
AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar	NEWA
AB		10MG	A090051	002	Apr 10, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun	CMFD
	@	5MG	A079225	001	Jan 30, 2015	Mar	DISC
AB		5MG	A079225	001	Jan 30, 2015	Jan	NEWA
AB		10MG	A079225	002	Jan 30, 2015	Jun	CMFD
	@	10MG	A079225	002	Jan 30, 2015	Mar	DISC
AB		10MG	A079225	002	Jan 30, 2015	Jan	NEWA
AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May	CMFD
AB		10MG	A090052	002	Oct 25, 2011	May	CMFD
AB	UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul	NEWA
AB		10MG	A090043	002	Jul 31, 2015	Jul	NEWA
>A> AB	WOCKHARDT LTD	5MG	A090073	001	Sep 04, 2015	Aug	NEWA
>A> AB		10MG	A090073	002	Sep 04, 2015	Aug	NEWA
	NAMENDA						
AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar	CAHN
AB	+	10MG	N021487	002	Oct 16, 2003	Mar	CAHN

MENOTROPINS (FSH; LH)

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

@ FERRING	75 IU/VIAL; 75 IU/VIAL	N021047	001	Aug 27, 1999	May	DISC
-----------	------------------------	---------	-----	--------------	-----	------

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb	CAHN
AP		50MG/ML	A080445	002		Feb	CAHN
AP		75MG/ML	A080445	003		Feb	CAHN
AP		100MG/ML	A080445	004		Feb	CAHN
	@ IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May	CAHN
	@	50MG/ML	A089782	001	Mar 31, 1989	Mar	CAHN
	@	50MG/ML	A089783	001	Mar 31, 1989	Mar	CAHN
	@	50MG/ML	A089784	001	Mar 31, 1989	Mar	CAHN
	@	75MG/ML	A089785	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089786	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@ EUROHLTH INTL SARL	25MG/ML; 25MG/ML	N011730	001		Jun	CAHN
----------------------	------------------	---------	-----	--	-----	------

MEROPENEM

POWDER; IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr	NEWA
	1GM/VIAL	N202106	002	Apr 30, 2015	Apr	NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

+ VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008	Jul	CAHN
-----------------------	-------	---------	-----	--------------	-----	------

ENEMA; RECTAL

MESALAMINE

>A> AB	G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Aug	CAHN
>D> AB	TEVA	4GM/60ML	A076841	001	Sep 30, 2004	Aug	CAHN

SUPPOSITORY; RECTAL

CANASA

>D>	@ FOREST LABS INC	500MG	N021252	001	Jan 05, 2001	Aug	CAHN
>D>	+	1GM	N021252	002	Nov 05, 2004	Aug	CAHN
>A>	@ FOREST LABS LLC	500MG	N021252	001	Jan 05, 2001	Aug	CAHN
>A>	+	1GM	N021252	002	Nov 05, 2004	Aug	CAHN

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

@ ACTAVIS LABS UT INC	0.1MG; 2MG	N013625	004		Mar	CAHN
-----------------------	------------	---------	-----	--	-----	------

TABLET; ORAL-21

NORINYL 1+50 21-DAY

@ ACTAVIS LABS UT INC	0.05MG; 1MG	N013625	002		Mar	CAHN
-----------------------	-------------	---------	-----	--	-----	------

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC	0.05MG; 1MG	N016659	001		Mar	CAHN
-----------------------	-------------	---------	-----	--	-----	------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

@ MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	Apr	DISC
@	0.6%	A070804	001	Aug 17, 1987	Apr	DISC
@ WOCKHARDT	0.4%	A075586	001	May 30, 2002	Apr	DISC
@	0.6%	A075586	002	May 30, 2002	Apr	DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@ G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992	Apr	CAHN
@	10MG/5ML	A073034	001	Aug 30, 1991	Apr	CAHN

METAXALONETABLET; ORAL
METAXALONE

COREPHARMA

400MG
640MGA040486 001 Feb 27, 2015 Feb NEWA
N022503 001 Jun 01, 2015 Jun NEWAMETFORMIN HYDROCHLORIDESOLUTION; ORAL
RIOMET

+ SUN PHARM INDS LTD 500MG/5ML

N021591 001 Sep 11, 2003 Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDETABLET; ORAL
PRANDIMETAB NOVO NORDISK INC 500MG; 1MG
AB + 500MG; 2MGN022386 001 Jun 23, 2008 Jun CFTG
N022386 002 Jun 23, 2008 Jun CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB LUPIN LTD 500MG; 1MG
AB 500MG; 2MGA200624 001 Jul 15, 2015 Jun NEWA
A200624 002 Jul 15, 2015 Jun NEWAMETFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATETABLET; ORAL
AVANDAMET@ SB PHARMCO 500MG; EQ 2MG BASE
@ 500MG; EQ 4MG BASE
@ 1GM; EQ 2MG BASE
@ 1GM; EQ 4MG BASEN021410 002 Oct 10, 2002 May DISC
N021410 003 Oct 10, 2002 May DISC
N021410 004 Aug 25, 2003 May DISC
N021410 005 Aug 25, 2003 May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA 500MG; EQ 2MG BASE
500MG; EQ 4MG BASEA077337 001 May 07, 2014 May CTEC
A077337 002 May 07, 2014 May CTEC+ 1GM; EQ 4MG BASE
1GM; EQ 2MG BASEA077337 004 May 07, 2014 May CRLD
A077337 003 May 07, 2014 May CTECMETHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

>A> AA AUROLIFE PHARMA LLC 5MG
>A> AA 10MG
>A> AA COREPHARMA 5MG
>A> AA 10MGA203502 001 Aug 31, 2015 Aug NEWA
A203502 002 Aug 31, 2015 Aug NEWA
A090065 001 Aug 18, 2015 Aug NEWA
A090065 002 Aug 18, 2015 Aug NEWAMETHIMAZOLETABLET; ORAL
METHIMAZOLEAB HERITAGE PHARMA 5MG
AB 10MGA040734 001 Dec 14, 2007 Mar CAHN
A040734 002 Dec 14, 2007 Mar CAHNMETHOCARBAMOLSOLUTION; IM-IV
ROBAXIN

AP + EUROHLTH INTL SARL 1GM/10ML (100MG/ML)

N011790 001 Jun CAHN

METHOTREXATE SODIUMINJECTABLE; INJECTION
METHOTREXATE PRESERVATIVE FREE

AP FRESENIUS KABI USA EQ 25MG BASE/ML

A040265 001 Feb 26, 1999 May CMFD

TABLET; ORAL

METHOTREXATE SODIUM

AB ORION CORP ORION EQ 2.5MG BASE

A201749 001 May 21, 2015 May NEWA

METHOXSALLENCAPSULE; ORAL
METHOXSALLEN

AB ACTAVIS INC 10MG

A202603 001 Jun 09, 2015 May NEWA

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
APTENSIO XR

		RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr	NEWA
			15MG	N205831	002	Apr 17, 2015	Apr	NEWA
			20MG	N205831	003	Apr 17, 2015	Apr	NEWA
			30MG	N205831	004	Apr 17, 2015	Apr	NEWA
			40MG	N205831	005	Apr 17, 2015	Apr	NEWA
			50MG	N205831	006	Apr 17, 2015	Apr	NEWA
		+	60MG	N205831	007	Apr 17, 2015	Apr	NEWA
		RITALIN LA						
AB1		NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb	CRLD
		+	60MG	N021284	005	Oct 27, 2014	Feb	CRLD

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AA	NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015	Aug	NEWA
>A>	AA		10MG/5ML	A204602	002	Aug 14, 2015	Aug	NEWA

TABLET, CHEWABLE;ORAL

METHYLIN

	AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb	CFTG
	AB		5MG	N021475	002	Apr 15, 2003	Feb	CFTG
	AB	+	10MG	N021475	003	Apr 15, 2003	Feb	CFTG

METHYLPHENIDATE HYDROCHLORIDE

	AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb	NEWA
	AB		5MG	A204115	002	Feb 25, 2015	Feb	NEWA
	AB		10MG	A204115	003	Feb 25, 2015	Feb	NEWA

TABLET, EXTENDED RELEASE;ORAL

METHYLIN ER

	AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May	CTEC
		METHYLPHENIDATE HYDROCHLORIDE						
	AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May	NEWA
	AB		20MG	A207488	002	Jun 09, 2015	May	NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr	CAHN
----	--	----------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

METOPROLOL TARTRATE

		MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar	NEWA
			75MG	A076704	005	Mar 18, 2015	Mar	NEWA

METRONIDAZOLE

CREAM;TOPICAL

NORITATE

		+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb	CAHN
--	--	---	----------------------	----	---------	-----	--------------	-----	------

GEL;VAGINAL

METRONIDAZOLE

		+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CAHN
			NUVESSA						

		+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CTNA
--	--	---	---------------------	------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

METRONIDAZOLE

>A>		@ EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984	Aug	CAHN
>D>		@ HIKMA MAPLE	500MG/100ML	N018907	001	Mar 30, 1984	Aug	CAHN

METRONIDAZOLE IN PLASTIC CONTAINER

AP		CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr	CAHN
----	--	----------------------	-------------	---------	-----	--------------	-----	------

TABLET;ORAL

METRONIDAZOLE

	AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May	NEWA
	AB		500MG	A203974	002	May 29, 2015	May	NEWA

MICONAZOLE

TABLET;BUCCAL

ORAVIG

		+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr	CAHN
--	--	---	------------------	------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr CAHN
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun CAHN
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun CAHN
	@ IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr CAHN
	@ WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar DISC
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr CAHN
----	--------------------	----------------	---------	-----	--------------	----------

MIGLITOL

TABLET; ORAL

GLYSET

AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar CTEC
AA		25MG	N020682	001	Dec 18, 1996	Feb CFTG
AB		50MG	N020682	002	Dec 18, 1996	Mar CTEC
AA		50MG	N020682	002	Dec 18, 1996	Feb CFTG
AB	+	100MG	N020682	003	Dec 18, 1996	Mar CTEC
AA	+	100MG	N020682	003	Dec 18, 1996	Feb CFTG

MIGLITOL

AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar CTEC
AA		25MG	A203965	001	Feb 24, 2015	Feb NEWA
AB		50MG	A203965	002	Feb 24, 2015	Mar CTEC
AA		50MG	A203965	002	Feb 24, 2015	Feb NEWA
AB		100MG	A203965	003	Feb 24, 2015	Mar CTEC
AA		100MG	A203965	003	Feb 24, 2015	Feb NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CRLD
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun CAHN
AP	+ HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010	Jan CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

	@ SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CAHN
	@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Apr CAHN
	@	EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CAHN
	@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Apr CAHN
	@	EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CAHN

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr CAHN
AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr CAHN
AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr CAHN
AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN

MIVACURIUM CHLORIDESOLUTION; INTRAVENOUS
MIVACRON

ABBVIE

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

N020098 004

Jan 22, 1992

Jan NEWA

+

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

N020098 005

Jan 22, 1992

Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

COREPHARMA

5MG

A090453 001

Mar 20, 2015

Mar NEWA

10MG

A090453 002

Mar 20, 2015

Mar NEWA

+

25MG

A090453 003

Mar 20, 2015

Mar NEWA

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB

AJANTA PHARMA LTD

EQ 4MG BASE/PACKET

A203438 001

Jul 31, 2015

Jul NEWA

TABLET; ORAL

MONTELUKAST SODIUM

AB

AJANTA PHARMA LTD

EQ 10MG BASE

A203432 001

Jul 31, 2015

Jul NEWA

>A>

AB

AMNEAL PHARMS

EQ 10MG BASE

A204604 001

Sep 04, 2015

Aug NEWA

AB

KREMERS URBAN PHARMS

EQ 10MG BASE

A201522 001

Aug 03, 2012

Mar CAHN

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB

AJANTA PHARMA LTD

EQ 4MG BASE

A203328 001

Jul 31, 2015

Jul NEWA

AB

EQ 5MG BASE

A203328 002

Jul 31, 2015

Jul NEWA

AB

HETERO LABS LTD V

EQ 4MG BASE

A204093 001

May 22, 2015

May NEWA

AB

EQ 5MG BASE

A204093 002

May 22, 2015

May NEWA

AB

JUBILANT GENERICS

EQ 4MG BASE

A203795 001

Feb 27, 2015

Feb NEWA

AB

EQ 5MG BASE

A203795 002

Feb 27, 2015

Feb NEWA

AB

KREMERS URBAN PHARMS

EQ 4MG BASE

A200405 001

Aug 03, 2012

Mar CAHN

AB

EQ 5MG BASE

A200405 002

Aug 03, 2012

Mar CAHN

AB

MACLEODS PHARMS LTD

EQ 4MG BASE

A203582 001

Mar 12, 2015

Feb NEWA

AB

EQ 5MG BASE

A203582 002

Mar 12, 2015

Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB1

+

ACTAVIS LABS UT INC

10MG

N020616 008

Apr 20, 2007

Mar CAHN

AB1

20MG

N020616 001

Jul 03, 1996

Mar CAHN

AB1

30MG

N020616 004

Mar 09, 2001

Mar CAHN

AB1

40MG

N020616 009

Jul 09, 2012

May CTEC

40MG

N020616 009

Jul 09, 2012

Mar CAHN

AB1

50MG

N020616 002

Jul 03, 1996

Mar CAHN

AB1

60MG

N020616 005

Mar 09, 2001

Mar CAHN

AB1

70MG

N020616 010

Jul 09, 2012

May CTEC

70MG

N020616 010

Jul 09, 2012

Mar CAHN

AB1

80MG

N020616 006

Oct 27, 2006

Mar CAHN

AB1

+

100MG

N020616 003

Jul 03, 1996

Mar CAHN

130MG

N020616 011

Jul 09, 2012

Mar CAHN

150MG

N020616 012

Jul 09, 2012

Mar CAHN

AB1

+

200MG

N020616 007

Feb 27, 2007

Mar CAHN

MORPHINE SULFATE

AB1

TEVA PHARMS USA

40MG

A202718 007

Jun 03, 2015

May NEWA

AB1

70MG

A202718 008

Jun 03, 2015

May NEWA

INJECTABLE; INJECTION

DURAMORPH PF

AP

+

EUROHLTH INTL SARL

0.5MG/ML

N018565 001

Sep 18, 1984

Jun CAHN

AP

+

1MG/ML

N018565 002

Sep 18, 1984

Jun CAHN

INFUMORPH

EUROHLTH INTL SARL

10MG/ML

N018565 003

Jul 19, 1991

Jun CAHN

EUROHLTH INTL SARL

25MG/ML

N018565 004

Jul 19, 1991

Jun CAHN

MORPHINE SULFATE

AP

EUROHLTH INTL SARL

4MG/ML

A205758 001

May 21, 2015

May NEWA

AP

8MG/ML

A205758 002

May 21, 2015

May NEWA

AP

10MG/ML

A205758 003

May 21, 2015

May NEWA

AP

+

HOSPIRA INC

4MG/ML

N202515 002

Nov 14, 2011

May CFTG

AP

+

8MG/ML

N202515 003

Nov 14, 2011

May CFTG

AP

+

10MG/ML

N202515 004

Nov 14, 2011

May CFTG

SOLUTION;ORAL

MORPHINE SULFATE

AA	TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
AA		100MG/5ML	A203518	002	May 12, 2015	May NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
AB		30MG	A203849	002	Apr 06, 2015	Mar NEWA
AB		60MG	A203849	003	Apr 06, 2015	Mar NEWA
AB		100MG	A203849	004	Apr 06, 2015	Mar NEWA
AB		200MG	A203849	005	Apr 06, 2015	Mar NEWA
AB	SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
AB		30MG	A078761	002	May 11, 2012	Apr CAHN
AB		60MG	A078761	003	May 11, 2012	Apr CAHN
AB		100MG	A078761	004	May 11, 2012	Apr CAHN
AB		200MG	A078761	005	May 11, 2012	Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

MOXIFLOXACIN HYDROCHLORIDE

+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr NEWA
---	--------------------	--	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CFTG
			MOXIFLOXACIN HYDROCHLORIDE				
AT1		LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May CTEC
AT2			EQ 0.5% BASE	A204079	001	May 28, 2015	May NEWA
AT1		WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May CTEC
AT			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb NEWA

VIGAMOX

AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May CTEC
-----	---	------------------	--------------	---------	-----	--------------	----------

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

>A>	AB	MYLAN PHARMS INC	EQ 400MG BASE	A204635	001	Aug 31, 2015	Aug NEWA
-----	----	------------------	---------------	---------	-----	--------------	----------

NADOLOL

TABLET;ORAL

NADOLOL

>A>	AB	ORION CORP ORION	40MG	A201893	001	Sep 16, 2015	Aug NEWA
>A>	AB		80MG	A201893	002	Sep 16, 2015	Aug NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar CAHN
@		10MG/ML	A072071	001	Apr 10, 1989	Mar CAHN
@		10MG/ML	A072072	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072073	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072074	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072075	001	Apr 10, 1989	Mar CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION

REVEX

@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun CAHN
@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

@	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar CAHN
---	--------------------	----------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

@	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar CAHN

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

@ 1MG/ML

A072091 001 Apr 11, 1989 Mar CAHN

@ 1MG/ML

A072092 001 Apr 11, 1989 Mar CAHN

@ 1MG/ML

A072093 001 Apr 11, 1989 Mar CAHN

NARCAN

>A> @ ADAPT 0.02MG/ML

N016636 002 Aug CAHN

>A> @ 0.4MG/ML

N016636 001 Aug CAHN

>A> @ 1MG/ML

N016636 003 Jun 14, 1982 Aug CAHN

>D> @ ENDO PHARMS 0.02MG/ML

N016636 002 Aug CAHN

>D> @ 0.4MG/ML

N016636 001 Aug CAHN

>D> @ 1MG/ML

N016636 003 Jun 14, 1982 Aug CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB SUN PHARM INDS LTD EQ 0.5MG BASE; EQ 50MG BASE

A075523 001 Mar 17, 2000 Apr CAHN

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

AB + PEDIAPHARM INC 25MG/ML

N018965 001 Mar 23, 1987 Apr CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

PERNIX IRELAND LTD 60MG; EQ 10MG BASE

N021926 002 May 14, 2015 Jun NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

@ ALKEM LABS LTD EQ 2.5MG BASE

A203741 001 Jun 24, 2015 Jun DISC

@ EQ 2.5MG BASE

A203741 001 Jun 24, 2015 Jun NEWA

@ EQ 5MG BASE

A203741 002 Jun 24, 2015 Jun DISC

@ EQ 5MG BASE

A203741 002 Jun 24, 2015 Jun NEWA

@ EQ 10MG BASE

A203741 003 Jun 24, 2015 Jun DISC

@ EQ 10MG BASE

A203741 003 Jun 24, 2015 Jun NEWA

@ EQ 20MG BASE

A203741 004 Jun 24, 2015 Jun DISC

@ EQ 20MG BASE

A203741 004 Jun 24, 2015 Jun NEWA

AB @ AMERIGEN PHARMS LTD EQ 2.5MG BASE

A203659 001 Apr 16, 2015 Apr DISC

AB @ EQ 2.5MG BASE

A203659 001 Apr 16, 2015 Mar NEWA

AB @ EQ 5MG BASE

A203659 002 Apr 16, 2015 Apr DISC

AB @ EQ 5MG BASE

A203659 002 Apr 16, 2015 Mar NEWA

AB @ EQ 10MG BASE

A203659 003 Apr 16, 2015 Apr DISC

AB @ EQ 10MG BASE

A203659 003 Apr 16, 2015 Mar NEWA

AB @ EQ 20MG BASE

A203659 004 Apr 16, 2015 Apr DISC

AB @ EQ 20MG BASE

A203659 004 Apr 16, 2015 Mar NEWA

@ INDCHEMIE HEALTH EQ 2.5MG BASE

A203828 001 Jul 29, 2015 Jul DISC

@ EQ 2.5MG BASE

A203828 001 Jul 29, 2015 Jul NEWA

@ EQ 5MG BASE

A203828 002 Jul 29, 2015 Jul DISC

@ EQ 5MG BASE

A203828 002 Jul 29, 2015 Jul NEWA

@ EQ 10MG BASE

A203828 003 Jul 29, 2015 Jul DISC

@ EQ 10MG BASE

A203828 003 Jul 29, 2015 Jul NEWA

@ EQ 20MG BASE

A203828 004 Jul 29, 2015 Jul DISC

@ EQ 20MG BASE

A203828 004 Jul 29, 2015 Jul NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@ IDT AUSTRALIA LTD 50MG

A076072 001 Sep 16, 2003 Apr CAHN

@ 100MG

A076072 002 Sep 16, 2003 Apr CAHN

@ 150MG

A076072 003 Sep 16, 2003 Apr CAHN

@ 200MG

A076072 004 Sep 16, 2003 Apr CAHN

@ 250MG

A076072 005 Sep 16, 2003 Apr CAHN

AB SUN PHARM INDS LTD 50MG

A076409 001 Sep 16, 2003 Apr CAHN

AB 100MG

A076409 002 Sep 16, 2003 Apr CAHN

AB 150MG

A076409 003 Sep 16, 2003 Apr CAHN

AB 200MG

A076409 004 Sep 16, 2003 Apr CAHN

AB 250MG

A076409 005 Sep 16, 2003 Apr CAHN

NELARABINE

INJECTABLE;IV (INFUSION)
ARRANON

+ NOVARTIS PHARMS CORP 250MG/50ML (5MG/ML) N021877 001 Oct 28, 2005 Mar CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

FRESENIUS KABI USA 5MG/10ML (0.5MG/ML) N203629 001 Jan 08, 2015 Jan NEWA
10MG/10ML (1MG/ML) N203629 002 Jan 08, 2015 Jan NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

AB ALVOGEN PINE BROOK 400MG A204621 001 Jul 10, 2015 Jun NEWA

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB AMNEAL PHARMS 500MG A203578 001 Jul 24, 2015 Jul NEWA
AB 1GM A203578 002 Jul 24, 2015 Jul NEWA

NIFEDIPINE

CAPSULE;ORAL
NIFEDIPINE

AB HERITAGE PHARMA 10MG A202644 001 Apr 25, 2013 Mar CAHN
AB 20MG A202644 002 Apr 25, 2013 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

>D> AB2 VALEANT INTL 30MG A075289 002 Feb 06, 2001 Aug CAHN
>D> AB2 60MG A075289 001 Sep 27, 2000 Aug CAHN
>A> AB2 VALEANT PHARMS NORTH 30MG A075289 002 Feb 06, 2001 Aug CAHN
>A> AB2 60MG A075289 001 Sep 27, 2000 Aug CAHN

NILUTAMIDE

TABLET;ORAL
NILANDRON

@ CONCORDIA PHARMS INC 50MG N020169 001 Sep 19, 1996 Apr CAHN
+ 150MG N020169 002 Apr 30, 1999 Apr CAHN

NIMODIPINE

CAPSULE;ORAL
NIMODIPINE

AB + BANNER LIFE SCIENCES 30MG A076740 001 Jan 17, 2008 Jan CAHN
AB SOFGEN PHARMS 30MG A201832 001 Jul 24, 2015 Jul NEWA

NINTEDANIB ESYLATE

CAPSULE;ORAL
OFEV

BOEHRINGER INGELHEIM EQ 100MG BASE N205832 001 Oct 15, 2014 Mar CAIN
+ EQ 150MG BASE N205832 002 Oct 15, 2014 Mar CAIN

NITRIC OXIDE

GAS;INHALATION
INOMAX

@ INO 100PPM N020845 002 Dec 23, 1999 Jun DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
MACRODANTIN

AB ALVOGEN INC 25MG N016620 003 Jun CTEC
NITROFURANTOIN
AB ACTAVIS LABS FL INC 25MG A091095 001 Jun 18, 2015 Jun NEWA
AB 50MG A091095 002 Jun 18, 2015 Jun NEWA
AB 100MG A091095 003 Jun 18, 2015 Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun NEWA
----	--	-----------------	-----------	---------	-----	--------------	----------

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

AB1	+	ACTAVIS LABS UT INC	0.35MG	N017060	001		Mar CAHN
-----	---	---------------------	--------	---------	-----	--	----------

NORGESTREL

TABLET;ORAL

OVRETTE

@ LABORATOIRE HRA

0.075MG

N017031 001

Jun CAHN

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun CMFD
----	--	------------------	------------------	---------	-----	--	----------

SUSPENSION;ORAL

NYSTATIN

AA		G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr CAHN
----	--	------------------	------------------	---------	-----	--------------	----------

@

100,000 UNITS/ML

A062776 001

Dec 17, 1987

Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT		G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar CMFD
----	--	------------------	-----------------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

MYKACET

AT		G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar CMFD
----	--	------------------	-----------------------	---------	-----	--------------	----------

OFLOXACIN

TABLET;ORAL

OFLOXACIN

AB		LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Jul CMFD
----	--	-------------	-------	---------	-----	--------------	----------

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB		IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr NEWA
----	--	-----------------	------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB		MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb NEWA
----	--	---------------------	-----	---------	-----	--------------	----------

AB			10MG	A203044	002	Feb 20, 2015	Feb NEWA
----	--	--	------	---------	-----	--------------	----------

AB			15MG	A203044	003	Feb 20, 2015	Feb NEWA
----	--	--	------	---------	-----	--------------	----------

AB			20MG	A203044	004	Feb 20, 2015	Feb NEWA
----	--	--	------	---------	-----	--------------	----------

AB		ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb NEWA
----	--	-----------------	-----	---------	-----	--------------	----------

AB			10MG	A202937	002	Mar 02, 2015	Feb NEWA
----	--	--	------	---------	-----	--------------	----------

AB			15MG	A202937	003	Mar 02, 2015	Feb NEWA
----	--	--	------	---------	-----	--------------	----------

AB			20MG	A202937	004	Mar 02, 2015	Feb NEWA
----	--	--	------	---------	-----	--------------	----------

OLAPARIB

CAPSULE;ORAL

LYNPARZA

ASTRAZENECA PHARMS

50MG

N206162 001

Dec 19, 2014

Jan CTNA

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH
---	----------------------	---

N206756 001

May 21, 2015

May NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT		BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun NEWA
----	--	---------------	--------------	---------	-----	--------------	----------

PATADAY

AT	+	ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun CFTG
----	---	------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

PAZEO

+	ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan NEWA
---	---------------	--------------	---------	-----	--------------	----------

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL

TECHNIVIE

>D>	+	ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 25, 2015	Aug CMS1
>A>	+		12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Aug CMS1
	+		12.5MG;75MG;50MG	N207931	001	Jul 25, 2015	Jul NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

>A>	AB	AUROBINDO PHARMA USA	10MG	A203270	001	Aug 19, 2015	Aug NEWA
>A>	AB		20MG	A203270	002	Aug 19, 2015	Aug NEWA
>A>	AB		40MG	A203270	003	Aug 19, 2015	Aug NEWA
>A>	AB	LUPIN LTD	40MG	A202384	001	Aug 25, 2015	Aug NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr CAHN
AB			8MG	A078602	002	Feb 24, 2011	Apr CAHN
		ZOFTRAN ODT					
AB		NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar CAHN
AB	+		8MG	N020781	002	Jan 27, 1999	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun NEWA
AP		CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr CAHN
AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr CAHN
AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun CAHN
		@ TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan DISC
		ZOFTRAN					
AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN
		ZOFTRAN PRESERVATIVE FREE					
AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN
		SOLUTION;ORAL					
		ZOFTRAN					
AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN
		TABLET;ORAL					
		ZOFTRAN					
AB		NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN
AB			EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN
AB	+		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

NORFLEX

		@ IGI LABS INC	30MG/ML	N013055	001		Apr CAHN
		@ MEDICIS	30MG/ML	N013055	001		Mar DISC
		ORPHENADRINE CITRATE					
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar CRLD

OXACILLIN SODIUM

CAPSULE;ORAL

OXACILLIN SODIUM

>A>		@ ANI PHARMS INC	EQ 250MG BASE	A062222	001		Aug CAHN
>A>		@	EQ 500MG BASE	A062222	002		Aug CAHN
>D>		@ TEVA	EQ 250MG BASE	A062222	001		Aug CAHN
>D>		@	EQ 500MG BASE	A062222	002		Aug CAHN

OXANDROLONETABLET; ORAL
OXANDRIN

>D>	AB	CREALTA PHARMS LLC	2.5MG	N013718	001		Aug	CAHN
>D>	AB	+	10MG	N013718	002	Nov 05, 2001	Aug	CAHN
>A>	AB	GEMINI LABS LLC	2.5MG	N013718	001		Aug	CAHN
>A>	AB	+	10MG	N013718	002	Nov 05, 2001	Aug	CAHN

OXCARBAZEPINESUSPENSION; ORAL
OXCARBAZEPINE

AB	SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr	CAHN
----	--------------------	-----------	---------	-----	--------------	-----	------

OXYBUTYNINFILM, EXTENDED RELEASE; TRANSDERMAL
OXYTROL

AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar	CAHN
----	---	---------------------	------------	---------	-----	--------------	-----	------

GEL, METERED; TRANSDERMAL
GELNIQUE 3%

+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar	CAHN
---	---------------------	----	---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDEGEL; TRANSDERMAL
GELNIQUE

+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar	CAHN
---	---------------------	-------------------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB	AVANTHI INC	5MG	A202773	001	Aug 17, 2015	Aug	NEWA
>A>	AB	NOVEL LABS INC	5MG	A204752	001	Aug 24, 2015	Aug	NEWA

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May	NEWA
AA	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr	NEWA
AA	WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun	NEWA

TABLET; ORAL

OXAYDO

ACURA PHARMS INC

5MG

N202080	001	Jun 17, 2011	Mar	CTNA
---------	-----	--------------	-----	------

7.5MG

N202080	002	Jun 17, 2011	Mar	CTNA
---------	-----	--------------	-----	------

EGALET LTD

5MG

N202080	001	Jun 17, 2011	May	CAHN
---------	-----	--------------	-----	------

7.5MG

N202080	002	Jun 17, 2011	May	CAHN
---------	-----	--------------	-----	------

EGALET US INC

5MG

N202080	001	Jun 17, 2011	Jul	CAHN
---------	-----	--------------	-----	------

7.5MG

N202080	002	Jun 17, 2011	Jul	CAHN
---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar	NEWA
AB	VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar	NEWA
AB		20MG	A077712	005	Apr 13, 2015	Mar	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr	NEWA
AB		7.5MG	A203506	002	Apr 24, 2015	Apr	NEWA
AB		10MG	A203506	003	Apr 24, 2015	Apr	NEWA
AB		15MG	A203506	004	Apr 24, 2015	Apr	NEWA
AB		20MG	A203506	005	Apr 24, 2015	Apr	NEWA
AB		30MG	A203506	006	Apr 24, 2015	Apr	NEWA
AB		40MG	A203506	007	Apr 24, 2015	Apr	NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb	CAHN

PALBOCICLIBCAPSULE;ORAL
IBRANCE

PFIZER INC	75MG	N207103	001	Feb 03, 2015	Feb NEWA
	100MG	N207103	002	Feb 03, 2015	Feb NEWA
+	125MG	N207103	003	Feb 03, 2015	Feb NEWA

PALIPERIDONETABLET, EXTENDED RELEASE;ORAL
INVEGA

AB	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul CFTG
AB		3MG	N021999	001	Dec 19, 2006	Jul CFTG
AB	+	6MG	N021999	002	Dec 19, 2006	Jul CFTG
AB		9MG	N021999	003	Dec 19, 2006	Jul CFTG

PALIPERIDONE

AB	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul NEWA
AB		3MG	A202645	002	Aug 03, 2015	Jul NEWA
AB		6MG	A202645	003	Aug 03, 2015	Jul NEWA
AB		9MG	A202645	004	Aug 03, 2015	Jul NEWA

PALIPERIDONE PALMITATESUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA

JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May NEWA
	410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May NEWA
	546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May NEWA
+	819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May NEWA

PANCURONIUM BROMIDEINJECTABLE;INJECTION
PANCURONIUM BROMIDE

@ IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072211	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072212	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072213	001	Mar 31, 1988	Mar CAHN

PANOBINOSTATCAPSULE;ORAL
FARYDAK

NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb NEWA
	15MG	N205353	002	Feb 23, 2015	Feb NEWA
+	20MG	N205353	003	Feb 23, 2015	Feb NEWA

PANOBINOSTAT LACTATECAPSULE;ORAL
FARYDAK

NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CAIN
	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CPOT
	EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CAIN
	EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CPOT
+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CAIN
+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CPOT

PANTOPRAZOLE SODIUMINJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun NEWA
----	------------	-------------------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOLCAPSULE;ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN

PAZOPANIB HYDROCHLORIDETABLET; ORAL
VOTRIENT

>D>	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar CAHN
>A>	@		EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug DISC
			EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug DISC
			EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar CAHN

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB		VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb CAHN
----	--	----------------	-------	---------	-----	--------------	----------

PHENDIMETRAZINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
BONTRIL@ VALEANT 105MG
PHENDIMETRAZINE TARTRATE

A088021 001 Sep 21, 1982 Jan DISC

+ SANDOZ 105MG

N018074 001 Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE; ORAL
DIBENZYLINE

AB	+	CONCORDIA PHARMS INC	10MG	N008708	001		Jun CAHN
----	---	----------------------	------	---------	-----	--	----------

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

AA		MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun CMFD
----	--	------------------	--------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDEAKORN INC 2.5%
10%

N207926	001	Jan 15, 2015	Jan NEWA
N207926	002	Jan 15, 2015	Jan NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORAL
PROMETH VC PLAIN

AA	+	G AND W LABS INC	5MG/5ML; 6.25MG/5ML	A088761	001	Nov 08, 1984	Jul CAHN
----	---	------------------	---------------------	---------	-----	--------------	----------

PHENYTOIN SODIUMCAPSULE; ORAL
EXTENDED PHENYTOIN SODIUM@ WOCKHARDT 30MG EXTENDED
@ WOCKHARDT USA 100MG EXTENDED
PHENYTOIN SODIUM

A040759	001	Dec 18, 2007	Jun DISC
A040732	001	Jan 30, 2008	Jun DISC

AB		AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May NEWA
----	--	----------------------	----------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001		Feb CAHN
----	---	--------------------	---------	---------	-----	--	----------

PHYTONADIONEINJECTABLE; INJECTION
AQUAMEPHYTON@ IGI LABS INC 1MG/0.5ML
@ 10MG/ML

N012223	002		Apr CAHN
N012223	001		Apr CAHN

PILOCARPINE HYDROCHLORIDEGEL; OPHTHALMIC
PILOPINE HS

>D>	+	ALCON	4%	N018796	001	Oct 01, 1984	Aug DISC
>A>	@		4%	N018796	001	Oct 01, 1984	Aug DISC

TABLET; ORAL
PILOCARPINE HYDROCHLORIDE

AB		ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar CAHN
----	--	----------------------	-----	---------	-----	--------------	----------

PINDOLOL

TABLET; ORAL

PINDOLOL

@	G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr	CAHN
@		5MG	A073687	001	Feb 26, 1993	Apr	CAHN
@		5MG	A074123	001	Apr 17, 1997	Apr	CAHN
@		10MG	A073661	002	Oct 31, 1993	Apr	CAHN
@		10MG	A073687	002	Feb 26, 1993	Apr	CAHN
@		10MG	A074123	002	Apr 17, 1997	Apr	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

@	MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Jan	DISC
---	---------	-------------------	---------	-----	--------------	-----	------

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+	GENENTECH INC	267MG	N022535	001	Oct 15, 2014	Feb	CAHN
---	---------------	-------	---------	-----	--------------	-----	------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	MYLAN PHARMS INC	10MG	A074116	001	Jun 15, 1993	May	CAHN
AB		20MG	A074118	001	Jun 15, 1993	May	CAHN

PODOFILOX

GEL; TOPICAL

CONDYLOX

+	ACTAVIS LABS UT INC	0.5%	N020529	001	Mar 13, 1997	Feb	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CONDYLOX

AT	+	ACTAVIS LABS UT INC	0.5%	N019795	001	Dec 13, 1990	Jan	CAHN
----	---	---------------------	------	---------	-----	--------------	-----	------

PODOFILOX

AT		BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010	May	CAHN
----	--	---------------------	------	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		ALCON RES LTD	10,000 UNITS/ML; EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Jan	CAHN
----	--	---------------	---------------------------------	---------	-----	--------------	-----	------

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

	ARIAD	EQ 30MG BASE	N203469	003	Apr 23, 2015	Apr	NEWA
--	-------	--------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

AB	UPSHER SMITH	8MEQ	A203106	001	Jul 10, 2015	Jun	NEWA
----	--------------	------	---------	-----	--------------	-----	------

AB		10MEQ	A203106	002	Jul 10, 2015	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

>A> FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

>A>		PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Aug	NEWA
-----	--	---------------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1	ADARE PHARMS INC	20MEQ	A076368	001	Aug 18, 2004	Jul	CAHN
-----	------------------	-------	---------	-----	--------------	-----	------

AB2	MYLAN PHARMS INC	8MEQ	A204662	001	Aug 21, 2014	Feb	CPOT
-----	------------------	------	---------	-----	--------------	-----	------

AB2		10MEQ	A204662	002	Aug 21, 2014	Feb	CPOT
-----	--	-------	---------	-----	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB	GLENMARK GENERICS	0.75MG	A090781	006	Sep 11, 2015	Aug	NEWA
-----	----	-------------------	--------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	DR REDDYS LABS LTD	0.375MG	A203354	001	Aug 07, 2015	Jul	NEWA
----	--------------------	---------	---------	-----	--------------	-----	------

AB		0.75MG	A203354	002	Aug 07, 2015	Jul	NEWA
----	--	--------	---------	-----	--------------	-----	------

AB		1.5MG	A203354	003	Aug 07, 2015	Jul	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		3MG	A203354	004	Aug 07, 2015	Jul	NEWA
----	--	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL									
PRAMIPEXOLE DIHYDROCHLORIDE									
AB		4.5MG		A203354	005	Aug 07, 2015	Jul	NEWA	
<u>PREDNICARBATE</u>									
OINTMENT;TOPICAL									
DERMATOP									
AB	+	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Apr	CAHN	
<u>PREDNISON</u>									
TABLET;ORAL									
PREDNISON									
>D> AB		HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	Aug	DISC	
>A>	@		1MG	A040890	001	Nov 01, 2010	Aug	DISC	
<u>PREGABALIN</u>									
CAPSULE;ORAL									
LYRICA									
		PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Apr	CTEC	
			50MG	N021446	002	Dec 30, 2004	Apr	CTEC	
			75MG	N021446	003	Dec 30, 2004	Apr	CTEC	
			100MG	N021446	004	Dec 30, 2004	Apr	CTEC	
			150MG	N021446	005	Dec 30, 2004	Apr	CTEC	
			200MG	N021446	006	Dec 30, 2004	Apr	CTEC	
			225MG	N021446	007	Dec 30, 2004	Apr	CTEC	
	+		300MG	N021446	008	Dec 30, 2004	Apr	CTEC	
<u>PROCAINAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
PROCAINAMIDE HYDROCHLORIDE									
	@	IDT AUSTRALIA LTD	250MG	A089219	001	Jul 01, 1986	Jun	CAHN	
	@		500MG	A089221	001	Jul 01, 1986	Jun	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
PROCAINAMIDE HYDROCHLORIDE									
	@	IDT AUSTRALIA LTD	250MG	A089369	001	Aug 14, 1987	Jun	CAHN	
	@		500MG	A089370	001	Jan 09, 1987	Jun	CAHN	
	@		750MG	A089371	001	Aug 14, 1987	Jun	CAHN	
<u>PROCHLORPERAZINE EDISYLATE</u>									
INJECTABLE;INJECTION									
PROCHLORPERAZINE EDISYLATE									
AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb	CAHN	
<u>PROGESTERONE</u>									
CAPSULE;ORAL									
PROGESTERONE									
AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN	
AB			200MG	A200900	002	Aug 16, 2013	Jan	CAHN	
GEL;VAGINAL									
CRINONE									
		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb	CAHN	
	+		8%	N020701	002	Jul 31, 1997	Feb	CAHN	
INJECTABLE;INJECTION									
PROGESTERONE									
AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar	CAHN	
<u>PROMETHAZINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
PROMETHAZINE HYDROCHLORIDE									
AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun	CAHN	
AP	+		50MG/ML	A083312	002		Jun	CAHN	
SUPPOSITORY;RECTAL									
PHENERGAN									
	@	DELCOR ASSET CORP	12.5MG	N010926	002		Apr	CAHN	
	@		25MG	N010926	001		Apr	CAHN	
TABLET;ORAL									
PROMETHAZINE HYDROCHLORIDE									
AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN	
AB			25MG	A040673	002	Mar 05, 2008	Mar	CAHN	
AB			50MG	A040673	003	Mar 05, 2008	Mar	CAHN	

PROPAFENONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

>A>	AB	WATSON LABS INC	225MG	A202688	001	Aug 24, 2015	Aug NEWA
>A>	AB		325MG	A202688	002	Aug 24, 2015	Aug NEWA
>A>	AB		425MG	A202688	003	Aug 24, 2015	Aug NEWA

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

>A>		@ ANI PHARMS INC	30MG	A040512	002	Jul 20, 2005	Aug CAHN
>A>		@	60MG	A040512	001	Oct 08, 2003	Aug CAHN
>D>		@ BARR	30MG	A040512	002	Jul 20, 2005	Aug CAHN
>D>		@	60MG	A040512	001	Oct 08, 2003	Aug CAHN
	AB	ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun NEWA

TABLET, EXTENDED RELEASE;ORAL
MESTINON

	AB	+ VALEANT PHARMS LLC	180MG	N011665	001		Jun CFTG
	AB	ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun NEWA
>A>	AB	IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Aug NEWA

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

>D>		+ AMEDRA PHARMS	25MG	N008578	001		Aug CAHN
>A>		+ TURING PHARMS AG	25MG	N008578	001		Aug CAHN

QUAZEPAM

TABLET;ORAL

DORAL

		@ SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun DISC
--	--	-----------------------	------	---------	-----	--------------	----------

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

AB		+ ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May CAHN
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May CAHN
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May CAHN
		@	EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN
AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May CAHN
AB		+	EQ 300MG BASE	N020639	005	Jul 26, 2000	May CAHN
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
AB			EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
AB			EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
AB			EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

		@ CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun CAHN
--	--	--------------------	-------	---------	-----	--------------	----------

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

		@ CYCLE PHARMS LTD	200MG	A083640	001		Jun CAHN
		@	300MG	A085632	001		Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE SULFATE

		+ G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN
--	--	--------------------	-------	---------	-----	--------------	----------

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

AB	AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun NEWA
AB	LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA
AB	RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul NEWA

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

AB	AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul NEWA
----	---------------	------	---------	-----	--------------	----------

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	60MG	A204310	001	Aug 28, 2015	Aug NEWA
AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

>A> AB	ACTAVIS LABS FL INC	8MG	A091610	001	Aug 19, 2015	Aug NEWA
--------	---------------------	-----	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

AP	+ CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN
----	------------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 150MG BASE

A075439 001 Apr 19, 2000 Apr CAHN

@ EQ 300MG BASE

A075439 002 Apr 19, 2000 Apr CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB	STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr NEWA
AB		1MG	A091517	002	Apr 24, 2015	Apr NEWA
AB		2MG	A091517	003	Apr 24, 2015	Apr NEWA

RIBAVIRIN

CAPSULE;ORAL

REBETOL

@ MERCK SHARP DOHME 200MG

N020903 001 Jun 03, 1998 Jun DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	+ WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May CFTG
----	-----------------------	------	---------	-----	--------------	----------

RISEDRONATE SODIUM

AB	TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May NEWA
----	-----------------	------	---------	-----	--------------	----------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB	SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr CAHN
AB		1MG	A077542	002	Aug 06, 2010	Apr CAHN
AB		2MG	A077542	003	Aug 06, 2010	Apr CAHN
AB		3MG	A078474	001	Aug 06, 2010	Apr CAHN
AB		4MG	A078474	002	Aug 06, 2010	Apr CAHN

RIVAROXABAN

TABLET;ORAL

XARELTO

JANSSSEN PHARMS 10MG

N022406 001 Jul 01, 2011 Apr CRLD

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL
EXELON

>D>	NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007	Aug CFTG
>A> AB		4.6MG/24HR	N022083	001	Jul 06, 2007	Aug CFTG
>D>	+	9.5MG/24HR	N022083	002	Jul 06, 2007	Aug CFTG
>A> AB	+	9.5MG/24HR	N022083	002	Jul 06, 2007	Aug CFTG
>D>		13.3MG/24HR	N022083	005	Aug 31, 2012	Aug CFTG
>A> AB		13.3MG/24HR	N022083	005	Aug 31, 2012	Aug CFTG
>A>	RIVASTIGMINE					
>A> AB	ALVOGEN INC	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug NEWA
>A> AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Aug NEWA
>A> AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Aug NEWA
>A> AB	ALVOGEN PINE BROOK	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug CAHN
>A> AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Aug CAHN
>A> AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Aug CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB	ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May NEWA
AB		EQ 3MG BASE	A090879	002	Jun 10, 2015	May NEWA
AB		EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May NEWA
AB		EQ 6MG BASE	A090879	004	Jun 10, 2015	May NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

>A> AP	SAGENT PHARMS	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug CAHN
>A> AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug CAHN
>D> AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug CAHN
>D> AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar CAHN
---	--------------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

SACUBITRIL; VALSARTAN

TABLET;ORAL

ENTRESTO

	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015	Jul NEWA
		49MG;51MG	N207620	002	Jul 07, 2015	Jul NEWA
+		97MG;103MG	N207620	003	Jul 07, 2015	Jul NEWA

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA
AB	TRANSDERM SCOP					
AB	+	NOVARTIS	1MG/72HR	N017874	001	Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996	Apr CAHN
@		5MG	A074744	001	Jan 27, 1997	Apr CAHN
@		5MG	A074756	001	Nov 25, 1998	Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May DISC
	@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May DISC
	@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May DISC
AB		SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr CAHN
AB			EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr CAHN
AB			EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr CAHN
			EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr CAHN
			EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr CAHN

SILDENAFIL CITRATE

SOLUTION; INTRAVENOUS

REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar CFTG
AP		SILDENAFIL CITRATE					
AP		AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar CAHN
			8MG	N022206	002	Oct 08, 2008	Mar CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB		SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr CAHN
AB			10MG	A076285	002	Dec 20, 2006	Apr CAHN
AB			20MG	A076285	003	Dec 20, 2006	Apr CAHN
AB			40MG	A076285	004	Dec 20, 2006	Apr CAHN
AB			80MG	A076285	005	Jun 23, 2006	Apr CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb CAHN
		SODIUM CHLORIDE 0.9%					
		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN
	+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN
----	--	--------------------	------------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP		CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul NEWA
AP		HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul NEWA
>A> AP		IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Aug NEWA
AP		MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul NEWA
AP		PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
AP		SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
AP		UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr CAHN

SODIUM POLYSTYRENE SULFONATE

		POWDER;ORAL, RECTAL					
		KALEXATE					
		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar NEWA
		KAYEXALATE					
AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr CAHN

SODIUM TETRADECYL SULFATE

		INJECTABLE;INJECTION					
		SOTRADECOL					
	+	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul CRLD

SOMATROPIN RECOMBINANT

		INJECTABLE;INJECTION					
		NORDITROPIN FLEXPRO					
		NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan NEWA
		NORDITROPIN NORDIFLEX					
		@ NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Jul DISC
			30MG/3ML	N021148	007	Mar 10, 2009	Mar CMFD
		@	30MG/3ML	N021148	007	Mar 10, 2009	Jan DISC
		NUTROPIN					
		@ GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun DISC
		@	10MG/VIAL	N020168	002	Nov 17, 1993	Jun DISC
BX	+		10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC
		NUTROPIN AQ					
		@ GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun DISC
		NUTROPIN AQ NUSPIN					
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun CTNA
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun NEWA
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun CTNA
		NUTROPIN AQ PEN					
	+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun NEWA
		ZOMACTON					
BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr CRLD
BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar NEWA

SONIDEGIB PHOSPHATE

		CAPSULE;ORAL					
		ODOMZO					
	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015	Jul NEWA

SOTALOL HYDROCHLORIDE

		SOLUTION;INTRAVENOUS					
		SOTALOL HYDROCHLORIDE					
	+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr CAHN
		TABLET;ORAL					
		BETAPACE					
AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar CAHN
AB1			120MG	N019865	005	Apr 20, 1994	Mar CAHN
AB1	+		160MG	N019865	002	Oct 30, 1992	Mar CAHN
AB1			240MG	N019865	003	Oct 30, 1992	Mar CAHN
	@		320MG	N019865	004	Oct 30, 1992	Mar CAHN

STERILE WATER FOR INJECTION

		LIQUID;N/A					
		STERILE WATER FOR INJECTION					
>A>	AP	EUROHLTH INTL SARL	100%	A206369	001	Sep 02, 2015	Aug NEWA

SUCCINYLCHOLINE CHLORIDE

		INJECTABLE;INJECTION					
		QUELICIN PRESERVATIVE FREE					
	@	HOSPIRA	100MG/ML	N008845	004		Jun DISC

SUCRALFATE

		TABLET;ORAL					
		SUCRALFATE					
AB		MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTANIL CITRATE

AP	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun CAHN
----	--------------------	-------------------	---------	-----	--------------	----------

SULFACETAMIDE SODIUM

LOTION; TOPICAL
KLARON

AB	+ VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar CAHN
----	------------------------	-----	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT	AKORN	10%	A040215	001	May 25, 1999	Mar CMFD
----	-------	-----	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

	@ ANI PHARMS INC	200MG/5ML; 40MG/5ML	A070028	001	Jun 02, 1987	Jul CAHN
--	------------------	---------------------	---------	-----	--------------	----------

SULFANILAMIDE

CREAM; VAGINAL
SULFANILAMIDE

	@ G AND W LABS INC	15%	A088718	001	Sep 19, 1985	Apr CAHN
--	--------------------	-----	---------	-----	--------------	----------

SULINDAC

TABLET; ORAL
SULINDAC

>A>	@ ANI PHARMS INC	150MG	A072972	001	Feb 28, 1992	Aug CAHN
>A>	@	200MG	A072973	001	Feb 28, 1992	Aug CAHN
>D>	@ TEVA	150MG	A072972	001	Feb 28, 1992	Aug CAHN
>D>	@	200MG	A072973	001	Feb 28, 1992	Aug CAHN

SUMATRIPTAN SUCCINATE

TABLET; ORAL
SUMATRIPTAN SUCCINATE

AB	SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr CAHN
AB		EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr CAHN
AB		EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr CAHN

TACROLIMUS

TABLET, EXTENDED RELEASE; ORAL
ENVARUS XR

	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015	Jul NEWA
		EQ 1MG BASE	N206406	002	Jul 10, 2015	Jul NEWA
+		EQ 4MG BASE	N206406	003	Jul 10, 2015	Jul NEWA

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL
NUCYNTA

+	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May CAHN
---	-------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL
NUCYNTA

	DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May CAHN
		EQ 75MG BASE	N022304	002	Nov 20, 2008	May CAHN
+		EQ 100MG BASE	N022304	003	Nov 20, 2008	May CAHN

TABLET, EXTENDED RELEASE; ORAL
NUCYNTA ER

	DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May CAHN
		EQ 100MG BASE	N200533	002	Aug 25, 2011	May CAHN
		EQ 150MG BASE	N200533	003	Aug 25, 2011	May CAHN
		EQ 200MG BASE	N200533	004	Aug 25, 2011	May CAHN
+		EQ 250MG BASE	N200533	005	Aug 25, 2011	May CAHN

TELAPREVIR

TABLET; ORAL
INCIVEK

	@ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan DISC
--	-----------------	-------	---------	-----	--------------	----------

TELMISARTAN

TABLET; ORAL

TELMISARTAN

>A>	AB	AMNEAL PHARMS	20MG	A204415	001	Sep 08, 2015	Aug NEWA
>A>	AB		40MG	A204415	002	Sep 08, 2015	Aug NEWA
>A>	AB		80MG	A204415	003	Sep 08, 2015	Aug NEWA
>A>	AB	AUROBINDO PHARMA LTD	20MG	A206511	001	Sep 03, 2015	Aug NEWA
>A>	AB		40MG	A206511	002	Sep 03, 2015	Aug NEWA
>A>	AB		80MG	A206511	003	Sep 03, 2015	Aug NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May NEWA
AB		15MG	A201781	002	Jun 04, 2015	May NEWA
AB		22.5MG	A201781	003	Jun 04, 2015	May NEWA
AB		30MG	A201781	004	Jun 04, 2015	May NEWA

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr NEWA
AB		20MG	A203691	002	May 08, 2015	Apr NEWA
AB		100MG	A203691	003	May 08, 2015	Apr NEWA
AB		140MG	A203691	004	May 08, 2015	Apr NEWA
AB		180MG	A203691	005	May 08, 2015	Apr NEWA
AB		250MG	A203691	006	May 08, 2015	Apr NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar NEWA
	VIREAD					
AB	+ GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar CFTG

TERBINAFINE

GEL; TOPICAL

LAMISIL

>A>	@ GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998	Aug CAHN
>D>	@ NOVARTIS	1%	N020846	001	Apr 29, 1998	Aug CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL

LAMISIL

>A>	@ GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997	Aug CAHN
>D>	@ NOVARTIS	1%	N020749	001	Oct 17, 1997	Aug CAHN

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

@ WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb DISC
-------------	---------------	---------	-----	--------------	----------

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan CTEC
AB1	+ TESTIM	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan CTEC
AB2	+ AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan CTEC
	TESTOSTERONE					
	@ ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar CAHN
	@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar CAHN
AB1		25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul CMFD
AB1		50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul CMFD
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May CAHN
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May CAHN
>D>	@ PAR PHARM	1% (2.5GM/PACKET)	A076744	001	May 23, 2007	Aug CMFD
>D>	@	1% (5GM/PACKET)	A076744	002	May 23, 2007	Aug CMFD
>A>	AB1	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Aug CMFD
>A>	AB1	50MG/5GM PACKET	A076744	002	May 23, 2007	Aug CMFD
AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan CTEC
AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan CTEC

		GEL;TRANSDERMAL							
		VOGELXO							
AB2		UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan	CTEC	
		GEL, METERED;TRANSDERMAL							
		ANDROGEL							
AB	+	ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul	CFTG	
		FORTESTA							
AB	+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul	CFTG	
		TESTOSTERONE							
AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul	NEWA	
>A>	AB		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Aug	NEWA	
AB		PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul	NEWA	
		<u>TETRABENAZINE</u>							
		TABLET;ORAL							
>A>		TETRABENAZINE							
>A>	AB	SUN PHARMA GLOBAL	12.5MG	A206129	001	Aug 17, 2015	Aug	NEWA	
>A>	AB		25MG	A206129	002	Aug 17, 2015	Aug	NEWA	
		XENAZINE							
>D>		VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Aug	CFTG	
>A>	AB		12.5MG	N021894	001	Aug 15, 2008	Aug	CFTG	
			12.5MG	N021894	001	Aug 15, 2008	Feb	CAHN	
>D>	+		25MG	N021894	002	Aug 15, 2008	Aug	CFTG	
>A>	AB	+	25MG	N021894	002	Aug 15, 2008	Aug	CFTG	
		+	25MG	N021894	002	Aug 15, 2008	Feb	CAHN	
		<u>TETRACYCLINE HYDROCHLORIDE</u>							
		CAPSULE;ORAL							
		ACHROMYCIN V							
AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr	CRLD	
		TETRACYCLINE HYDROCHLORIDE							
		@ IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr	DISC	
		@	500MG	A060704	002		Apr	DISC	
		<u>THEOPHYLLINE</u>							
		TABLET;ORAL							
		THEOLAIR							
		@ MEDICIS	125MG	A086399	001		Mar	DISC	
		@	250MG	A086399	002		Mar	DISC	
		TABLET, EXTENDED RELEASE;ORAL							
		THEOPHYLLINE							
AB		MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May	CAHN	
AB	+		600MG	A040560	002	Apr 21, 2006	May	CAHN	
		<u>THIOTEPA</u>							
		INJECTABLE;INJECTION							
		THIOTEPA							
	+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May	CRLD	
		<u>TIGECYCLINE</u>							
		INJECTABLE;IV (INFUSION)							
		TIGECYCLINE							
AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May	NEWA	
		TYGACIL							
AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May	CFTG	
		<u>TIMOLOL MALEATE</u>							
		SOLUTION/DROPS;OPHTHALMIC							
		ISTALOL							
AT2	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr	CFTG	
		TIMOLOL MALEATE							
AT1		AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr	CTEC	
AT1			EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr	CTEC	
AT1		ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr	CTEC	
AT2		APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr	NEWA	
AT1		BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr	CTEC	
AT1		FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr	CTEC	
AT1		HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr	CTEC	
AT1		PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr	CTEC	
AT1		WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr	CTEC	

SOLUTION/DROPS;OPHTHALMIC
TIMOPTIC

AT1	+	ATON	EQ 0.5% BASE	N018086	002		Apr	CTEC
-----	---	------	--------------	---------	-----	--	-----	------

TINIDAZOLETABLET;ORAL
TINIDAZOLE

AB		EDENBRIDGE PHARMS	250MG	A203808	001	Aug 04, 2015	Jul	NEWA
AB			500MG	A203808	002	Aug 04, 2015	Jul	NEWA

TOBRAMYCINSOLUTION;INHALATION
KITABIS PAK

AN		PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb	CTEC
----	--	---------------	-----------	---------	-----	--------------	-----	------

TOBRAMYCIN

AN		AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	Jun	NEWA
----	--	---------------	-----------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC
TOBREX

AT	+	ALCON LABS INC	0.3%	N050541	001		Mar	CAHN
----	---	----------------	------	---------	-----	--	-----	------

TOBRAMYCIN SULFATEINJECTABLE;INJECTION
TOBRAMYCIN SULFATE

		@ IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar	CAHN
		@	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar	CAHN
		@	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar	CAHN
		@	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar	CAHN
		TOBRAMYCIN SULFATE (PHARMACY BULK)						
	+	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul	CTEC
AP	+		EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul	CRLD
		@ HOSPIRA	EQ 40MG BASE/ML	A063116	001	May 18, 1992	Jul	DISC
AP			EQ 40MG BASE/ML	A063116	001	May 18, 1992	Jul	CTNA

TOLAZAMIDETABLET;ORAL
TOLAZAMIDE

		@ G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
		@	250MG	N018894	002	Nov 02, 1984	Apr	CAHN
		@	500MG	N018894	003	Nov 02, 1984	Apr	CAHN

TOLCAPONETABLET;ORAL
TASMAR

AB	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar	CFTG
----	---	--------------------	-------	---------	-----	--------------	-----	------

TOLCAPONE

AB		PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	NEWA
----	--	---------------	-------	---------	-----	--------------	-----	------

TOLMETIN SODIUMTABLET;ORAL
TOLMETIN SODIUM

		@ G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May	CAHN
		@	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE;ORAL
TOLTERODINE TARTRATE

AB		TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul	NEWA
AB			4MG	A203016	002	Aug 11, 2015	Jul	NEWA

TABLET;ORAL

TOLTERODINE TARTRATE

AB		IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb	NEWA
AB			2MG	A077006	002	Feb 23, 2015	Feb	NEWA
>A> AB		MACLEODS PHARMS LTD	1MG	A203409	001	Aug 31, 2015	Aug	NEWA
>A> AB			2MG	A203409	002	Aug 31, 2015	Aug	NEWA

TOPIRAMATETABLET;ORAL
TOPIRAMATE

AB		SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr	CAHN
AB			100MG	A076327	002	Mar 27, 2009	Apr	CAHN
AB			200MG	A076327	003	Mar 27, 2009	Apr	CAHN
		@ WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr	DISC

TABLET;ORAL									
TOPIRAMATE									
	@	50MG		A090353	002	Sep 01, 2010	Apr	DISC	
	@	100MG		A090353	003	Sep 01, 2010	Apr	DISC	
	@	200MG		A090353	004	Sep 01, 2010	Apr	DISC	
TOPIRAMATE									
	@ HIKMA PHARMS	25MG		A091185	001	Nov 25, 2013	May	DISC	
	@	50MG		A091185	002	Nov 25, 2013	May	DISC	
	@	100MG		A091185	003	Nov 25, 2013	May	DISC	
	@	200MG		A091185	004	Nov 25, 2013	May	DISC	
<u>TOPOTECAN HYDROCHLORIDE</u>									
CAPSULE;ORAL									
HYCANTIN									
	NOVARTIS PHARMS CORP	EQ 0.25MG BASE		N020981	001	Oct 11, 2007	Mar	CAHN	
+		EQ 1MG BASE		N020981	002	Oct 11, 2007	Mar	CAHN	
INJECTABLE;INJECTION									
HYCANTIN									
AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar	CAHN	
		TOPOTECAN HYDROCHLORIDE							
AP		CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN	
<u>TORSEMIDE</u>									
INJECTABLE;INJECTION									
TORSEMIDE									
	@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)		A078007	001	Jun 11, 2008	Jan	DISC	
	@	50MG/5ML (10MG/ML)		A078007	002	Jun 11, 2008	Jan	DISC	
	@ LUITPOLD	20MG/2ML (10MG/ML)		A090656	001	Apr 21, 2010	Jan	DISC	
	@	50MG/5ML (10MG/ML)		A090656	002	Apr 21, 2010	Jan	DISC	
<u>TRAMETINIB DIMETHYL SULFOXIDE</u>									
TABLET;ORAL									
MEKINIST									
	NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT		N204114	001	May 29, 2013	Mar	CAHN	
		EQ 1MG NON-SOLVATED PARENT		N204114	002	May 29, 2013	Mar	CAHN	
+		EQ 2MG NON-SOLVATED PARENT		N204114	003	May 29, 2013	Mar	CAHN	
<u>TRANEXAMIC ACID</u>									
INJECTABLE;INJECTION									
TRANEXAMIC ACID									
AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD	
<u>TRANLYCYPROMINE SULFATE</u>									
TABLET;ORAL									
PARNATE									
AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN	
<u>TRAVOPROST</u>									
SOLUTION/DROPS;OPHTHALMIC									
IZBA									
	@ ALCON LABS INC	0.003%		N204822	001	May 15, 2014	Jul	DISC	
		TRAVATAN Z							
AT	+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun	CTEC	
		TRAVOPROST							
AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun	NEWA	
<u>TRAZODONE HYDROCHLORIDE</u>									
TABLET;ORAL									
DESYREL									
	@ PRAGMA PHARMS LLC	50MG		N018207	001		May	CAHN	
	@	100MG		N018207	002		May	CAHN	
	@	150MG		N018207	003	Mar 25, 1985	May	CAHN	
	@	300MG		N018207	004	Nov 07, 1988	May	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
OLEPTRO									
	@ ANGELINI PHARMA	150MG		N022411	001	Feb 02, 2010	Mar	DISC	
	@	300MG		N022411	002	Feb 02, 2010	Mar	DISC	

TRETINOIN

		CREAM;TOPICAL					
		RENOVA					
AB2	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr CAHN
	+		0.05%	N019963	001	Dec 29, 1995	Apr CAHN
		RETIN-A					
AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr CAHN
		GEL;TOPICAL					
		ATRALIN					
AB	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul CTEC
		TRETINOIN					
AB		SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul NEWA

TRIAMCINOLONE ACETONIDE

		CREAM;TOPICAL					
		TRIAMCINOLONE ACETONIDE					
AT		G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr CMFD
AT			0.1%	A089798	001	May 31, 1991	Apr CMFD
		TRIDERM					
AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar NEWA
AT			0.5%	A088042	003	Mar 25, 2015	Mar NEWA
		LOTION;TOPICAL					
		TRIAMCINOLONE ACETONIDE					
AT		G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar CMFD
		OINTMENT;TOPICAL					
		KENALOG					
AT		DELCOR ASSET CORP	0.025%	N011600	003		Mar CMFD
AT			0.1%	N011600	001		Mar CMFD
		TRIAMCINOLONE ACETONIDE					
>D>		@ G AND W LABS	0.025%	A089795	001	Dec 23, 1988	Aug CMFD
>A>	AT		0.025%	A089795	001	Dec 23, 1988	Aug CMFD
>D>		@	0.1%	A089796	001	Dec 23, 1988	Aug CMFD
>A>	AT		0.1%	A089796	001	Dec 23, 1988	Aug CMFD
		SPRAY;TOPICAL					
		KENALOG					
>D>	AT	+	RANBAXY	0.147MG/GM	N012104	001	Aug CAHN
	AT	+		0.147MG/GM	N012104	001	Mar CFTG
>A>	AT	+	SUN PHARM INDS LTD	0.147MG/GM	N012104	001	Aug CAHN
		TRIAMCINOLONE ACETONIDE					
AT		PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar NEWA

TRIAMTERENE

		CAPSULE;ORAL					
		DYRENIUM					
		CONCORDIA PHARMS INC	50MG	N013174	001		Apr CAHN
		+	100MG	N013174	002		Apr CAHN

TRIMIPRAMINE MALEATE

		CAPSULE;ORAL					
		SURMONTIL					
AB	+	ODYSSEY PHARMS	EQ 50MG BASE	N016792	002		Jun CRLD
AB			EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun CRLD

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

		CREAM;VAGINAL					
		VAGILIA					
		@ G AND W LABS INC	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987	Jul CAHN

TRIPTORELIN PAMOATE

		INJECTABLE;INTRAMUSCULAR					
		TRELSTAR					
		+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000
		+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001
		+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
SANCTURA XR							
	@ ALLERGAN	60MG	N022103	001	Aug 03, 2007	May	DISC
TROSPIUM CHLORIDE							
AB	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Jun	CRLD
AB	+	60MG	A091289	001	Oct 12, 2012	May	CRLD
AB	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	NEWA
TABLET;ORAL							
SANCTURA							
	@ ALLERGAN	20MG	N021595	001	May 28, 2004	May	DISC
TROSPIUM CHLORIDE							
AB	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Jun	CRLD
AB	+	20MG	A091575	001	Aug 13, 2010	May	CRLD

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC							
RESCULA							
+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May	CAHN
+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan	CAHN

URSODIOL

CAPSULE;ORAL							
ACTIGALL							
	@ ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
AB	+	300MG	N019594	002	Dec 31, 1987	Mar	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL							
VALACYCLOVIR HYDROCHLORIDE							
AB	HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar	NEWA
AB		EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr	CAHN
AB		EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr	CAHN

VALPROIC ACID

CAPSULE;ORAL							
VALPROIC ACID							
AB	BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan	CAHN
CAPSULE, DELAYED RELEASE;ORAL							
STAVZOR							
	@ BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan	CAHN
	@	250MG	N022152	002	Jul 29, 2008	Jan	CAHN
	@	500MG	N022152	003	Jul 29, 2008	Jan	CAHN

VALSARTAN

TABLET;ORAL							
VALSARTAN							
AB	PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May	NEWA
AB		80MG	A204821	002	Jun 09, 2015	May	NEWA
AB		160MG	A204821	003	Jun 09, 2015	May	NEWA
AB		320MG	A204821	004	Jun 09, 2015	May	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL							
VANCOMYCIN HYDROCHLORIDE							
AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan	NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan	NEWA
INJECTABLE;INJECTION							
VANCOLED							
	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun	CAHN
	@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun	CAHN
	@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun	CAHN
	@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun	CAHN
	@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun	CAHN
VANCOMYCIN HYDROCHLORIDE							
>A> AP	XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015	Aug	NEWA
>A> AP		EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015	Aug	NEWA

VARDENAFIL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING;ORAL
STAXYN

AB	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG
VARDENAFIL HYDROCHLORIDE							
AB		WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB		VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB			EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB			EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
AB			EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB			EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
AB			EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
AB			EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VERELAN

AB		RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB			180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB			240MG	N019614	002	May 29, 1990	Apr CAHN
	+		360MG	N019614	004	May 10, 1996	Apr CAHN

VERELAN PM

AB		RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB			200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+		300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE;INJECTION

CALAN

>A>		@ EXELA PHARMA SCS LLC	2.5MG/ML	N018925	001	Mar 30, 1984	Aug CAHN
>D>		@ GD SEARLE LLC	2.5MG/ML	N018925	001	Mar 30, 1984	Aug CAHN
ISOPTIN							
		@ MT ADAMS	2.5MG/ML	N018485	001		Apr CAHN

TABLET;ORAL

ISOPTIN

		@ MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CAHN
		@	80MG	N018593	001	Mar 08, 1982	Apr CAHN
		@	120MG	N018593	002	Mar 08, 1982	Apr CAHN

VERTEPORFININJECTABLE;INJECTION
VISUDYNE

	+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar CAHN
--	---	--------------------	-----------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

	+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar CAHN
			20MG	N022567	002	Jan 21, 2011	Mar CAHN
			40MG	N022567	003	Jan 21, 2011	Mar CAHN

VORICONAZOLE

TABLET;ORAL

VORICONAZOLE

>A>	AB	GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015	Aug NEWA
>A>	AB		200MG	A203503	002	Sep 02, 2015	Aug NEWA

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB		PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb CAHN
AB	+		20MG	N020547	001	Sep 26, 1996	Feb CAHN

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr NEWA
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar NEWA
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CPOT

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

	@ HIKMA	5MG	A078129	001	Apr 30, 2008	Mar DISC
	@	10MG	A078129	002	Apr 30, 2008	Mar DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr CAHN
AB		10MG	A078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL

INTERMEZZO

AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May CFTG
AB	+	3.5MG	N022328	002	Nov 23, 2011	May CFTG
	ZOLPIDEM TARTRATE					
AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May NEWA
AB		3.5MG	A204299	002	Jun 03, 2015	May NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

TYLENOL

>A>	@ J AND J CONSUMER INC	120MG	N017756	002		Aug	CAHN
>A>	@	650MG	N017756	001		Aug	CAHN
>D>	@ MCNEIL CONS	120MG	N017756	002		Aug	CAHN
>D>	@	650MG	N017756	001		Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD

650MG

A078569 001 Dec 14, 2011 Apr CAHN

@

650MG

A090205 001 Nov 18, 2009 Apr CAHN

TYLENOL

>A>	+ J AND J CONSUMER INC	650MG	N019872	001	Jun 08, 1994	Aug	CAHN
>A>	+	650MG	N019872	002	Jan 11, 2001	Aug	CAHN
>D>	+ MCNEIL CONS	650MG	N019872	001	Jun 08, 1994	Aug	CAHN
>D>	+	650MG	N019872	002	Jan 11, 2001	Aug	CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992	Mar	CAHN
---	----------------------	------------	---------	-----	--------------	-----	------

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

+	ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015	Mar	NEWA
---	--------------------	---------------	---------	-----	--------------	-----	------

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

LOTRIMIN ULTRA

+	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001	Mar	CAHN
---	----------------------	----	---------	-----	--------------	-----	------

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

PEPCID COMPLETE

>A>	+	J AND J CONSUMER INC	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Aug	CAHN
>D>	+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Aug	CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES

5MG

N022429 001 Jul 23, 2009 Jan CAHN

+		10MG	N022429	004	Jul 23, 2009	Jan	CAHN
---	--	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES

5MG

N022429 003 Jul 23, 2009 Jan CAHN

+		10MG	N022429	002	Jul 23, 2009	Jan	CAHN
---	--	------	---------	-----	--------------	-----	------

SYRUP;ORAL

CHILDREN'S ZYRTEC ALLERGY

>A>	+	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Aug	CAHN
>D>	+	MCNEIL CONSUMER	5MG/5ML	N022155	002	Nov 16, 2007	Aug	CAHN

CHILDREN'S ZYRTEC HIVES RELIEF

>A>	+	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Aug	CAHN
>D>	+	MCNEIL CONSUMER	5MG/5ML	N022155	001	Nov 16, 2007	Aug	CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD

5MG

A090760 001 Aug 05, 2015 Jul NEWA

		10MG	A090760	003	Aug 05, 2015	Jul	NEWA
--	--	------	---------	-----	--------------	-----	------

SUN PHARM INDS LTD

5MG

A077498 001 Dec 27, 2007 Apr CAHN

		10MG	A077498	002	Dec 27, 2007	Apr	CAHN
--	--	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD

5MG

A077498 003 Dec 27, 2007 Apr CAHN

		10MG	A077498	004	Dec 27, 2007	Apr	CAHN
--	--	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA LTD

5MG

A090760 002 Aug 05, 2015 Jul NEWA

		10MG	A090760	004	Aug 05, 2015	Jul	NEWA
--	--	------	---------	-----	--------------	-----	------

ZYRTEC ALLERGY

>A>		J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007	Aug	CAHN
>A>	+		10MG	N019835	004	Nov 16, 2007	Aug	CAHN
>D>		MCNEIL CONSUMER	5MG	N019835	003	Nov 16, 2007	Aug	CAHN

TABLET;ORAL							
ZYRTEC ALLERGY							
>D>	+	10MG	N019835	004	Nov 16, 2007	Aug	CAHN
ZYRTEC HIVES RELIEF							
>A>	J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007	Aug	CAHN
>A>	+	10MG	N019835	006	Nov 16, 2007	Aug	CAHN
>D>	MCNEIL CONSUMER	5MG	N019835	005	Nov 16, 2007	Aug	CAHN
>D>	+	10MG	N019835	006	Nov 16, 2007	Aug	CAHN
TABLET, CHEWABLE;ORAL							
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY							
	JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015	Feb	NEWA
		10MG	A091116	002	Feb 19, 2015	Feb	NEWA
	SANDOZ	5MG	A078692	001	Feb 14, 2008	Feb	CTNA
	+	10MG	A078692	002	Feb 14, 2008	Feb	CTNA
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
	JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015	Feb	NEWA
		10MG	A091116	004	Feb 19, 2015	Feb	NEWA
CHILDREN'S ZYRTEC ALLERGY							
>A>	@ J AND J CONSUMER INC	5MG	N021621	003	Nov 16, 2007	Aug	CAHN
>A>	@	10MG	N021621	004	Nov 16, 2007	Aug	CAHN
>D>	@ MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Aug	CAHN
>D>	@	10MG	N021621	004	Nov 16, 2007	Aug	CAHN
CHILDREN'S ZYRTEC HIVES RELIEF							
>A>	@ J AND J CONSUMER INC	5MG	N021621	005	Nov 16, 2007	Aug	CAHN
>A>	@	10MG	N021621	006	Nov 16, 2007	Aug	CAHN
>D>	@ MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Aug	CAHN
>D>	@	10MG	N021621	006	Nov 16, 2007	Aug	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
CETIRIZINE HYDROCHLORIDE ALLERGY							
>A>	PAR PHARM INC	10MG	A205490	001	Sep 02, 2015	Aug	NEWA
ZYRTEC ALLERGY							
>A>	+	J AND J CONSUMER INC 10MG	N022578	001	Sep 03, 2010	Aug	CAHN
>D>	+	MCNEIL CONSUMER 10MG	N022578	001	Sep 03, 2010	Aug	CAHN
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
ZYRTEC-D 12 HOUR							
>A>	+	J AND J CONSUMER INC 5MG;120MG	N021150	002	Nov 09, 2007	Aug	CAHN
>D>	+	MCNEIL 5MG;120MG	N021150	002	Nov 09, 2007	Aug	CAHN
<u>CHLORPHENIRAMINE MALEATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
CHLOR-TRIMETON							
	@ BAYER HEALTHCARE LLC	8MG	N007638	001		Mar	CAHN
	+	12MG	N007638	002		Mar	CAHN
<u>CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
CHLOR-TRIMETON							
	+	BAYER HEALTHCARE LLC 8MG;120MG	N018397	001		Mar	CAHN
<u>CLEMASTINE FUMARATE</u>							
TABLET;ORAL							
CLEMASTINE FUMARATE							
	@ ANI PHARMS INC	1.34MG	A073282	002	Dec 03, 1992	Jul	CAHN
<u>CLOTTRIMAZOLE</u>							
CREAM;VAGINAL							
GYNE-LOTRIMIN							
	+	BAYER HEALTHCARE LLC 1%	N018052	002	Nov 30, 1990	Mar	CAHN
		GYNE-LOTRIMIN 3					
	+	BAYER HEALTHCARE LLC 2%	N020574	001	Nov 24, 1998	Mar	CAHN
CREAM, TABLET;TOPICAL, VAGINAL							
GYNE-LOTRIMIN COMBINATION PACK							
	+	BAYER HEALTHCARE LLC 1%,100MG	N020289	002	Apr 26, 1993	Mar	CAHN
TABLET;VAGINAL							
GYNE-LOTRIMIN							
	+	BAYER HEALTHCARE LLC 100MG	N017717	002	Nov 30, 1990	Mar	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	ACTAVIS LABS FL INC	30MG;600MG	A091070	001	Aug 31, 2015	Aug NEWA
>A>		60MG;1.2GM	A091070	002	Aug 31, 2015	Aug NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

SUN PHARM INDS LTD 10MG
20MG

A090283	001	Nov 17, 2009	Apr CAHN
A090283	002	Nov 17, 2009	Apr CAHN

PEPCID AC

J AND J CONSUMER INC 10MG
+ 20MG

N020325	001	Apr 28, 1995	Jul CAHN
N020325	002	Sep 23, 2003	Jul CAHN

PEPCID AC

J AND J CONSUMER INC 10MG
MCNEIL CONS 10MG

N020902	001	Aug 05, 1999	Aug CAHN
N020902	001	Aug 05, 1999	Aug CAHN

TABLET, CHEWABLE;ORAL

PEPCID AC

@ J AND J CONSUMER INC 10MG
+ 20MG

N020801	001	Sep 24, 1998	Aug CAHN
N020801	002	Dec 17, 2007	Aug CAHN

@ MCNEIL CONS 10MG
+ 20MG

N020801	001	Sep 24, 1998	Aug CAHN
N020801	002	Dec 17, 2007	Aug CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

SCIEGEN PHARMS INC 60MG
180MG

A204507	002	Sep 16, 2015	Aug NEWA
A204507	003	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

SCIEGEN PHARMS INC 60MG
180MG

A204507	004	Sep 16, 2015	Aug NEWA
A204507	005	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL 60MG;120MG

A090818 001 Jan 29, 2015 Jan NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

ACTAVIS LABS FL INC 1.2GM

A091009 002 Sep 03, 2015 Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC 600MG;60MG
1.2GM;120MG

A091071	001	May 27, 2015	May NEWA
A091071	002	May 27, 2015	May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES EQ 200MG FREE ACID AND POTASSIUM
SALT

A078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BANNER LIFE SCIENCES 200MG

N021472 001 Oct 18, 2002 Jan CAHN

SUSPENSION;ORAL

CHILDREN'S MOTRIN

+ J AND J CONSUMER INC 100MG/5ML
+ MCNEIL 100MG/5ML

N020516	001	Jun 16, 1995	Aug CAHN
N020516	001	Jun 16, 1995	Aug CAHN

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+ J AND J CONSUMER INC 40MG/ML
+ MCNEIL CONS 40MG/ML

N020603	001	Jun 10, 1996	Aug CAHN
N020603	001	Jun 10, 1996	Aug CAHN

TABLET;ORAL

IBUPROFEN

>A>	@ ANI PHARMS INC	200MG	A072901	001	Dec 19, 1991	Aug CAHN
>A>	@	200MG	A072903	001	Dec 19, 1991	Aug CAHN
>D>	@ IVAX SUB TEVA PHARMS	200MG	A072901	001	Dec 19, 1991	Aug CAHN
>D>	@	200MG	A072903	001	Dec 19, 1991	Aug CAHN
	JUNIOR STRENGTH MOTRIN					
>A>	J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996	Aug CAHN
>D>	MCNEIL CONS	100MG	N020602	001	Jun 10, 1996	Aug CAHN
	MOTRIN IB					
>A>	+ J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990	Aug CAHN
>D>	+ MCNEIL	200MG	N019012	003	Dec 17, 1990	Aug CAHN
	MOTRIN MIGRAINE PAIN					
>A>	+ J AND J CONSUMER INC	200MG	N019012	004	Feb 25, 2000	Aug CAHN
>D>	+ MCNEIL	200MG	N019012	004	Feb 25, 2000	Aug CAHN
	NUPRIN					
>A>	@ J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984	Aug CAHN
>A>	@	200MG	N019012	002	Jul 29, 1987	Aug CAHN
>D>	@ MCNEIL	200MG	N019012	001	May 18, 1984	Aug CAHN
>D>	@	200MG	N019012	002	Jul 29, 1987	Aug CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S MOTRIN

>A>	J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Aug CAHN
>D>	MCNEIL CONS	50MG	N020601	001	Nov 15, 1996	Aug CAHN
	JUNIOR STRENGTH MOTRIN					
>A>	+ J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996	Aug CAHN
>D>	+ MCNEIL CONS	100MG	N020601	003	Nov 15, 1996	Aug CAHN

IBUPROFEN SODIUM

TABLET;ORAL

IBUPROFEN SODIUM

PERRIGO R AND D

EQ 200MG BASE

A206581 001 Aug 03, 2015 Jul NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S MOTRIN COLD

>A>	+ J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000	Aug CAHN
>D>	+ MCNEIL CONS	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000	Aug CAHN

TABLET;ORAL

SINE-AID IB

>A>	J AND J CONSUMER INC	200MG;30MG	N019899	001	Dec 31, 1992	Aug CAHN
>D>	MCNEIL CONS	200MG;30MG	N019899	001	Dec 31, 1992	Aug CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB

EQ 0.035% BASE

N021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD

1.5MG

A202246 001 Jun 05, 2015 May NEWA

OC PHARMA

1.5MG

A202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES

1MG

N021855 001 Aug 04, 2005 Jan CAHN

+

2MG

N021855 002 Aug 04, 2005 Jan CAHN

SOLUTION;ORAL

IMODIUM A-D

>A>	+ J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988	Aug CAHN
>D>	+ MCNEIL CONS	1MG/5ML	N019487	001	Mar 01, 1988	Aug CAHN

SUSPENSION;ORAL

IMODIUM A-D

>A>	+ J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004	Aug CAHN
>D>	+ MCNEIL CONS	1MG/7.5ML	N019487	002	Jul 08, 2004	Aug CAHN

TABLET;ORAL

IMODIUM A-D

>A>	+ J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989	Aug CAHN
>D>	+ MCNEIL CONS	2MG	N019860	001	Nov 22, 1989	Aug CAHN

TABLET, CHEWABLE;ORAL
 IMODIUM A-D EZ CHEWS

>A>	+	J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997	Aug CAHN
>D>	+	MCNEIL	2MG	N020448	001	Jul 24, 1997	Aug CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

>A>	+	J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000	Aug CAHN
>D>	+	MCNEIL CONS	2MG;125MG	N021140	001	Nov 30, 2000	Aug CAHN

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG;125MG

A077500 001 Sep 06, 2006 Apr CAHN

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

>A>	+	J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996	Aug CAHN
>D>	+	MCNEIL	2MG;125MG	N020606	001	Jun 26, 1996	Aug CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008	Mar CAHN
---	----------------------	------	---------	-----	--------------	----------

SYRUP;ORAL

CLARITIN

+	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002	Mar CAHN
---	----------------------	--------	---------	-----	--------------	----------

CLARITIN HIVES RELIEF

@	BAYER HEALTHCARE LLC	1MG/ML	N020641	003	Nov 19, 2003	Mar CAHN
---	----------------------	--------	---------	-----	--------------	----------

LORATADINE

TARO 1MG/ML

A201865 001 Jul 31, 2015 Jul NEWA

TABLET;ORAL

LORATADINE

SUN PHARM INDS LTD 10MG

A076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Mar CAHN
---	----------------------	-----	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN REDITABS

+	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006	Mar CAHN
---	----------------------	-----	---------	-----	--------------	----------

LORATADINE REDIDOSE

SUN PHARM INDS LTD 10MG

A077153 001 Apr 11, 2007 Apr CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

+	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar CAHN
---	----------------------	-----------	---------	-----	--------------	----------

CLARITIN-D 24 HOUR

+	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar CAHN
---	----------------------	------------	---------	-----	--------------	----------

LORATADINE AND PSEUDOEPHEDRINE SULFATE

SUN PHARM INDS LTD 10MG;240MG

A076557 001 Sep 22, 2004 Apr CAHN

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+	BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan CAHN
---	----------------------	---------------	---------	-----	--------------	----------

CATALENT EQ 200MG BASE

A202807 001 Feb 13, 2015 Feb NEWA

OHM LABS INC EQ 200MG BASE

A202807 001 Feb 13, 2015 Jun CAHN

TABLET;ORAL

NAPROXEN SODIUM

SUN PHARM INDS LTD EQ 200MG BASE

A091183 001 May 20, 2011 Apr CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

@ IVAX SUB TEVA PHARMS EQ 2MG BASE

A076880 001 Feb 18, 2009 Mar DISC

@ EQ 4MG BASE

A077850 001 Feb 18, 2009 Mar DISC

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

PERRIGO R AND D EQ 20MG BASE

A204152 001 Jul 30, 2015 Jul NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL
ZEGERID OTC

+ BAYER HEALTHCARE LLC 20MG; 1.1GM N022281 001 Dec 01, 2009 Mar CAHN
FOR SUSPENSION; ORAL

ZEGERID OTC

+ BAYER HEALTHCARE LLC 20MG/PACKET; 1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUCLEAR

BAYER HEALTHCARE LLC 0.025% N018471 001 May 30, 1986 Mar CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
MIRALAX

+ BAYER HEALTHCARE LLC 17GM/SCOOPFUL N022015 001 Oct 06, 2006 Mar CAHN
POLYETHYLENE GLYCOL 3350

RARITAN PHARMS INC 17GM/SCOOPFUL A202071 001 Dec 28, 2012 Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE
SUN PHARM INDS LTD 120MG
SUDAFED 24 HOUR

A077442 001 Sep 28, 2005 Apr CAHN

>A> + J AND J CONSUMER INC 240MG N020021 002 Dec 15, 1992 Aug CAHN

>D> + MCNEIL CONS 240MG N020021 002 Dec 15, 1992 Aug CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 75MG BASE
@ WOCKHARDT EQ 75MG BASE

A075132 001 Jan 14, 2000 Apr CAHN

A078884 001 Jul 31, 2008 Jan DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2015

NO AUGUST 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9056100	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8909305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	>A> 8733341	Dec 16, 2029	DP			
	>A> 9027967	Mar 31, 2027	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jun 04, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8778924	Dec 08, 2026	DS DP U-897			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 6967208	Feb 03, 2023	DS DP U-1167			
	>A> 6967208	Feb 03, 2023	DS DP U-1200			
	>A> 6967208	Feb 03, 2023	DS DP U-1301			
	>A> 6967208	Feb 03, 2023	DS DP U-1302			
	>A> 6967208	Feb 03, 2023	DS DP U-1323			
	>A> 6967208	Feb 03, 2023	DS DP U-1501			
	>A> 6967208	Feb 03, 2023	DS DP U-1502			
	>A> 6967208	Feb 03, 2023	DS DP U-1729			
	>A> 6967208	Feb 03, 2023	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6413980	Dec 22, 2019	DS DP U-1301			
	6413980	Dec 22, 2019	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREPITANT - EMEND</u>						
N 021549 001				>A> NPP		Aug 28, 2018
<u>APREPITANT - EMEND</u>						
N 021549 002				>A> NPP		Aug 28, 2018
<u>APREPITANT - EMEND</u>						
N 021549 003				>A> NPP		Aug 28, 2018
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	>A> 9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	>A> 9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 003 >A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 004 >A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 005 >A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006 >A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002 >A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003 >A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 0202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
>A>	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 0202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
>A>	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
>A>	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
>A>	9089567	Jan 28, 2022	U-543			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	>A> 9101637	Mar 23, 2022	U-1731			
	>A> 9101637	Mar 23, 2022	U-1732			
	>A> 9101637	Mar 23, 2022	U-1733			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			PED	Dec 02, 2017
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	>A> 6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
	>A> 7700076	Sep 18, 2027	DP			
	>A> 8435498	Mar 01, 2024	U-1727			
	>A> 8722021	Oct 24, 2023	DP			
	>A> 8900554	Oct 24, 2023	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	9066936	Mar 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9066936	Mar 26, 2028	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8895070	Jun 03, 2029	U-124			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	>A> 5780454	May 03, 2017	DS DP		>A> D-141	Oct 08, 2017
	>A> 5780454*PED	Nov 03, 2017			>A> D-142	Oct 08, 2017
	>A> 6713446	Jan 25, 2022	DS DP		>A> I-695	Oct 08, 2017
	>A> 6713446*PED	Jul 25, 2022			>A> M-139	Aug 08, 2017
	>A> 6958319	Jan 25, 2022	DS DP		>A> ODE	Oct 08, 2021
	>A> 6958319*PED	Jul 25, 2022			>A> PED	Feb 08, 2018
					>A> PED	Apr 08, 2018
					>A> PED	Apr 08, 2018
					>A> PED	Apr 08, 2018
					>A> PED	Apr 08, 2022
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9044484	Oct 30, 2030	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8877708	Jun 07, 2030	DP U-1706			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	>A> 9132093	Sep 07, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425		>A> I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425		>A> I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425		>A> I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425		>A> I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		>A> I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
	>A> 9107837	Jun 04, 2027	U-1639			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	>A> 9089528	Jul 20, 2027	U-1469			
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026 001					ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026 002					ODE	Jan 13, 2022
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-712	Jul 24, 2018
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 004					PC	Jun 02, 2015
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323 001	6248363	Nov 23, 2019	DP U-1716			
	6383471	Apr 06, 2019	DP U-1716			
	9066942	Jan 03, 2032	U-1716			
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					ODE	Mar 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					>A> NPP	Aug 14, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	002				>A> NPP	Aug 14, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	001	8703781	Oct 15, 2030	DS DP U-1713		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	002	8703781	Oct 15, 2030	DS DP U-1713		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	001	>A> 8329159	Apr 13, 2028	DS	NCE	Jul 24, 2020
		>A> 8629171	Jun 13, 2031	DS DP U-1724		
		>A> 8642025	Aug 11, 2027	DS DP U-1724		
		>A> 8642025	Aug 11, 2027	DS DP U-1725		
		>A> 8900566	Aug 08, 2027	U-1724		
		>A> 8900566	Aug 08, 2027	U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	002	>A> 8329159	Apr 13, 2028	DS	NCE	Jul 24, 2020
		>A> 8629171	Jun 13, 2031	DS DP U-1724		
		>A> 8642025	Aug 11, 2027	DS DP U-1724		
		>A> 8642025	Aug 11, 2027	DS DP U-1725		
		>A> 8900566	Aug 08, 2027	U-1724		
		>A> 8900566	Aug 08, 2027	U-1725		
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001				ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293	001				M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293	002				M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001	6037157	Jun 26, 2016	U-1635		
		6703403	Jun 26, 2016	U-1635		
		7148359	Jul 19, 2019	DP		
		7364752	Nov 10, 2020	DP		
		8188104	May 17, 2029	DS DP U-1636		
		8268349	Aug 25, 2024	DP		
		8399015	Aug 25, 2024	DP		
		8420596	Apr 10, 2031	DS DP		
		8466159	Sep 04, 2032	U-1637		
		8492386	Sep 04, 2032	U-1637		
		8501238	Sep 17, 2028	DS DP U-1636		
		8642538	Sep 10, 2029	DS DP U-1638		
		8680106	Sep 04, 2032	U-1637		
		8685984	Sep 04, 2032	U-1637		
		8686026	Jun 09, 2031	DP		
		8691938	Apr 13, 2032	DS DP		
		9006387	Jun 10, 2030	U-1687		
		9044480	Apr 10, 2031	U-1638		
<u>DEFERASIROX - EXJADE</u>						
N 021882	001				ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882	002				ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882	003				ODE	Jan 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS		U-735	
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS		U-735	
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS		U-735	
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027			U-1690	
	7754230	Dec 10, 2027			U-1690	
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025			U-1690	
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP		U-1690	
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025			U-1690	
	8883770	Feb 21, 2028	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP		U-1412	
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS		U-860	
	6673838	Mar 01, 2022	DS		U-1364	
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020			U-1205	
	8088407	Oct 20, 2020			U-1205	
	9012437	Oct 20, 2020			U-1205	
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8784885	Oct 15, 2023	DP		U-1552	
	8784885	Oct 15, 2023	DP		U-1553	
	8784885	Oct 15, 2023	DP		U-1554	
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019			U-1472	
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					PC	Dec 19, 2015
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
>A>	9132110	Oct 17, 2027	U-1488			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001 >A>	9107898	May 01, 2028	DP U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002 >A>	9107898	May 01, 2028	DP U-620			
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001 >A>	9107900	Apr 16, 2029	U-1726			
	>A> 9107900	Apr 16, 2029	U-1728			
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090694 003					PC	Jan 11, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001 >A>	6280959	Oct 30, 2018	DS DP U-930	>A> D-149		Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306	>A> I-711		Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575	>A> ODE		Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1714	>A> PED		Dec 11, 2018
	>A> 6280959*PED	Apr 30, 2019		>A> PED		Dec 11, 2018
	>A> 7160870	Nov 20, 2022	DS DP U-930	>A> PED		Feb 26, 2022
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7160870*PED	May 20, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP U-1714			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1714			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7790704	May 24, 2021	U-1714			
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293	May 21, 2023	U-1714			
	>A> 7795293*PED	Nov 21, 2023				
	>A> 8052993	Aug 01, 2027	DP U-930			
	>A> 8052993	Aug 01, 2027	DP U-1306			
	>A> 8052993	Aug 01, 2027	DP U-1575			
	>A> 8052993	Aug 01, 2027	DP U-1714			
	>A> 8052993*PED	Feb 01, 2028				
	>A> 8052994	Aug 01, 2027	DP U-1714			
	>A> 8052994*PED	Feb 01, 2028				
	>A> 8062665	Aug 01, 2027	DP U-1714			
	>A> 8062665*PED	Feb 01, 2028				
	>A> 8071129	Aug 01, 2027	DP U-1714			
	>A> 8071129*PED	Feb 01, 2028				
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
	>A> 8828430	Aug 01, 2027	DP U-1714			
	>A> 8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
	>A> 6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
	>A> 7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP U-1714			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7473686*PED	Nov 24, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1714			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7790704	May 24, 2021	U-1714			
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293	May 21, 2023	U-1714			
	>A> 7795293*PED	Nov 21, 2023				
	>A> 8052993	Aug 01, 2027	DP U-1714			
	>A> 8052993*PED	Feb 01, 2028				
	>A> 8052994	Aug 01, 2027	DP U-930			
	>A> 8052994	Aug 01, 2027	DP U-1306			
	>A> 8052994	Aug 01, 2027	DP U-1575			
	>A> 8052994	Aug 01, 2027	DP U-1714			
	>A> 8052994*PED	Feb 01, 2028				
	>A> 8062665	Aug 01, 2027	DP U-1714			
	>A> 8062665*PED	Feb 01, 2028				
	>A> 8071129	Aug 01, 2027	DP U-1714			
	>A> 8071129*PED	Feb 01, 2028				
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
	>A> 8828430	Aug 01, 2027	DP U-1714			
	>A> 8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
	>A> 6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
	>A> 7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP U-1714			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1714			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7790704	May 24, 2021	U-1714			
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293	May 21, 2023	U-1714			
	>A> 7795293*PED	Nov 21, 2023				
	>A> 8052993	Aug 01, 2027	DP U-1714			
	>A> 8052993*PED	Feb 01, 2028				
	>A> 8052994	Aug 01, 2027	DP U-1714			
	>A> 8052994*PED	Feb 01, 2028				
	>A> 8062665	Aug 01, 2027	DP U-714			
	>A> 8062665	Aug 01, 2027	DP U-930			
	>A> 8062665	Aug 01, 2027	DP U-1306			
	>A> 8062665	Aug 01, 2027	DP U-1575			
	>A> 8062665*PED	Feb 01, 2028				
	>A> 8071129	Aug 01, 2027	DP U-1714			
	>A> 8071129*PED	Feb 01, 2028				
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
	>A> 8828430	Aug 01, 2027	DP U-1714			
	>A> 8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
	>A> 6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
	>A> 7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP U-1714			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1714			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7790704	May 24, 2021	U-1714			
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293	May 21, 2023	U-1714			
	>A> 7795293*PED	Nov 21, 2023				
	>A> 8052993	Aug 01, 2027	DP U-1714			
	>A> 8052993*PED	Feb 01, 2028				
	>A> 8052994	Aug 01, 2027	DP U-1714			
	>A> 8052994*PED	Feb 01, 2028				
	>A> 8062665	Aug 01, 2027	DP U-1714			
	>A> 8062665*PED	Feb 01, 2028				
	>A> 8071129	Aug 01, 2027	DP U-930			
	>A> 8071129	Aug 01, 2027	DP U-1306			
	>A> 8071129	Aug 01, 2027	DP U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 8071129	Aug 01, 2027	DP U-1714			
	>A> 8071129*PED	Feb 01, 2028				
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
	>A> 8828430	Aug 01, 2027	DP U-1714			
	>A> 8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
	>A> 6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
	>A> 7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP U-1714			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293*PED	Nov 21, 2023				
	>A> 8052995	Aug 01, 2027	DP U-1306			
	>A> 8052995	Aug 01, 2027	DP U-1575			
	>A> 8052995*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001					>A> D-149	Jun 11, 2018
					>A> I-711	Jun 11, 2018
					>A> ODE	Nov 20, 2015
					>A> PED	Dec 11, 2018
					>A> PED	Dec 11, 2018
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8691860	Jul 07, 2028	DS U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001					>A> NCE >A> NP	Aug 01, 2019 Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002					>A> NCE >A> NP	Aug 01, 2019 Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003					>A> NCE >A> NP	Aug 01, 2019 Aug 26, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004					>A> NCE >A> NP	Aug 01, 2019 Aug 26, 2018
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001 >A>	9119876	Mar 13, 2035	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001 >A>	9107912	Sep 08, 2031	U-1346			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002 >A>	9107912	Sep 08, 2031	U-1346			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Jan 17, 2033	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
>A>	9119859	Jul 02, 2030	U-1679			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001 >A>	7151103	May 09, 2023	U-1734		>A> NCE	Aug 18, 2020
>A>	7420057	Aug 01, 2022	DS DP			
>A>	8227471	May 09, 2023	U-1734			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GEFITINIB - IRESSA</u>						
N 206995 001	5770599	May 05, 2017	DS DP U-1403		NP	Jul 13, 2018
				>A>	ODE	Jul 13, 2022
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	>A> 9095559	Mar 09, 2032	U-1383			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	001				M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	002				M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003				M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004				M-154	Mar 18, 2018
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	001	9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	002	9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	003	9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	004	9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	005	9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	006	9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	007	9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2019	DS DP U-1187			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8658673	Jun 02, 2020	DS DP U-1168			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001 >A>	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002 >A>	7943572	Aug 10, 2026	U-1539			
	>A> 8424518	Oct 17, 2031	DP			
	>A> 8623817	Sep 18, 2029	U-1537			
	>A> 8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	>A> 8912193	Jun 12, 2029	DP U-1538			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027		U-1311		
	8354427	Jul 06, 2026		U-1311		
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027		U-1311	ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP	U-1718		
	8741933	Nov 08, 2026		U-1717		
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028		U-1717		
	8993600	Dec 11, 2030	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018		U-1631		
	6133310	Apr 26, 2019		U-1631		
	7550440	Apr 22, 2024	DP	U-1631		
	8080530	Apr 22, 2024	DP	U-1631		
	8093219	Apr 22, 2024	DP	U-1631		
	8415311	Apr 22, 2024	DP	U-1631		
	8470788	Apr 22, 2024	DP	U-1631		
	8815816	Apr 22, 2024	DP	U-1631		
	9089587	Mar 13, 2034		U-1631		
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024		U-1662		
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	9066856	Oct 23, 2033	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP	U-248		
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP	U-1663		
	7820660	Apr 25, 2023	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	8980327	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	8980327	Dec 01, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	8821927	Sep 18, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9085573	Mar 21, 2028	DS DP U-1470			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A> 9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A> 9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A> 9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A> 9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A> 9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A> 9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A> 9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A> 9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A> 9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A> 9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS	U-1211	I-706	Feb 17, 2018
	9056120	Apr 11, 2023		U-1215	ODE	Feb 17, 2022
	>A> 9101621	May 15, 2023		U-1216		
	>A> 9101622	May 15, 2023		U-1216		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	>A> 6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	>A> 6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	>A> 6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	>A> 6471992	Feb 20, 2018	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					PC	Dec 19, 2015
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-703	Jan 30, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	RE45573	Jun 23, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	RE45573	Jun 23, 2025	DS			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	9040088	Apr 22, 2024	U-755			
	>A> 9101540	Apr 22, 2024	DP U-755			
	>A> 9101549	Apr 22, 2024	U-755			
	>A> 9107827	Apr 22, 2024	U-755			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	>A> 9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	>A> 9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	9060941	Sep 19, 2023	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	>A> 8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	>A> 8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	>A> 8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	>A> 8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	>A> 8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
>A>	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
>A>	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028		U-1682		
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032		U-1664		
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028		U-1643		
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9084802	May 12, 2031		U-282		
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP	U-702		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029		U-1640		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001 >A>	9114168	May 29, 2029	DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	6060499	Aug 14, 2017	DP U-1719			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-1719			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027			U-1634	
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031			U-1634	
	8912187	Mar 12, 2024	U-1634			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	>A> 8733341	Dec 16, 2029	DP			
	>A> 9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP		U-1703	
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
	6037157*PED	Dec 26, 2016			NP	Jul 24, 2018
	6703403	Jun 26, 2016	U-1635			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
<u>OMEPRazole - OMEPRazole</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	>A> 9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	>A> 9095577	Jul 13, 2030	DP			
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	>A> 9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	>A> 9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	>A> 9119791	Apr 13, 2027	U-1298			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	>A> 9101543	Feb 21, 2026	U-1434			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	>A> 9125905	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	>A> 9125905	Jan 30, 2024	DP			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006					I-710	Jun 19, 2018
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027	U-1601			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	9040085	Apr 23, 2024	U-1362			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9045519	Jun 22, 2019	DP			
	>A> 9085601	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	6861053	Aug 11, 2019	U-1708			
	7452857	Aug 11, 2019	U-1707			
	7452857	Aug 11, 2019	U-1708			
	7605240	Aug 11, 2019	U-1707			
	7605240	Aug 11, 2019	U-1708			
	7718608	Aug 11, 2019	U-1707			
	7718608	Aug 11, 2019	U-1708			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	7935799	Aug 11, 2019	U-1707			
	7935799	Aug 11, 2019	U-1708			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001					>A> NPP	Aug 26, 2018
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					PC	Nov 28, 2015
<u>RIVASTIGMINE - RIVASTIGMINE</u>						
A 204403 003					>A> PC	Feb 29, 2016
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	>A> 5712298	Jan 27, 2020	DS DP U-1115			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	>A> 8101659	Jan 14, 2023	DP			
	>A> 8404744	Jan 14, 2023	DP			
	>A> 8796331	Jan 14, 2023	U-1723			
	>A> 8877938	May 27, 2027	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	>A> 8101659	Jan 14, 2023	DP			
	>A> 8404744	Jan 14, 2023	DP			
	>A> 8796331	Jan 14, 2023	U-1723			
	>A> 8877938	May 27, 2027	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	>A> 8101659	Jan 14, 2023	DP			
	>A> 8404744	Jan 14, 2023	DP			
	>A> 8796331	Jan 14, 2023	U-1723			
	>A> 8877938	May 27, 2027	DS DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9040562	Jul 28, 2026	DS DP U-1467			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					ODE	May 28, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9085573	Mar 21, 2028	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DS DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001 >A>	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8124630	Jan 12, 2020	U-1459			
	8841330	Jan 12, 2020	U-1696			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001 >A>	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002 >A>	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003 >A>	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9060995	Jan 25, 2033	U-1710			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
	9060992	Nov 01, 2025	U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001 >A>	9125816	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002 >A>	9125816	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003 >A>	9125816	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001 >A>	9125816	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002 >A>	9125816	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003 >A>	9125816	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	>A> 8733341	Dec 16, 2029	DP			
	>A> 9027967	Mar 31, 2027	DP			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9101545	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	>A> 8178582	Oct 10, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004	8133893	Mar 13, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003					>A> NPP	Jun 12, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 004					>A> NPP	Jun 12, 2018

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>